The present disclosure relates generally to renal therapy systems and more specifically to systems and methods for prescribing, tracking, servicing and organizing home medical devices.
Due to disease, insult or other causes, a person's renal system can fail. In renal failure of any cause, there are several physiological derangements. The balance of water, minerals and the excretion of daily metabolic load is no longer possible in renal failure. During renal failure, toxic end products of nitrogen metabolism (urea, creatinine, uric acid, and others) can accumulate in blood and tissues.
Kidney failure and reduced kidney function have been treated with dialysis. Dialysis removes waste, toxins and excess water from the body that would otherwise have been removed by normal functioning kidneys. Dialysis treatment for replacement of kidney functions is critical to many people because the treatment is life saving. One who has failed kidneys could not continue to live without replacing at least the filtration functions of the kidneys.
Hemodialysis and peritoneal dialysis are two types of dialysis therapies commonly used to treat loss of kidney function. Hemodialysis treatment uses the patient's blood to remove waste, toxins and excess water from the patient. The patient is connected to a hemodialysis machine and the patient's blood is pumped through the machine. Catheters are inserted into the patient's veins and arteries to connect the blood flow to and from the hemodialysis machine. As blood passes through a dialyzer in the hemodialysis machine, the dialyzer removes the waste, toxins and excess water from the patient's blood and returns the blood back to the patient. A large amount of dialysate, for example about one-hundred twenty liters, is used to dialyze the blood during a single hemodialysis treatment. The spent dialysate is then discarded. Hemodialysis treatment lasts several hours and is generally performed in a treatment center about three or four times per week.
Peritoneal dialysis uses a dialysis solution or “dialysate”, which is infused into a patient's peritoneal cavity through a catheter implanted in the cavity. The dialysate contacts the patient's peritoneal membrane in the peritoneal cavity. Waste, toxins and excess water pass from the patient's bloodstream through the peritoneal membrane and into the dialysate. The transfer of waste, toxins, and water from the bloodstream into the dialysate occurs due to diffusion and osmosis, i.e., an osmotic gradient occurs across the membrane. The spent dialysate drains from the patient's peritoneal cavity and removes the waste, toxins and excess water from the patient. This cycle is repeated.
There are various types of peritoneal dialysis therapies, including continuous ambulatory peritoneal dialysis (“CAPD”), automated peritoneal dialysis and continuous flow peritoneal dialysis. CAPD is a manual dialysis treatment, in which the patient connects an implanted catheter to a drain and allows a spent dialysate fluid to drain from the peritoneal cavity. The patient then connects the catheter to a bag of fresh dialysate and manually infuses fresh dialysate through the catheter and into the patient's peritoneal cavity. The patient disconnects the catheter from the fresh dialysate bag and allows the dialysate to dwell within the cavity to transfer waste, toxins and excess water from the patient's bloodstream to the dialysate solution. After a dwell period, the patient repeats the manual dialysis procedure.
In CAPD the patient performs several drain, fill, and dwell cycles during the day, for example, about four times per day. Each treatment cycle typically takes about an hour. Manual peritoneal dialysis performed by the patient requires a significant amount of time and effort from the patient. This inconvenient procedure leaves ample room for improvement and therapy enhancements to improve patient quality of life.
Automated peritoneal dialysis (“APD”) is similar to CAPD in that the dialysis treatment includes a drain, fill, and dwell cycle. APD machines, however, automatically perform three to four cycles of peritoneal dialysis treatment, typically overnight while the patient sleeps. The APD machines fluidly connect to an implanted catheter. The APD machines also fluidly connect to a source or bag of fresh dialysate and to a fluid drain.
The APD machines pump fresh dialysate from the dialysate source, through the catheter, into the patient's peritoneal cavity and allow the dialysate to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysate solution can take place. The APD machines then pump spent dialysate from the peritoneal cavity, though the catheter, to the drain. APD machines are typically computer controlled so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. That is, the APD systems automatically and sequentially pump fluid into the peritoneal cavity, allow for a dwell, pump fluid out of the peritoneal cavity and repeat the procedure.
As with the manual process, several drain, fill, and dwell cycles will occur during APD. A “last fill” is typically used at the end of APD, which remains in the peritoneal cavity of the patient when the patient disconnects from the dialysis machine for the day. APD frees the patient from having to manually perform the drain, dwell, and fill steps.
For patients suffering from renal diseases, frequent dialysis is a way of life. Most peritoneal dialysis patients perform dialysis once a day. Hemodialysis patients typically require dialysis several times a week. To allow patients to continue to live their lives as normally as possible, there has been an increased desire to provide home dialysis solutions. Peritoneal dialysis is typically performed at home. Hemodialysis and other blood treatment therapies, such as hemofiltration, are performed largely in centers and clinics.
Performing hemodialysis at home presents more challenges and complexity than peritoneal dialysis because blood is actually removed from a patient for cleaning. Hemodialysis may require a water treatment system to prepare dialysate online. Home hemodialysis may also require some form of patient supervision. Home hemodialysis can also be complicated by the fact that the patient's treatment prescription may change over time and that patients may have multiple treatment prescriptions. Also, consumables used in hemodialysis can be expensive. Their use, efficacy and inventory should be tightly monitored. Hemodialysis machines may also require maintenance or service from a skilled technician. It is thus desirable to have a way to manage service calls to a patient's home to keep the machines running correctly. A schedule may also be needed for the delivery of the necessary consumables without delivering more than needed and risking waste of consumables.
It is desirable to transfer the results of treatment for both home peritoneal dialysis and hemodialysis. The results should be accurate, timely and provide the level of detail that clinicians expect from in-clinic therapies. It is also desirable for clinicians to modify prescriptions.
A need accordingly exists for a home dialysis system, for both peritoneal dialysis and hemodialysis, that provides at least some of the above-described features.
The present system and method involve a medical device infrastructure that integrates many aspects of providing home renal therapy. The system and method in one embodiment integrates the training of patients to properly use various medical devices, transferring data to a central repository maintained by a therapy provider, providing reports of treatment data to clinicians, integrating with billing and ordering systems, tracking consumables usage and delivering consumables as needed, and servicing and maintaining the machines on a network of the system.
In one embodiment, a home medical device system includes a plurality of home medical devices including a renal therapy machine, such as, but not limited to, a home hemodialysis (“HD”) machine, a home peritoneal dialysis (“PD”) machine, a home hemofiltration (“HF”) machine, a home hemodiafiltration (“HDF”) machine, and a home continuous renal replacement (“CRRT”) machine. While renal therapy is one focus of the present disclosure, the present disclosure also contemplates the integration of any home fluid delivery therapy, such as in addition, a home drug delivery therapy or a nutritional therapy. The machine may be at the home of the patient, or any other dwelling, such as, for example, a hotel room, vacation home, temporary shelter, nursing home, etc. The medical device system includes a system hub coupled to the renal therapy machine through a connectivity server, a web portal configured to access the system hub, and an enterprise resource planning system coupled to the system hub. The enterprise resource planning system may store a doctor's prescription for example. Renal therapy, for example, according to the prescription is performed by a home medical machine on a patient.
In one embodiment, the home medical device system also includes a method for home renal therapy training. A patient is trained on a first renal therapy machine in a clinic. A unique patient identification (“ID”) is generated for that patient. A second renal therapy machine is sent to the patient's home. The second renal therapy machine is linked to the patient by entering the patient ID. The second renal therapy machine is then used by the patient for home renal therapy. The second machine is at least substantially similar to the first machine so that the patient is already familiar with the machine and the corresponding therapy.
In one embodiment, the home medical device system also includes a method for obtaining and transferring treatment prescriptions. A doctor's prescription for a renal or other type of therapy is retrieved. A clinician can remotely select, based upon the doctor's prescription, supplies to send to the patient's home, such as a dialyzer. The clinician can also remotely set settings for operating the renal therapy machine according to the prescription. The settings can be in the form of parameters or ranges that allow the patient to select a value within the range. Any selection is doctor approved. Nevertheless, the patient has some input into the treatment that the home therapy machine performs. The clinician may remotely update the settings for the renal therapy machine. The supplies and the treatment program for the renal therapy machine are sent to the patient and the patient performs renal treatment at home according to the settings.
In one embodiment, the system includes a method for safely allowing network or internet access. A connectivity agent resides on each renal therapy machine. The connectivity agent is turned off before each treatment and is turned on after the renal therapy machine is finished with the treatment. This way, the network connection cannot interrupt treatment. In one embodiment, the connectivity agent is not turned on until the renal therapy machine is finished disinfecting itself. During treatment, the renal therapy machine generates log files that document events that occur during treatment. The connectivity agent sends the log files to a connectivity server after treatment is completed, or alternatively after disinfection. In one embodiment, before each treatment and before the connectivity agent is turned off, the renal therapy machine checks whether the connectivity server has any updates or modifications to the renal therapy machine settings.
In one embodiment, the system includes a method for upgrading firmware on a renal therapy machine. When upgraded firmware is generated, a director, e.g., a service director, may need to approve the upgraded firmware. The director may for example decide that renal therapy machines in only certain regions should receive the upgraded firmware. Authority is given by the director to local service personnel. The service personnel work closely with their patients and their associated renal therapy machines and are allowed leeway for when to actually upgrade the firmware on the service person's approved renal therapy machines. In one embodiment, the system includes a method for securely adding users and submitting new device programs. When certain changes are made to settings within the system, the system may require additional authentication information from the user. Or, the system may require another user to agree with certain changes before the changes are implemented.
The present systems and methods also manage and keep track of consumables at a patient's home. In one embodiment, a large number of patient prescriptions for a given patient can be supported. The duration of use of the machine and components thereof are also tracked. Machine performance is also tracked. When a machine component expires or shows signs of disrepair, a local service person assigned to monitor the particular machine notices same and schedules a service call.
The present systems and methods store large amounts of treatment and associated data. In one embodiment, sensitive patient data is stored in a Health Insurance Portability and Accountability Act (“HIPAA”) compliant database, billing and ordering information is stored in a billing and ordering database, and customer management information is stored in a customer relationship database.
While dialysis, such as hemodialysis, is one type of therapy that can be implemented at home via the systems and method of the present disclosure, other blood therapies, such as hemofiltration, hemodiafiltration, continuous renal replacement therapy (“CRRT”) may alternatively or additionally be implemented at the patient's home. Other dialysis treatments, such as peritoneal dialysis, may alternatively or additionally be implemented at the patient's home. Other home-related therapies, such as nutritional supplementing or medical delivery of a drug via one or more infusion pump may alternatively or additionally be implemented. With any of these therapies, it is contemplated to train the patient initially using the system and method of the present disclosure at a training facility or a hospital.
Based on the foregoing and following description, it should be appreciated that it is an advantage of the present disclosure to provide a high level of supervision and reporting for home renal therapy.
It is another advantage of the present disclosure to provide an efficient and timely inventory management system for home renal therapy consumables.
It is a further advantage of the present disclosure to provide a reliable maintenance and service infrastructure.
It is yet another advantage of the present disclosure to provide clinicians, doctors and nurses the ability to remotely review and monitor treatment data and to modify and update settings of the renal therapy machines.
It is yet a further advantage of the present disclosure to provide easy to use and secure user interfaces for specifying supplies and for specifying settings of the renal therapy machines via the development and remote transfer of one or more therapy prescriptions for the patient.
It is yet another advantage of the present disclosure to provide training to familiarize patients with the renal therapy and to allow patients flexibility in administering the treatment at home.
It is yet another advantage of the present disclosure to conveniently provide and transfer customized software for a user interface of the renal therapy machine.
It is a further advantage of the present disclosure to provide a reliable verification technique for verifying that correct types and amounts of consumables are used at home with the renal therapy machines.
Moreover, it is an advantage of the present disclosure to provide multiple home medical devices all working cohesively to reliably recreate the in-clinic dialysis experience in the convenience of a patient's home.
Additional features and advantages are described herein and will be apparent from the following Detailed Description and the figures.
Referring now to the drawings and in particular to
The renal therapy machine 100 is in general the nexus or hub between the components at the patient's home and can communicate with devices 104, 106, 108 and 122. The scale 106, blood pressure monitor 104, tablet 122, and water treatment device 108 communicate in one embodiment only with renal therapy machine 100. Any of components 104, 106, 108 and 122 may communicate wirelessly with renal therapy machine 100 or be in wired communication with same. Wireless communication may be via Bluetooth™ or WiFi™ wireless communication technology. Alternatively, any of components 104, 106, 108 and 122 can communicate with renal therapy machine 100 via wired communication.
The blood pressure monitor 104 may be provided with a blood pressure module that plugs into the renal therapy machine 100. For example, the blood pressure module of monitor 104 may include a printed circuit board controller that plugs into a controller bus of machine 100. The module of monitor 104 communicates thereafter via data bus communication with a primary control processor (“ACPU”) 112. The blood pressure module of monitor 104 is connected pneumatically to a blood pressure cuff that extends outside of machine 100. The patient then presses a button on user interface 122, e.g., a wireless tablet user interface, to pressurize the cuff. The cuff may be pressurized via pneumatics located within therapy machine 100. Or, the module of monitor 104 may be provided with its own small pneumatic air pump that inflates the cuff. The patient's blood pressure is logged by ACPU 112 and may be read out to the patient on one or both of the cuff of monitor 104 or user interface 122. One suitable module for blood pressure monitor 104 is provided by Microlife, model 3AC1-PC, which is embedded into renal therapy machine so only the tube and the cuff of blood pressure monitor 104 are visible to a patient. Again, monitor and cuff 104 may be wireless alternatively.
The patient weighs himself or herself via scale 106. The weight is then sent to ACPU 112, e.g., via wired or wireless communication. ACPU 112 uses the weight in one embodiment to calculate how much ultrafiltration or ultrafiltrate (“UF”) is removed from the patient. One suitable wireless weight scale 106 is provided by LifeSource (A&D)®, model UC-321PBT. In a further alternative embodiment, the patient weighs himself or herself and enters that value into system 110, e.g., via tablet user interface 122.
The water treatment device 108 connects to the renal therapy machine 100 through an Ethernet cable in one embodiment. The water treatment device 108 is normally powered. The renal therapy machine 100 can request water as needed from water treatment device 108. Water treatment device 108 is configured to supply, on an online basis, any amount of water that machine 100 needs. Renal therapy machine 100 controls and receives data from the water treatment device 108. In one embodiment, the tablet 122 does not control water treatment device 108. Instead, water treatment device 108 is a slave to the programmed ACPU 112. The water treatment device 108 can inform the renal therapy machine 100 of its status, such as an alarm situation, and send any other pertinent data to ACPU 112. Renal therapy machine 100 stores and acts upon the data, e.g., decides whether to raise an alarm. Water treatment device 108 in an embodiment include a small user interface and display.
In one embodiment, the renal therapy machine 100 performs hemodialysis on a patient at the patient's home and then reports the results of that treatment to clinicians, doctors and nurses who are responsible for managing the health and well-being of that patient. To generate reports, renal therapy machine 100 can use a Linux™ operating system operated by ACPU 112. Renal therapy machine 100 writes log files using the operating system. The log files document pertinent parameters and activities of the renal therapy machine 100 and the patient over the course of treatment. The log files may be any one or more of Extensible Markup Language (“XML”), comma-separated values (“CSV”) or text files. The log files are placed into a file server box of the software of renal therapy machine 100. The treatment may take several hours and have many steps and sub-steps, each yielding logged data. As illustrated in
In one embodiment, ACPU 112 and user interface 122 of renal therapy machine 100 walk the patient through the entire treatment process and instruct the patient on a step-by-step basis to perform the treatment. The user interface screens are standardized but are populated with data that machine 100 receives from clinicians (as described in detail below). The instructions are according to a doctor's prescription and provide parameters by which machine 100 operates, such as the blood flowrate, dialysate flowrate and ultrafiltrate volume. Renal therapy machine 100 performs a treatment and records that the treatment has been performed according to the parameters. Errors, alerts, alarm conditions and whether or not treatment steps have been successfully performed are recorded. The renal therapy machine 100 records this information by creating the log files that document each treatment.
The treatment may occur over several hours. After the treatment, the renal therapy machine 100 instructs the patient to disconnect from the machine. The renal therapy machine 100 then enters into a disinfection mode and prepares itself for the next treatment, which may take place the next day or a few days later. The water treatment device 108, which provides water to the renal therapy machine 100 as needed, also records and maintains its own log files that document the actions taken by the water treatment device 108 and any alarm or alert events that occur over a treatment. The water treatment device 108 in one embodiment does not write directly to the log files of renal therapy machine 100 log files. Renal therapy machine 100 may however include some data or parameters sent from water treatment device 108 that machine 100 records in its own log files. For example, the renal therapy machine 100 may record how much water treatment device 108 has made and delivered to machine 100 and add that information to the machine's own log files. Data stored on water treatment device 108 that is not sent to machine 100 may otherwise be obtained via the Ethernet data connection to water treatment device 108. For example, a service person can access the additional data via a laptop connection to water treatment device 108 via the Ethernet connection.
In one embodiment, the user interface 122 is a tablet that runs a custom, secure interface that only allows access to the renal therapy machine 100. In one implementation, tablet 122 operates wirelessly. Tablet 122 here can plug into the renal therapy machine 100 initially for pairing the tablet 122 with the renal therapy machine 100 and for performing software (e.g., firmware) upgrades. Tablet 122 may also plug into the renal therapy machine 100 to power or charge the tablet 122. Connectivity between tablet 122 and renal therapy machine 100 may be via a serial data connection, over a universal serial bus (“USB”) connection, parallel connection or via another suitable data transfer interface. Once the tablet 122 is paired to the renal therapy machine 100, the tablet 122 communicates wirelessly (e.g., using Bluetooth™ or WiFi™) with the renal therapy machine 100.
In one embodiment, renal therapy machine 100 is Bluetooth™ or WiFi™ enabled via an associated chip located with the other electronics of machine 100, e.g., with ACPU 112 discussed below. If it is found however that having a Bluetooth™ or WiFi™ chip on a renal therapy machine 100 circuit board (inside the renal therapy machine 100) causes electromagnetic interference with the circuit board, tablet 122 may alternatively use a Bluetooth™ dongle, WiFi™ dongle or other like device that plugs removably into the renal therapy machine 100, e.g., over a USB connection, which adds Bluetooth™ functionality, for example, to a non-Bluetooth™ device.
In one embodiment, tablet 122 serves as a user interface to the renal therapy machine 100 in the sense that the user can send data to and receive data from machine 100 via tablet 122. Data entered into the user interface is securely sent to the renal therapy machine 100 and processed in ACPU 112, which actually controls the machine. In one embodiment, all treatment data is stored in the renal therapy machine 100, not the tablet 122. Storing no treatment data in the tablet 122 is advantageous because if the tablet 122 is disconnected or lost no sensitive or important data is lost.
While user interface 122 is described below as a wireless user interface, mainly, user interface can alternatively be tethered to machine 100, for example, as shown and described in U.S. Patent Publication No. 2009/0114582, the entire contents of which are incorporated herein by reference and relied upon. Unless otherwise stated, however, the functional relationship between user interface 122 and machine 100 remains the same.
In one embodiment, tablet 122 runs a customized version of the Android™ operating system. The standard Android™ operating system displays a toolbar that always remains on the screen, even when applications are running on a tablet 122. The toolbar can pose a security risk for home medical device system 110 because the toolbar may allow other applications on tablet 122 to access the renal therapy machine 100. The toolbar may also allow the user to access other applications when the user interface of system 110 should be displayed. The customized tablet operating system in one embodiment removes all functionality of the Android™ operating system, including the toolbar, and only allows the use of the system application, which provides the user interface to the renal therapy machine 100. The tablet 122 in one embodiment can only communicate with the renal therapy machine 100. Tablet 122 accordingly does not need its own Internet connection.
Renal therapy machine 100 in one embodiment accesses the Internet using a separate 3G modem 102 provided as part of the home medical device system 110. The 3G modem 102 may use an Internet Service Provider (“ISP”), such as Vodafone™. In one embodiment, because the patient can potentially connect other personal devices, e.g., laptop or mobile phone, to the 3G modem 102, system 110 monitors the usage on the 3G modem 102 to ensure that only the renal therapy machine 100 uses 3G modem 102. Clinics associated with a particular patient may receive periodic reports containing usage information from a provider of the 3G modem 102. Clinicians can review the reports to determine if a particular 3G modem 102 is accessing the Internet more often than generally needed to connect renal therapy machine 100 to the connectivity server 118. The system 110 may send a signal to clinics notifying clinics that a 3G modem 102's Internet usage exceeds a predetermined amount. In an alternative embodiment, system 110 places software restrictions on the 3G modem 102 so that no device other than renal therapy machine 100 can use the 3G modem 102 to connect to the Internet. That is, a patient may be able to physically connect personal devices to the 3G modem 102, but software running on the 3G modem 102 is configured to only provide Internet connectivity to the renal therapy machine 100. Alternatively, the 3G modem 102 may be hardwired directly to the renal therapy machine 100 and no other device can physically connect to the 3G modem 102. In this embodiment, the renal therapy machine 100 and 3G modem 102 are permanently attached. The system 110 sends a signal to the associated clinic if a patient tampers with the 3G modem 102 by removing the hardwired connection to renal therapy machine 100 or trying to connect a personal device to the 3G modem 102.
It should be understood that even though modem 102 is described as being a 3G modem, the modem 102 may use other available networking technologies and protocols, such as 4G and technologies developed in the future. In one embodiment, a dedicated line is provided at each patient's home for connecting the renal therapy machine 100 to the connectivity server 118 via modem 102.
Renal therapy machine 100 in one embodiment, via the Internet, uses a connectivity service to transfer data between modem 102 and a system hub 120. There are various ways in which it is contemplated to implement the connectivity service. In one implementation, software is stored on ACPU 112 that accesses the software libraries needed to use the connectivity service. In another implementation a connectivity agent 114 developed by the connectivity service provider is installed onto the renal therapy machine 100 and run on ACPU 112. An example connectivity service provider is Axeda™. While this application is discussed primarily with connectivity agent 114, the functionality attributed to it herein is also applicable to the customized connectivity service alternative. The connectivity service provides a secure managed connection 116 between medical devices and the connectivity server 118. The connectivity service in one embodiment also maintains information about all of the renal therapy machines 100 connected to server 118 and system 110.
The connectivity agent 114 allows the renal therapy machine 100 to connect to connectivity server 118 and transfer data to and from the connectivity server 118. The connectivity service operating via agent 114 and server 118 ensures that the connection with machine 100 is secure, ensures that the data correctly passes through its firewalls, checks whether there has been a data or system crash and checks whether and ensures that the connectivity server 118 is communicating with the correct renal therapy machine 100. The renal therapy machine 100 creates the log files and provides the log files to the connectivity agent 114. The renal therapy machine 100 works with the connectivity agent 114 to transport the log files to the connectivity server 118. To send data to the connectivity server 118, the renal therapy machine 100 allows the connectivity service to run remote scripts on the renal therapy machine 100.
In one embodiment, renal therapy machine 100 can only connect to the connectivity server 118 when the connectivity agent 114 is turned on. During treatment and post-treatment disinfection, while machine 100 is functioning, connectivity agent 114 is turned off. This prevents the renal therapy machine 100 from communicating with any entity and sending or receiving data during treatment and disinfection or when machine 100 is live or running. In an alternative embodiment, the connectivity agent 114 is turned on after treatment but before post-treatment disinfection. The 3G modem 102 may or may not remain on or activated at these machine live times, but connectivity agent 114 is off. Renal therapy machine 100, however, compiles the data it has collected during treatment, encrypts that data into log files and then places the log files in a directory on the renal therapy machine 100. In one embodiment, when the renal therapy machine 100 is idle, e.g., after treatment is complete, the ACPU 112 turns connectivity agent 114 on. Connectivity agent 114 then retrieves the log files from the renal therapy machine 100 and transfers data to the connectivity server 118 using the connectivity service. The connectivity service routes data packets to their proper destination but in one embodiment does not modify, access, or encrypt the data. Indeed, the data may be sensitive patient-related data that should only be manipulated or “looked at” by authorized users.
In system 110 of
In one embodiment, the renal therapy machine 100 may be operated in a service mode for service personnel to access, diagnose and troubleshoot the renal therapy machine 100 on site and/or remotely. For example, if a patient using a renal therapy machine 100 encounters a problem, the patient may be able to call a service personnel or technician. The patient and/or service person may then be able to place the renal therapy machine 100 into a service mode that allows the service technician to remotely verify machine settings and functionality for various components of renal therapy machine 100. For example, the service person may be able to logon onto machine 100 while treatment is paused. Alternatively, machine 100 must be in an idle state, or even powered down, for the service person to be able to access the machine. Further alternatively, the machine 100 need only be disconnected from the patient for the service person to be able to access the machine. Once accessed, the service technician may be able to remotely investigate and retrieve the log files stored on the renal therapy machine 100 to determine the cause of the error. The service person may also be able to toggle valves and run a heater, for example, to see if a related sensor, e.g., pressure, conductivity or temperature sensor is operating properly and/or if the valve or heater (for example) is operating properly.
The connectivity server 118 communicates with much of home medical device system 110 via a home medical device system hub 120. System hub 120 enables data and information concerning each renal therapy machine 100 on system 110 to travel back and forth via the connectivity service between the machines 100 and the clients connected to server 118. In the illustrated embodiment, system hub 120 is connected to an enterprise resource planning system 140, a service portal 130, a web portal 150, a business intelligence portal 160, a HIPAA compliant database 124, a product development team 128 and electronic medical records databases 126a to 126n. Web portal 150 in turn enables patients and clinics 152a to 152n treating the patients to access a publicly available website for system 110. Thus while machine 100 and associated instructions and data are kept in a protected and regulated environment, the patient and patient's clinic are free to access the website. The patient may do so using the patient's own computer but not using tablet 122 or machine 100 in one embodiment. System 110 may require that the patient or clinic enter a username and password to access a patient or clinician's account on the website at portal 150. In this manner, the public is restricted from patient-specific data that the patient can receive. Clinician data is restricted to that clinic.
The enterprise resource planning system 140 obtains and compiles data generated by patient and clinician website access, such as complaints, billing information and life cycle management information. Data sent from the system hub 120 or portal 150 to the enterprise resource planning system 140 may be de-identified data, meaning the patient cannot be identified from the sent data. For example, data about complaints will not be associated with a patient. Data sent to marketing 162, research and development 164 and product development 128 may also be de-identified. Other data can be patient specific. For example, billing data over hub 120 will be associated with a patient. Or, quality/pharmacovigilance 166 data may also be associated with a patient. The enterprise resource planning system 140 is connected in the illustrated embodiment to a billing and ordering database 142. Billing and ordering database 142 contains a doctor's electronic signature authorizing certain supplies for carrying out patient prescriptions. The enterprise resource planning system 140 is also connected in the illustrated embodiment to a customer relationship management (“CRM”) database 144 storing information about enterprise resource planning system 140.
The electronic medical records (“EMR”) databases 126a to 126n contain electronic information about patients. The system hub 120 can send the data collected from the log files of machine 100 to hospital or clinic databases 126a to 126n to merge or supplement that patient's medical records. Databases 126a to 126n contain patient-specific treatment and prescription data and therefore access to such databases is highly restricted.
As discussed, web portal 150 is a portal for clinicians and patients to access the website and system hub 120. Clinicians can use the web portal 150 to update one or more device programs for the renal therapy machines 100. The system hub 120 scans through the renal therapy machine 100 log files to display the treatment data to a clinician through the web portal 150. Clinicians can access the web portal 150 from anywhere they can access the Internet, including their homes. A password is required in one embodiment. A clinician will see various web portal 150 administrative screens to set up an account. In one embodiment, the web portal 150 also connects to the enterprise resource planning system 140. Clinicians may also use the web portal 150 to send questionnaires or alerts to a patient. For example, a clinician may send a questionnaire to a patient asking the patient about a recent therapy. The questions may be multiple choice questions or Yes/No questions that can be easily and quickly answered by the patient. The clinician may also use web portal 150 to send reminders or alerts about an upcoming doctor's visit or the status of a shipment of supplies.
Business intelligence portal 160 collects data from the system hub 120 and provides data to marketing 162, research and development 164, and quality/pharmacovigilance 166. In one embodiment, the system hub 120 de-identifies data by removing any patient-specific information and sends de-identified data periodically, e.g., once a day, to the business intelligence portal 160. Marketing 162, research and development 164, and quality/pharmacovigilance 166 can analyze the de-identified data and provide reporting information about treatment data.
A block diagram of the electrical systems of any of the devices or subsystems of the home medical device system (e.g., machine 100, modem 102, blood pressure monitor 104, scale 106, water treatment device 108, server 118, system hub 120, user interface 122, service portal 130, enterprise resource planning system 140, web portal 150, business intelligence portal 160) is illustrated in
The interface circuit 180 may be implemented using any suitable interface standard, such as an Ethernet interface and/or a Universal Serial Bus (“USB”) interface. One or more input devices 194 may be connected to the interface circuit 180 for entering data and commands into the main unit 170. For example, the input device 194 may be a keyboard, mouse, touch screen, track pad, track ball, isopoint, and/or a voice recognition system. The interface circuit 180 may be connected to any type of network 182, such as an Internet, a local area network (“LAN”), a telephone network (“POTS”), and/or other networks.
One or more displays, printers, speakers, and/or other output devices 192 may also be connected to the main unit 170 via the interface circuit 180. The display 192 may be a cathode ray tube (“CRTs”), liquid crystal displays (“LCDs”), or any other type of display. The display 192 generates visual displays of data generated during operation of the device or subsystem 100, 102, 104, 106, 108, 118, 120, 122, 130, 150, 140, 160. For example, the display 192 may be used to display information received from the system hub 120. The visual displays may include prompts for human input, run time statistics, calculated values, data, etc.
One or more storage devices 190 may also be connected to the main unit 170 via the interface circuit 180. For example, a hard drive, CD drive, DVD drive, and/or other storage devices may be connected to the main unit 170. The storage devices 190 may store any type of suitable data.
Referring now to
As shown at block 204, the patient is then set up as an account on system hub 120. As described in further detail below, a clinician, e.g., a nurse, may generate a unique patient identifier (“ID”) using the web portal 150. In particular, the billing and ordering database 142 receives new patient information from the clinician and generates the unique patient ID, which identifies that patient thereafter across the entire home medical device system 110. The unique patient ID identifies that patient to all clients and subsystems that are involved in providing and supporting the home medical device system 110.
In one embodiment, a patient receives four to eight weeks of training in the clinical setting with a training machine 100 before being allowed to perform home hemodialysis. Once the patient is properly trained, a second renal therapy machine 100 is sent to the patient's home as shown at block 206. This second renal therapy machine 100 will be a personal machine intended only for that patient. The personal renal therapy machine 100 is not linked on system 110 to the patient when it is shipped to the patient's home.
At the patient's home, the patient enters the unique patient ID generated at block 204 into the personal renal therapy machine 100 as shown at block 208. In one embodiment, a second patient identifier, e.g., a birth date or other information particular to the patient, is also entered into the renal therapy machine 100 as shown at block 208. Entering the patient's unique ID and/or second patient identifier can be performed via tablet 122 and links the home renal therapy machine 100 to that patient. Based upon this entered ID and/or second patient identifier, the home renal therapy machine 100 retrieves a patient prescription prescribed previously by a doctor and/or clinician and any other information needed to run a treatment from system hub 120, as shown at block 210.
The home renal therapy machine 100 displays patient information to the patient to verify that the correct patient prescription has been retrieved, as shown at block 212. For example, the home renal therapy machine 100 may display the patient's name. The home renal therapy machine 100 prompts the patient to confirm whether the patient information is correct, as shown at block 214. If the patient information is not correct, the home renal therapy machine may display an error message and prompt the patient to call his or her clinic, as shown at block 216. If the patient information is confirmed as being correct, the home renal machine settings are set initially based upon retrieving patient prescription as shown at block 218. The home renal therapy machine 100 now has the information needed to run a treatment that is prescribed specifically for the patient and his/her associated machine 100. Process 200 is then completed as indicated at the end oval.
In one embodiment, renal therapy machine 100 does not identify or verify the patient each time a patient uses the renal therapy machine 100 because machine 100 is used only by one patient in his or her own home. Renal therapy machine 100 may however display a message such as, “Hello, Bill Smith” each time renal therapy machine 100 is turned on and/or prompted for treatment. In the unlikely event that the wrong person attempts to use a renal therapy machine 100, the welcome message serves as a reminder or warning that the renal therapy machine 100 is only intended for one specific patient, e.g., Bill Smith.
Medical products and drugs are shipped or delivered to a patient's home for the renal therapy machine 100 to use during treatment. Only therapy products or drugs approved under a doctor's prescription can be shipped to the patient's home. In the U.S., prescriptions last one year. One or more prescription is stored for each patient in the system hub 120. Each renal therapy machine 100 uses supplies and settings according to the prescription. If the patient's prescription changes or if a prescription is added, the patient's clinician uses web portal 150 to update the renal therapy machine 100 settings to change or add the prescription. If the renal therapy machine 100 settings are updated, the system hub 120 sends the updated settings to the renal therapy machine 100 via the connectivity service as discussed previously.
Referring now to
To remotely program the renal therapy machine 100, the clinician selects the dialyzer model, treatment type and duration as shown at block 308. The clinician also sets various treatment parameters used to program the renal therapy machine 100 as shown at block 310, such as blood flowrate, dialysate flowrate, UF volume and heparin flowrate flush. The clinician also specifies allowed ranges for the various settings as shown at block 312. That is, the patient may be allowed to pick within a range of values for certain parameters under the specified device program. In this manner, the patient has a certain amount of control over the treatment that is performed. Dialysate temperature, for example, may be set within a range of allowable values based upon patient preference and comfort. The clinician further specifies whether or not the patient will have the ability to modify the settings at all as shown at block 314. If the patient is allowed to modify parameter settings, the setting variability is within an allowed range, such that the patient picks a value inside the range specified by the clinician at block 312. The clinician settings and parameter ranges are discussed in further detail with reference to
Before treatment begins, e.g., after disinfection the day before, ACPU 112 of renal therapy machine 100 checks whether the connectivity service via agent 114 has posted an updated prescription for that particular renal therapy machine 100. To do so, in one embodiment, the renal therapy machine 100 and the system hub 120, through the connectivity service, compare prescription version numbers to determine whether renal therapy machine 100 has the most updated prescription. If not, the most recent prescription version is delivered to therapy machine 100.
Referring now to
Machine 100 prompts the patient to accept the new device program. In one embodiment, the patient must accept the new device program to continue using the renal therapy machine 100. In one embodiment, machine 100 will not run an old device program if a new device program is present on machine 100. However, the new device program will not overwrite the old device program until the patient accepts the new or updated device program as shown at block 412. In this manner, the patient confirms that the patient knows that his or her treatment has changed. Upon accepting the new device program, the new device program is written into the memory of therapy machine 100. In an alternative embodiment, machine 100 can store multiple device programs in memory so even when a new device program is downloaded, the old device program is kept in memory. Machine 100 may be able to store different types or categories of device programs. Each different type of device program may provide a different treatment, e.g., to remove a low amount, medium amount, or large amount of ultrafiltration for dialysis. The machine 100 may be able to store one device program in each category.
The next time the patient is about to perform treatment, the connectivity agent 114 is turned off as shown at block 414. The renal therapy machine 100 as shown at block 416 now runs a treatment using the updated device program specified at block 402. Renal therapy machine 100 writes treatment data produced by the new treatment to the log files as shown at block 418. Connectivity agent 114 is turned on as shown at block 420. In one embodiment, the renal therapy machine 100 initiates the connection to the connectivity service. In an alternative embodiment, the connectivity service may initiate the connection to the renal therapy machine 100. At block 422, the log files are uploaded to connectivity server 118. Process 400 then ends as illustrated at the end oval.
Machine 100 can perform post treatment procedures, such as a disinfection procedure that cleans the machine and the disposables used for treatment for the next treatment. In one embodiment, system 110 allows the connectivity agent to be turned on at block 420 after treatment but while post-treatment disinfection is taken place. Writing treatment data at block 418 can also be done during disinfection. Alternatively, the renal therapy machine 100 waits to write data at block 418 or turn on the connectivity agent at block 420 until disinfection is completed and the machine 100 enters an idle mode.
In the illustrated embodiment, because the connectivity agent 114 turns off before treatment and does not turn on again until after treatment, system 110 provides no real-time monitoring of a treatment. Events that occur during a treatment, including alarms and alerts, are not reported to the system hub 120 immediately. Such information is part of the log files that are sent to the system hub 120 after treatment.
In an alternative embodiment, the connectivity agent 114 may remain on during treatment and may report information about the renal therapy machine 100 and the treatment in real-time. For example, in one embodiment, system 110 may allow a clinician to remotely and simultaneously view screens being viewed by the patient on user interface 122.
From time to time, the software that ACPU 112 runs on renal therapy machine 100, which may also be referred to herein as firmware, may need to be upgraded. The home medical device system 110 provides a seamless and reliable manner for upgrading firmware that integrates the product development team 128 and service personnel 132a to 132n.
As discussed above, service personnel 132a to 132n manage the day-to-day relationship with the patients. Service personnel 132a to 132n are familiar with patient schedules and are in the best position to determine when a patient should receive the firmware upgrade. For example, service personnel 132a to 132n will know the maintenance and activity schedule for the renal therapy machines 100 they normally service. If the patient's machine 100 is scheduled to soon receive a part needed for the firmware upgrade, then the service personnel 132a to 132n can wait until the new part is installed before upgrading the firmware (needing the new part) on the patient's renal therapy machine 100.
Each service personnel 132a to 132n selects which of its designated renal therapy machines 100 should receive the firmware upgrade as shown at block 510. The next time connectivity agents 114 on the selected renal therapy machines 100 are turned on, as shown at block 512, connectivity server 118, waiting for the agents to be turned on, sends the upgrade to the selected renal therapy machines 100 as shown at block 514.
In one embodiment, the selected renal therapy machines 100 may decide whether or not to accept the upgrade, as shown at block 516. If the selected renal therapy machines 100 do not accept the upgrade, process 500 ends as shown at block 516 and the end oval. If any of the selected renal therapy machines 100 accept the upgrade, the corresponding patients are prompted as to whether they would like to install the upgrade, as shown at block 518. If the patients using the selected renal therapy machines 100 do not choose to upgrade, the process 500 ends as shown at block 520 and the end oval. If the patients using the selected renal therapy machines 100 choose to upgrade, the upgrade is performed and the renal therapy machines 100 inform the patients that the software has been upgraded as shown at block 522. Some countries require by law that patient approval must be obtained before upgrading a patient's firmware. In one embodiment, system 110 may require that only renal therapy machines 100 in countries that require patient approval prompt patients to accept the firmware upgrade at blocks 518 and 520.
Renal therapy machines 100 may be allowed to retain the ability to revert back to a previous software version. For example, if a firmware upgrade is corrupt, or if the firmware on a renal therapy machine 100 becomes corrupt, renal therapy machine 100 in an embodiment is allowed to revert back to a previous, non-corrupt software version. Alternatively, renal therapy machine 100 cannot revert back to a previous software version. Here, if the software is or becomes corrupted, new software is installed or renal therapy machine 100 is swapped with a new renal therapy machine 100.
The connectivity service at server 118 documents all events related to firmware upgrades, such as which patients have received upgrades, and which service personnel 132a to 132n have been involved in the upgrades. The connectivity server 118 stores serial numbers, tracking numbers and software versions so the various steps in the upgrade process are documented and so that at any given moment the current software version of each machine 100 on system 110 can be readily obtained. At the end oval in
A clinician can view a list of the clinician's patients and a file for each patient showing how treatments for the patients have transpired. The treatment files are derived from the log files in the renal therapy machine 100, including flowrates achieved, ultrafiltrate removal, ultrafiltration rates achieved, blood pressure over the course of therapy, weight, etc. A clinician can sort the list of patients by numerous categories, including the type of treatment they have received, e.g., hemodialysis (sub-categorized as for example short daily, nocturnal, every other day, and every other night), peritoneal dialysis (sub-categorized as continuous cycling peritoneal dialysis (“CCPD”), tidal, for example), the supervising doctor, or by the notifications described below. A clinician can also view a patient snapshot and an overview for the week, month or other duration.
Web portal 150 provides a clinician dashboard having notifications about events that occurred during treatment. In one embodiment, the notifications include colored flags, with different colors corresponding to different notification conditions. The clinicians can choose which events generate the red or yellow flags that appear on the dashboard. In one embodiment, the flag settings are clinic-specific, not patient-specific. Thus, choosing to be notified about certain events applies to all patients in the clinic or under the clinician's case. For example, a clinician may set a rule that a yellow flag should appear on the dashboard if a treatment lasted less than four hours. This rule would then apply to all patients at that clinic or under that clinician's care. The dashboard will indicate, e.g., with yellow flags, any patients who have undergone a treatment that lasted less than four hours.
Alternatively or additionally, there can be notifications that are patient-specific. For example, the clinician may set for patient A that a yellow flag should appear on the dashboard if a treatment lasted less than four hours. The dashboard will then only apply this rule for patient A and only generate a yellow flag if a treatment for patient A lasts less than four hours. Here, the clinician can set flags for each patient individually. The dashboard may show multiple yellow flags even in this individualized embodiment, however, the flag may not be applied to all patients of the clinic or under the clinician's care.
There may also be an indicator indicating whether the same or different clinician has already reviewed certain one or more notifications for a particular treatment. For example, if a clinician reviewing the dashboard sees a flag for a treatment and an indicator next to that flag, the clinician knows that he or she or another clinician has already reviewed that treatment flag and its corresponding cause.
The notifications are evaluated based upon rules or settings set by a clinician. If the rules or settings are changed, the flags are re-evaluated. The dashboard reflects the most current updated notification rules. For example, if a clinician previously set a notification rule that he should be notified if an alarm went off three times during treatment, but then changes that rule to be notified if an alarm went off only two times, the flags are re-evaluated upon the change. Thus here, flags may appear (indicating only two alarms) that did not appear before (when three alarms were needed). The dashboard is updated based upon the updated rule. Web portal 150 enables each clinician and each clinic to tailor the flagging of treatment conditions to meet specific needs.
In one embodiment, the system 110 provides security features by requiring verification information before certain changes can be implemented. In one example, system 110 requires that a user, already authenticated and logged into web portal 150, must enter his or her password into web portal 150 again after making a certain change before the change is actually implemented. Here, the security feature includes a second user authentication. Or, system 110 may require that a change is only implemented in the system if that change is approved by a second user. Here, the security feature is an approval entered by an authorized approver.
Referring now to
The created clinic user can then log into system 110 and is authenticated as shown at block 706 by entering verification information established at user setup block 704. The clinic user can then create and/or update a device or treatment program as shown at block 708. The clinic user submits the created or updated device program, confirming the submission with secondary authentication, as shown at block 710.
In one embodiment, system hub 120 encrypts the created or updated device program before the device program is sent to a renal therapy machine 100. The renal therapy machine 100 downloads the encrypted device program from system hub 120 via connectivity server 118 and verifies patient identification, e.g., patient date of birth, and/or program settings as shown at block 712. Renal therapy machine 100 may verify the information by matching data tagged to the device program with like data stored in the memory of renal therapy machine 100. The patient then confirms or accepts the device program settings as shown at block 714. The process then ends as shown by the end oval for security and setup process 700.
In one embodiment, system 110 may implement various rules to enhance security. For example, system hub 120 and/or connectivity server 118 may keep a record of internet protocol (“IP”) addresses of all renal therapy machines 100 linked to system 110. If a renal therapy machine 100 is located at a different IP address than the IP address normally associated with that renal therapy machine 100, system 110 may require a second user, e.g., a second approver, to approve the submittal of a new device or treatment program to renal therapy machine 100.
Other events may also require approval from secondary sources. For example, if a clinic administrator tries to create a clinic user with a device management role (
System 110 may also monitor and track the total number of changes being made to the different device programs and settings for the various renal therapy machines. System 110 may expect a certain number of changes in a given timeframe. If the number of changes to device program settings exceeds the expected number of changes by a threshold amount, system 110 may conclude that a security breach has occurred and shut itself down. The expected number may be set for a particular clinic, for the patients within the clinic, or for both.
Clinicians and patients can access information about the home medical device system 110 via the web portal 150, which links to the rest of system 110 via system hub 120.
Clinicians also use the web portal 150 for information about the home medical device system 110. Clinicians generally have access to more information than do individual patients. In one embodiment, a clinician can view information about each of his or her patients through web portal 150. In one embodiment, the web portal 150 is “clinic-centric,” meaning clinicians that belong to one clinic cannot see information about patients or clinicians from other clinics. Nurses and clinicians may be associated with clinics and thus can view all patients for a given clinic. Doctors, however, may be associated with patients, not clinics, and thus system 110 may not allow a doctor to see all the patients associated with a clinic. A web portal administrator, usually a clinician or nurse for a particular clinic, specifies which patients a doctor can see.
Once logged in, the clinician can view a dashboard 916, which allows for patient-specific reports to be viewed. The patient-specific reports are shown on a treatment summary screen 918 and a patient snapshot screen 920. From the dashboard, system 110 also allows the clinician to set treatment parameters at patient management screens 922. The patient management screens 922 include screens for administrative tasks related to the patient such as obtaining patient information, searching for patients, and deactivating users. The patient management screens 922 include a physician therapy approval screen (not included in the figures), therapy prescription screen (
Therapy prescription screen 1000 allows the clinician to select the products and supplies that are to be delivered to a patient for treatment. The clinician enters into screen 100 the number of treatments per week 1004, whether the prescription expires 1006 and the duration of the treatment 1008. Screen 1000 also allows the clinician to run a search for products and accessories 1010, which then presents a list of the various products that the clinician searched for 1012. From the various products listed 1012, the clinician, according to the doctor's prescription, selects which products 1014 to send to the patient. The supplies selected at screen 1000 are then delivered to the patient's residence. Again, the therapy prescription screen 1000 is manipulated according to a doctor's prescription, which is stored in the billing and ordering database 142 linked to enterprise resource planning system 140. In other words, the clinician can only order products that conform or are in accordance with a doctor's prescription.
System 110 enables the clinician to apply a template at selection 1002. The templates are created for different kinds of prescriptions, so that selecting a specific prescription from the scroll-down menu at template selection 1002 specifies a list of products and amounts for the clinician without having to check off or select each individual field 1014. Selecting a template allows the clinician to choose from a preexisting set of products, thereby allowing the clinician to quickly place an order for an initial stock of supplies. The templates are extremely convenient because many patients use standard prescriptions needing the same supplies.
Various icons 1204, 1206 and 1208 indicate information about a treatment performed by that patient on a specific date. Icons 1204, 1206 and 1208 may indicate different types of events. For example, icon 1204 may be used to indicate that a treatment has been performed successfully. Icon 1206 may be used to notify the clinician about events that are not critical and do not need immediate action, but need to be closely monitored in the future. Icon 1208 for example may be used to notify the clinician of events that need immediate action.
A user is able to access a legend using link 1218. When a user selects link 1218, a popup window or new screen 1250 appears.
Referring again to
In one example embodiment, selecting a navigational tab such as tab 1220 displays more navigational options.
The clinician may also be able to filter specific treatment data, for example, using drop-down menu 1318. The clinician can specify which aspect of the treatment data to view in the patient snapshot screen 1300. In the illustrated embodiment, the clinician has selected patient volumes. The clinician can also filter information by selecting a time frame using drop-down menu 1320. In the illustrated embodiment, the clinician has selected to view treatment data over a timeframe of seven days. Selecting seven days using drop-down menu 1320 results in the calendar display 1322, which illustrates seven days of data for a specific patient. A link to a legend 1324 is again provided on patient snapshot screen 1300, which displays the same icons and explanations for the icons as described above in
From treatment summary screen 1400, a clinician can see a description of the flag symbols at chart 1401. The clinician can also see the date, start time and total dialysis time at chart 1402, the prescribed device program at chart 1404 and overall treatment summary log in table format showing exact times for various treatment events at chart 1406. The screen 1400, displayed on a clinician's display device 192, is continued on
A clinician may be able to change certain settings for renal therapy using a patient settings screen 1530 displayed on a clinician's display device 192 illustrated in
In the patient settings screen 1530 displayed on a clinician's display device 192 of
The system settings screen 1570 also allows the clinician to specify a clinician password 1584. The clinician password is required thereafter for any changes that are to be made to the renal therapy machine 100 from the patient's home. For example, if a patient at his or her home wishes to modify any of the settings for the renal therapy machine 100, the patient must either be given the clinician password 1584, or a clinician who knows the clinician password 1584 must be present at the patient's home to enter in the clinician password 1584 at the renal therapy machine 100. The clinician password thus provides a layer of security to ensure that only authorized users are able to change settings for a renal therapy machine 100 from the patient's home.
The system settings screen 1570 (for online hemodialysis for example) also allows a clinician to specify an acid configuration 1586 (e.g., whether the acid is in a jug), the water system filter pack configuration 1588, the water system reject valve setting 1590 and a home device setting 1592. Different therapies will have different system settings, e.g., dialysate dextrose level for peritoneal dialysis. In one embodiment, many of the screens and options available though web portal 150 are coded to match the screens and options that appear on the renal therapy machine 100. For example, a home device setting accessed through a renal therapy machine 100 allows a user to disable the renal therapy machine 100. Home device setting 1592, accessed through
As with the therapy prescription screen, the device program screens 16A to 16G also provide an option for the clinician to apply templates at scroll-down menu 1602. The templates are again convenient because templates allow the clinicians to enter preselected values for multiple parameters at once by selecting a template. For example, the clinician may have many patients that each require the same treatment duration, blood flowrate and heparin dose. The clinician may save the multi-use values under a template, giving the template a recognizable name. When the clinician wants to apply these settings to renal therapy machines 100 for multiple patients, the clinician can select a template instead of having to specify each field on device program screen 1600. Thus when creating or modifying a device program, the template pre-populates the fields with values. From there, the clinician can change the populated fields. If only a few fields are changed, the template has saved the clinician time and effort. The templates simplify settings for renal therapy, but the settings are nonetheless based upon a doctor's prescription. The templates can involve any one or more or all of the treatment device settings discussed below. The templates for the device program screens 16A to 16G are further described in
The device program screen 1600 contains various tabs such as a general tab 1604 (
Horizontal bar 1618 explains the various columns listed in each of the various tabs 1604 to 1616. The horizontal bar 1618 lists the same items on tabs 1604 to 1616 and indicates that a clinician can set values, set a patient settable range, and also specify whether those values are patient editable. Treatment features that are marked as not being patient editable in horizontal bar 1618 cannot be changed by a patient. For example, a clinician may be able to specify that a category or a portion thereof is not editable by a patient so that a patient would not be able to change any settings for those values. Or, the clinician can specify, using buttons 1619, that a patient may edit a certain value. In certain instances, the clinician may also allow a patient the flexibility to edit values within a range as described in further detail below. There can be certain items that a clinician has no control over, as indicated by the “Yes” and “No” 1617 that are hard coded into the system, with no ability for the clinician to change those values. Here, a clinician can only change the settings as far as the renal therapy machine 100 allows. Thus the renal therapy machine 100 may have machine limits or ranges that the clinician must stay within.
Device program screen 1600 displayed on a clinician's display device 192 in
At device program screen 1600, the clinician can specify the device program name at entry box 1620, the dialyzer model that the patient is using at drop-down menu 1622, the treatment or access type at drop- or scroll-down menu 1624 and the treatment duration at fields 1626, which have fields for both hours and minutes. Device program screen 1600 also allows a clinician to specify a setting range 1628.
It is advantageous to allow patients to tailor the renal treatment when appropriate to their schedules and moods but do so within an allowed range. For example, a patient may not be feeling well enough to run a long treatment, may have a prior commitment, or in any case may want to run a shorter treatment. Allowing clinicians to specify acceptable ranges and then letting patients choose the actual values run by machine 100 allows patients to have some control and autonomy over the treatment. Patient choice is important. In no case however, can a patient change a parameter setting outside of a range set by the clinician (per doctor's prescription), or change the range that the clinician has set. System 110 also forces the clinicians to stay within the machine limits described above. In other words, a clinician sets a specific value and a range. The range specified by the clinician is limited by the machine. The patient can then alter the value within the range specified by the clinician.
Pump pressure is the pressure by which the blood and dialysate pumps (for hemodialysis), dialysate pumps (for peritoneal dialysis, substitution pups (for hemofiltration and hemodiafiltration), drug pumps (for drug delivery, and so on, are operated. If the pumps are pneumatic pumps, for example, the pressure is set by setting the pump's pneumatic operating pressure.
The priming method can include whether or not the patient wishes to replace priming fluid in the blood set with dialysate before treatment is started. Target weight is the weight the patient wants to be at the end of treatment. Ultrafiltration is the amount of blood plasma or water that has to be removed from the patient over treatment for the patient to reach his or her target weight. UF rate is the rate at any given time during treatment that UF is being removed from the patient. Rinseback volume refers to the volume of fluid that is given at the end of the treatment as part of the process to return the patients blood. Fluid infusion volume to the volume of dialysate that can be given to the patient in response to a hypotensive event.
Loading dose hold time refers to the amount of time that the system waits after a heparin bolus is given to a patient prior to starting treatment. Heparin rate is the rate at which heparin is delivered to the blood circuit during treatment. Heparin time refers to the time before the end of treatment that heparin delivery is stopped to allow the patients blood to return to normal coagulation. Bottle volume sets how much heparin is available to be delivered over treatment.
At the temporary disconnect selection 1684, the clinician can decide whether the patient can get off of the machine during treatment. For example, the patient may have to use the bathroom or attend to some task during treatment. If temporary disconnect is allowed, the patient can pause treatment, disconnect from the blood needles, and attend to whatever needs attention. Blood in the blood tubes is typically rinsed back to the patient before the patient can get off of the machine. The clinician may not be comfortable yet with the patient rinsing back, disconnecting, and then reconnecting, and may therefore opt not to allow temporary disconnect at selection 1250.
Once all the fields have been filled, the clinician selects a Submit button 1686 in
In one embodiment, Submit button 1686 does not send the device program to therapy machine 100. Instead, the Submit button 1686 sends the new device program to the device programs listed at device settings screen 1500 (
The delete button 1688 allows a clinician to delete a specific device or treatment program. In one embodiment, the clinician must confirm that he or she would like to delete the program before the program is actually deleted or removed from the patient's arsenal of treatment or device programs. In one embodiment, the submit button 1686 and the delete button 1688 appear on each of tabs 1604 to 1616, so that the clinician can submit a program or delete a program from any one of tabs 1604 to 1616.
As discussed above, while machine 100 will not run a treatment until the new device program is approved by the patient, the patient still has to review and accept the new device program before it is finally download for operation via ACPU 112. Thus the patient can see if a new device program is questionable, e.g., if new settings depart radically from the old settings or if the patient is not comfortable with the new settings. The patient can contact the clinic and review the new device programs.
In one embodiment, once the settings are submitted and sent to the renal therapy machine 100, the settings can only be changed with a clinician password (
As discussed above, templates are provided for convenient entry of preselected values. The template values may be changed to refine the device program.
During a renal treatment, a large number of events take place, which machine 100 stores in its log files. Home medical device system 110 provides a proficient way to notify clinicians regarding pertinent treatment events and conditions. The clinicians can specify the events or conditions that are of most concern. When these events occur or when the conditions are met or not met, system 110 triggers and displays relevant notifications to the clinician who reviews the patient's treatment data.
Flag rules screen 1750 also allows the clinician to specify the parameters 1762 that either generate a first notification icon 1758 or a second notification icon 1760. Flag rules screen 1750 enables the clinician to quickly specify or check off the different events or conditions that the clinician desires to trigger a flag or a notification on dashboard 1200 described in
A clinic administrator may select maintain user 1804 to maintain information about a specific user that has been selected. As illustrated in
The clinic administrator may also select site access tab 1820 to specify the role of a user. A user may have more than one of the roles at the same time. Each role unlocks or opens up certain features and abilities for a user. The clinic administrator can specify how much control is given to a user based upon the role or roles selected for that user. For example, as illustrated in users screen 1800 displayed on a clinician's display device 192 in
The clinic user may also select patient access tab 1822 displayed on a clinician's display device 192 as illustrated in
As illustrated in
Camera 136 is used in one embodiment to scan consumables. For example, a patient may receive a delivery of supplies or consumables to perform treatment with renal therapy machine 100. The consumables may be in a container, e.g., a bottle of heparin or a blood set in a bag, each having a barcode or identifier containing information about the consumable, e.g., the amount and concentration of the heparin, or the type of dialyzer provided with the blood set. The patient can point camera 136 of tablet 122 at the barcode or identifier to photograph or scan the barcode or identifier and identify the concentration, amount, etc., of the heparin or the type, e.g., flex capacity, of the dialyzer. The software to identify the barcode or identifier is in one embodiment provided by machine 100 to tablet 122 along with the tablet's operating software and user information software. The tablet 122 passes the heparin, dialyzer or other information to the renal therapy machine 100. ACPU 112 processes the information received concerning the heparin and verifies that the heparin concentration, amount, etc., is correct according to the prescription or device program downloaded onto the renal therapy machine 100. The same check can be made for the dialyzer, acid concentrate, bicarbonate concentrate or other disposable item as desired. In one embodiment, the ACPU 112 accesses a lookup table stored in renal therapy machine 100, or alternatively accesses a device program stored in renal therapy machine 100, to ensure that the consumable associated with the scanned or photographed barcode is the correct consumable. It is contemplated for ACPU 112 to send to tablet 122, or to cause tablet 122 to recall, an animated picture of the consumables for display on tablet 122 for visual verification.
In this manner, the ACPU 112 can verify that the consumable, e.g., the heparin bottle, that the patient intends to use with renal therapy machine 100 is the correct bottle according to the prescription data contained in the device program. It should be appreciated that the tablet's camera 136 operating as an identifier or barcode reader can perform verification of consumables, so that the patient does not have to manually inspect and verify that the correct consumables have been shipped and selected. It is likely the case that multiple patients across home medical device system 110 use different concentrations or amounts of a consumable according to their different prescriptions and device programs. Thus there may be a possibility that the wrong type or amount of a consumable is shipped to a patient. Or, the patient may be prescribed multiple device programs that call for different types and/or amounts of the same consumable. The tablet 122's camera 136 operating as a barcode reader allows a patient using home medical device system 110 to easily and reliably verify that the correct consumable is used for a particular device program.
If consumable identification information sent from tablet 122 to machine 100 does not match that of the patient's prescription, machine 100 alarms in one embodiment and logs the event to be sent to the clinician. This mismatch is also displayed on tablet 122. The mismatch may be of a type that can be overridden and accepted by the patient if the patient wishes to continue with the current consumables. The patient may be given the opportunity to select and scan a substitute consumable to clear the mismatch. In doing so, tablet 122 instructs the patient to use the tablet camera 136 to take a photograph of the barcode or identifier of the substitute consumable. If the subsequent photograph produces a prescription match, treatment is allowed to continue and a consumable mismatch error corrected message is logged for delivery to a server.
Referring now to
The clinician's display device 192 may alternatively display a unified dashboard that includes hemodialysis patients and peritoneal dialysis patients. It is contemplated for the unified dashboard to indicate whether a patient is a hemodialysis patient or a peritoneal dialysis patient, and to allow the clinician to filter patients by therapy type, for example, based on whether patients receive hemodialysis or peritoneal dialysis therapy. Dashboard screen 3000 may also allow the clinician to sort by therapy sub-category, such as by an automated peritoneal dialysis patient versus a continuous ambulatory peritoneal dialysis patient. In another example, the clinician can sort by single needle nighttime versus dual needle daily hemodialysis.
In
Various icons 3004, 3006, 3008 and 3010 indicate information about a treatment performed by that patient on a specific date. The icons may indicate different types of events similar to the icons on dashboard screen 1200 (
Dashboard screen 3000 may also include navigational tabs to allow the clinician to access various portions of the web portal 150. For example, navigational tabs in dashboard 3000 may include a clinical tab 3015, a customer service tab 3016, a reports tab 3017, a clinic settings tab 3018 and a users tab 3019. A clinician can access different portions of the web portal 150 by selecting an associated navigational tab. The navigational tabs appear on multiple screens at all times in one example embodiment and thus serve to tie the different dashboard screens together. Certain tabs of screen 3000 may only appear if the current user has been given access to those tabs, based for example upon whether the user is a patient, clinician or a clinic administrator.
Tab 3015 is used to access patient snapshots and treatment summary screens and view and edit device settings for the patients handled by a particular clinic, as well as to return to dashboard 3000 if the user has navigated away from dashboard 3000. Tab 3016 is used to view and edit information such as contact and delivery information, therapy, solution and disposables information, and order information about an individual patient, and to add additional patients to the list of patients handled by a particular clinic. Tab 3017 is used to view various reports relating to patients, clinics, components of therapy machines and events that occur during treatments. Tab 3018 is used to view and edit device settings templates and flag rules that generate flags on the dashboard 3000. Tab 3019 is used to view, maintain and add authorized users that can access some or all of the various screens described below.
As illustrated in
Referring again to
Icon 3011 is a treatment review indicator that indicates whether a clinician has reviewed the treatment associated with the treatment review indicator. For example, in the illustrated embodiment, the treatment review indicator 3011 indicates to a clinician that the Jul. 30, 2011 treatment has already been reviewed by a clinician. Thus, a clinician viewing the dashboard is informed that the Jul. 30, 2011 treatment marked with a high priority flag 3008 has already been reviewed. Treatment review indicator 3011 also serves as a record that high priority flags 3008 has been reviewed. Without the treatment review indicator 3011, each time a clinician logs in and views the dashboard, the clinician may see various flags, some of them requiring immediate attention, but would not know whether the flags have already been reviewed.
Icon 3012 indicates that the patient performed multiple treatments on a certain day. One or more of the icons, including flag icons 3006 and 3008, can be selected to view more detailed information concerning the icon. Selecting the flag, for example, causes the reason for the flag occurring during a particular treatment to be displayed to the clinician.
Referring again to
The patient snapshot screen 3100 provides information such as the 24 hour ultrafiltrate volume 3108 and the patient weight before and after therapy 3110. The information displayed on snapshot screen 3100 may provide multiple items of information in the same graph. For example, chart 3108 provides a bar indicating how much ultrafiltrate was removed over the course of twenty-four hours. The bar is made up of three different colors or shades. As indicated by key 3109, each shade represents a different way in which the ultrafiltrate was removed, e.g., how much ultrafiltrate was removed by renal therapy machine 100 during the day and during the night, as well as how much ultrafiltrate was removed via manual peritoneal dialysis exchanges.
Similarly, in chart 3110, each graph indicating the patient's weight for a day indicates the patient's weight before and after treatment. As illustrated in key 3111, the darker bar graph for a day indicates the patient's weight before treatment and a lighter or different colored bar graph indicates the patient's weight after treatment. Chart 3110 could also display blood pressure and/or glucose level data for the patient on the highlighted days, for example.
It should be appreciated that the patient snapshot screen 3100 therefore allows a clinician to quickly view and visually assess how treatments have been performed for a specific patient over a defined period of time. The clinician can easily view data regarding the various parameters related to therapy, e.g., peritoneal dialysis. For example, the clinician can see a breakdown of the how the ultrafiltrate removal has progressed and can also visually assess the patient's weight, blood pressure, and pulse both before and after treatment. Although patient snapshot screen 3100 is displayed across
The screen 3200 displayed on a clinician's display device 192, including chart 3212, is continued in
The device program screen 3400 contains various tabs, such as a time tab 3406 (
In
It should therefore be appreciated that the dashboard 3400 on clinician's display device 192 allows a clinician to safely specify the parameters that will actually work for a given patient by only presenting fields that can be filled and only allowing the entry of values that can work or be performed with other selected values and/or the patient's prescription. Home medical device system 110 accordingly removes the burden from the clinician of having to ensure that the selected values are all consistent.
To accomplish the goal of relieving the clinician of having to verify all settings against one another, it is contemplated to make one or more tabs 3406 to 3416 sequentially dependent on one or more other tabs. In one example, the clinician can only proceed from the time tab 3406 to the volume tab 3408 after values have been specified in the time tab 3406, e.g., at least one of night therapy time 3416 and night dwell time 3418 have been selected by clinician and the associated amount of time in hours and minutes has been entered by the clinician. The values entered into the time tab 3406 limit the values that may be entered into subsequent tabs. The clinician then specifies information in the volume tab 3408, which may further limit or inform the values that can be entered in the settings tab 3410 and the solutions tab 3412. In this manner, the clinician is presented with a smart system in which the screens and fields that are presented to the user depend upon values entered in previous screens. It should therefore be appreciated that dashboard 3400 allows the clinician to specify one aspect of treatment at a time, which then influences the parameters that can be entered for other aspects of the treatment.
The smart system can use machine limitations and/or therapy limitations to help filter the values available in subsequent tabs. For example, once time is entered, available volume can be limited by knowing a safe maximum flow rate for machine 100, e.g., how fast can machine 100 fill or empty the patient in a peritoneal dialysis therapy. In another example, a particular type of solution may require a minimum dwell time to ensure that the benefit provided by the solution is used effectively. These types of rules are implemented on the clinician's software, which may be stored thereon by downloading the software via system hub 120 and web portal 150 to the clinician's computer.
Referring back to
The clinician may also be able to access advanced settings by pressing button 3438. Advanced settings may include additional settings for tailoring treatment for a particular patient, thereby increasing convenience and satisfaction for the patient. Advanced settings may include an option for enabling an effluent sample reminder, which pauses therapy before emptying solution bags at the end of treatment to allow a patient to collect an effluent sample before the unused solutions dilute the sample (assuming unused solution is collected with drained effluent). Advanced settings may also include an option for enabling an extra last drain mode, which is designed to ensure that a patient is completely drained before his or her last fill volume is delivered, and an extra drain UF limit, which is a percentage setting indicating the percentage of expected night UF needed before the patient receives the extra last drain mode option. Advanced settings may also include an option for enabling an extra last drain alert, which occurs at the end of the last drain and prompts the patient to press a confirm button on renal therapy machine 100 before receiving the last fill volume.
Advanced settings may further include an option for (i) modifying a minimum initial drain time, which is the minimum length of time allowed to complete an initial drain, (ii) modifying a minimum night drain time, which is the minimum length of time allowed to complete a night drain, (iii) modifying a minimum day drain time, which is the minimum length of time allowed to complete a day drain, and (iv) modifying a minimum day drain volume percentage, which is the percentage of day fill volume that needs to be drained before moving to next phase of therapy.
The solution volumes 3440 is the volume of solution for one days' worth of treatment. Thus the clinician must select a solution volume, the total programmed solution volume of all the lines set by the clinician in solution volumes 3440 (
The screen 3400 displayed on a clinician's display device 192, including list 3446, is continued in
If the clinician allows the patient to edit values for a parameter, the clinician selects “Yes” next to that parameter in column 3448. As shown in
As described above, the device program screen 3400 allows a clinician to control the treatment provided by machine 100. Patient settings screen 3500 described below in connection with
Once the templates are filtered according to the clinician's selections at drop-down items 3702 and 3704, the device settings templates screen 3700 displays table 3708 which lists the various templates that remain available to the clinician. Table 3708 lists the name of the template in column 3710, device version of the template in column 3712, setting type of the templates in column 3714, last user to modify the template in column 3716, date that the template was modified in column 3718, and actions that a clinician is allowed to perform on a template, such as to view or edit a template, in column 3720.
A clinician can also view the solutions that are used per line. In the illustrated embodiment, the clinician can view and edit information about two lines used for peritoneal dialysis, as indicated in column 4234. Column 4236 specifies the solutions that are used in the lines. Column 4238 specifies the bag type for a line. Column 4240 indicates a percentage of glucose, column 4242 indicates a volume, column 4244 indicates a frequency, column 4246 indicates units per frequency, column 4248 indicates the number of days of reserve solution and column 4250 indicates the maximum quantity of bags.
It should therefore be appreciated that the screens illustrated in
As described above, web portal 150 may be used by clinicians as well as patients to access system hub 120. In one embodiment, web portal 150 provides a patient dashboard that may be viewed on tablet 122 or on a dedicated display device of therapy machine 100 at the patient's home.
Order screen 4500 displayed on tablet 122 or dedicated display device of machine 100 displays a chart 4510 of different types of consumables that can be ordered. A solution type column 4514 lists different types of solutions such as ultra bag solutions or cycler solutions. Column 4516 lists fields for the number of boxes at the patient's home for each solution. Column 4518 allows the patient to enter in the quantity used per week. The patient may use check box 4520 to populate information into the fields from previous orders. The patient can thereby save time and conveniently order the same number of supplies as in a previous order using check box 4520. As values are entered into columns 4516 and 4518 in table 4510, renal therapy machine 100 calculates the number of boxes to order as illustrated in column 4522. Alternatively, the patient can press a calculator icon 4523, which causes renal therapy machine 100 to calculate the number of boxes to order for column 4522. The patient can then press the next link 4524 to proceed to the next step in the timeline 4502, disposables.
Alternatively, the patient may be able to directly enter in the quantities of boxes that need to be ordered as indicated in message 4506. Home medical device system 110 allows the patient to use his or her experience with a renal, nutritional or medical delivery therapy and its corresponding consumable and supply usage to ensure that the patient's home is stocked with a sufficient quantity of consumables and supplies. A patient can thus either provide information about the supplies remaining in the patient's home and let home medical device system 110 calculate the number of boxes that are needed, or the patient can directly order a specific number of boxes. It should therefore be appreciated that the patient dashboard 4400 and order screen 4500 provide flexibility as to how supplies may be ordered.
If the patient chooses to enter in direct quantities of boxes to order by pressing link 4508 in
Aspects of the subject matter described herein may be useful alone or in combination with any one or more of the other aspect described herein. Without limiting the foregoing description, in a first aspect of the present disclosure, a home medical device system comprising: a plurality of home therapy machines that perform a home therapy on a patient; a connectivity server; a system hub coupled to the home therapy machines through the connectivity server; a web portal configured to access the system hub; a plurality of clinics connected to the system hub via the web portal; and a website accessible via the web portal, the website including a patient portion available to patients using the plurality of home therapy machines, the website further including a clinician portion that enables the clinics to manage the home therapy machines.
In a second aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the home therapy includes renal therapy.
In a third aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the renal therapy includes any one or more of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or continuous renal replacement.
In a fourth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the home therapy machine is of at least one type selected from the group consisting of: (i) a hemodialysis machine, (ii) a peritoneal dialysis machine, (iii) a hemofiltration machine, (iv) a hemodiafiltration machine, (v) a continuous renal replacement machine, (vi) a medical delivery machine, or (vii) a machine running a nutritional therapy.
In a fifth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, each home therapy machine generates log files documenting treatments performed by the home therapy machine and sends the log files to the system hub through the connectivity server.
In a sixth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the connectivity server receives and stores data from the clinics until corresponding home therapy machines are turned on, after which the data is transferred to the corresponding home therapy machines.
In a seventh aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the system is configured such that if the data transferred includes a new device program, the patient for the corresponding home therapy machine must accept the new device program before the new device program is performed by the corresponding home therapy machine.
In an eighth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the clinician portion of the website includes a therapy prescription screen for specifying supplies needed at the patient's home for operating one of the home therapy machines.
In a ninth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the clinician portion of the website includes a device program screen for setting parameters by which one of the home therapy machines operates.
In a tenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the device program screen allows the parameters to be set differently in different device programs for the same home therapy machine and patient.
In an eleventh aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, at least one of the parameters is set as a range, and wherein the patient is enabled to choose within the range for operation with the home therapy machine.
In a twelfth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the device program screen allows for a template to be recalled for populating a plurality of the parameters with preselected values.
In a thirteenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the clinician portion of the website includes a patient settings screen, the patient settings screen enabling clinicians to set at least one treatment display aspect.
In a fourteenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the clinician portion of the website includes a clinician dashboard including a list of patients; and a notification associated with each patient indicating whether a predefined treatment condition or alert occurred during a treatment.
In a fifteenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the dashboard associates each patient in the list of patients with at least one of (i) a treatment summary providing detailed treatment data about the patient or (ii) a patient snapshot providing historical treatment data about the patient.
In a sixteenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the system includes a product development client in communication with the system hub, the product development client capable of providing a firmware upgrade that can be downloaded over the system hub and the connectivity server to the home therapy machine.
In a seventeenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the system includes a service personnel director in communication with the system hub, the service personnel director enabled to approve the firmware upgrade for one or more of the plurality of home therapy machines before the firmware upgrade is downloaded to the approved home therapy machine.
In an eighteenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the system includes at least one service personnel in communication with the system hub, each service personnel dedicated to at least one of the plurality of home therapy machines, the at least one service personnel enabled to determine when the firmware upgrade, after approval by the service personnel director, is delivered to the at least one dedicated home therapy machine.
In a nineteenth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the connectivity server is configured to provide a check that at least one of (i) all data in a packet of data is actually sent or (ii) data is sent to the proper home therapy machine.
In a twentieth aspect of the present disclosure, any one, or more, or all of the first to nineteenth aspects may be used in combination with any one, or more, or all of the other of the first to nineteenth aspects.
In a twenty-first aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a method for personalizing a therapy machine includes: generating a unique patient ID for a patient; generating information about the patient, the information including therapy machine settings based upon a prescription; and linking the therapy machine to the patient by entering the patient ID and a second patient identifier into the therapy machine, the linking causing the information to be sent to the therapy machine.
In a twenty-second aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the therapy machine is a second therapy machine, and further comprising: providing a first therapy machine in a clinic; training a patient to operate the first therapy machine to perform a renal therapy in the clinic; and sending the second therapy machine to the patient's home, the linking occurring after sending the second therapy machine to the patient's home.
In a twenty-third aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a clinician enters the patient ID into the second therapy machine.
In a twenty-fourth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the therapy machine is a second therapy machine, and wherein the linking is performed after a first therapy machine used by a patient malfunctions.
In a twenty-fifth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the second patient identifier is the patient's birth date.
In a twenty-sixth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the second therapy machine operates initially according to the therapy machine settings.
In a twenty-seventh aspect of the present disclosure, any one, or more, or all of the twenty-first to twenty-sixth aspects may be used in combination with any one, or more, or all of the other of the twenty-first to twenty-sixth aspects.
In a twenty-eighth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a method for performing renal therapy at a home or dwelling of a patient using a renal therapy machine includes: retrieving a doctor's prescription for renal therapy; based on the doctor's prescription, selecting supplies, including a dialyzer, at a first location other than the patient's home; and sending the supplies and the renal therapy machine to the patient's home or dwelling.
In a twenty-ninth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a method for performing renal therapy at a home of a patient using a renal therapy machine includes: retrieving a doctor's prescription for renal therapy; based on the doctor's prescription, selecting settings at a first location other than the patient's home or dwelling for operating the renal therapy machine; and performing renal therapy on the patient according to the settings.
In a thirtieth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the method further includes: modifying the settings at the first location for operating the renal therapy machine; and performing renal therapy on the patient at the patient's home or dwelling according to the modified settings.
In a thirty-first aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the settings include a parameter and an allowed range of values for the parameter.
In a thirty-second aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the settings further include a patient editable setting for the parameter, and wherein if the patient editable setting is enabled, the patient can modify the value of the parameter within the allowed range of values for the parameter.
In a thirty-third aspect of the present disclosure, any one, or more, or all of the twenty-ninth to thirty-second aspects may be used in combination with any one, or more, or all of the other of the twenty-ninth to thirty-second aspects.
In a thirty-fourth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a method for operating a home therapy machine includes: performing treatment using the home therapy machine; storing log files relating to the treatment; and using system communications to send the log files to a connectivity server.
In a thirty-fifth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the method further includes: before performing the treatment using the home therapy machine, querying the connectivity server for updated settings for the home therapy machine; and if updated settings exist, sending the updated settings to the home therapy machine via system communications.
In a thirty-sixth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the method includes performing at least one post-treatment operation after storing the log files relating to the treatment and before sending the log files to the connectivity server.
In a thirty-seventh aspect of the present disclosure, any one, or more, or all of the thirty-fourth to thirty-sixth aspects may be used in combination with any one, or more, or all of the other of the thirty-fourth to thirty-sixth aspects.
In a thirty-eighth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a method of upgrading firmware on a home therapy machine includes: generating upgraded firmware for a plurality of home therapy machines; approving the upgraded firmware for the plurality of home therapy machines; uploading the upgraded firmware to a first location; determining which of the approved home therapy machines should receive the upgraded firmware; and for each home therapy machine that should receive the upgraded firmware (i) uploading the upgraded firmware from the first location to a connectivity server associated with each home therapy machine that should receive the upgraded firmware; (ii) selecting a time to send the upgraded firmware to each home therapy machine that should receive the upgraded firmware; and (iii) sending the upgraded firmware at the selected time from the connectivity server to each home therapy machine that should receive the upgraded firmware.
In a thirty-ninth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the method includes prompting each patient associated with the home therapy machines receiving the upgraded firmware whether to install the upgraded firmware.
In a fortieth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the method includes a determination by the home therapy machines receiving the upgraded firmware whether to install the upgraded firmware.
In a forty-first aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the method includes prompting each patient associated with the home therapy machines receiving the upgraded firmware to approve installing the upgraded firmware and a determination by the home therapy machines receiving the upgraded firmware whether the upgraded firmware has been approved.
In a forty-second aspect of the present disclosure, any one, or more, or all of the thirty-eighth to forty-first aspects may be used in combination with any one, or more, or all of the other of the thirty-eighth to forty-first aspects.
In a forty-third aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a therapy entry, modification and reporting system includes: a website for displaying therapy entry, modification and reporting information; and a system hub for managing a flow of the information between the website and a plurality of home therapy machines that perform a home therapy on a patient, wherein the website includes a therapy prescription screen for specifying supplies needed at the patient's home for operating one of the home therapy machines, a device program screen for setting parameters by which one of the home therapy machines operates, and a clinician dashboard having a list of patients and a notification associated with each patient indicating whether a predefined treatment condition or alert occurred during a treatment.
In a forty-fourth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the device program screen includes a first parameter and a second parameter, and wherein values that can be entered into the second parameter depend upon values entered into the first parameter.
In a forty-fifth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the device program screen is a first device program screen, and which includes a second device program screen, wherein the first parameter appears on the first device program screen and the second parameter appears on the second device program screen.
In a forty-sixth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a clinician's access to the second device program screen depends upon values entered into parameters on the first device program screen.
In a forty-seventh aspect of the present disclosure, any one, or more, or all of the forty-third to forty-sixth aspects may be used in combination with any one, or more, or all of the other of the forty-third to forty-sixth aspects.
In a forty-eighth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a method of verifying supplies used by a home therapy machine having a user interface includes retrieving a doctor's prescription for home therapy; connecting a supply to the home therapy machine, the supply including a code indicating information about the supply; obtaining the code using the user interface of the home therapy machine; determining the information about the supply from the obtained code; comparing the determined information about the supply with the prescription; and performing home therapy if the determined information about the supply comports with the prescription.
In a forty-ninth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the supply includes a container of a medical substance, wherein the prescription includes a concentration of the medical substance that should be used in the home therapy, and wherein the code indicates the actual concentration of the medical substance in the container.
In a fiftieth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the supply includes a dialyzer, wherein the prescription includes a type of dialyzer, and wherein the code indicates the type of dialyzer.
In a fifty-first aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the user interface communicates wirelessly with the home therapy machine.
In a fifty-second aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the user interface includes a camera operable to read the code.
In a fifty-third aspect of the present disclosure, any one, or more, or all of the forty-eighth to fifty-second aspects may be used in combination with any one, or more, or all of the other of the forty-eighth to fifty-second aspects.
In a fifty-fourth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a computer readable medium storing instructions is structured to cause a home therapy machine to: allow patient selection of a prescription from a plurality of prescriptions stored on the home therapy machine; perform treatment using the home therapy machine according to the selected prescription; disinfect the home therapy machine; and generate log files documenting the treatment performed by the home therapy machine.
In a fifty-fifth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the instructions are further structured to cause the home therapy machine to: send the log files to a system hub; and query the system hub for at least one of (i) an update for one of the prescriptions from the plurality of prescriptions or (ii) a new prescription.
In a fifty-sixth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the instructions are further structured to cause the home therapy machine to receive data from at least one of a water treatment device, a weight scale, a blood pressure cuff, or a tablet.
In a fifty-seventh aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the home therapy machine is connected wirelessly to at least one of the weight scale, the blood pressure cuff, or the tablet.
In a fifty-eighth aspect of the present disclosure, any one, or more, or all of the fifty-fourth to fifty-seventh aspects may be used in combination with any one, or more, or all of the other of the fifty-fourth to fifty-seventh aspects.
In a fifty-ninth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, a computer readable medium storing instructions is structured to cause a computing device to display a clinician user interface that enables a clinician to manage a plurality of home therapy machines, the clinician user interface including (i) a device program screen for setting parameters by which one of the home therapy machines performs treatments, and a clinician dashboard including (a) a list of patients, and (b) a notification associated with each patient indicating whether a predefined condition occurred during a treatment.
In a sixtieth aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the instructions are further structured to cause the computing device to store a first value entered into a first parameter on the device program screen, and determine, based upon the first value, whether a second value can be entered into a second parameter on the device program screen.
In a sixty-first aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the instructions are further structured to cause the computing device to store templates that can be recalled for populating preselected values into at least one of the device program screen, a therapy prescription screen for ordering supplies for one of the home therapy machines, a patient settings screen for controlling how treatments appear to patients, or a system settings screen for controlling settings other than how treatments are performed on the home therapy machines.
In a sixty-second aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the instructions are further structured to cause the computing device to display a rules screen listing treatment events that can occur during the treatments, store conditions related to the treatment events entered by the clinician into the rules screen, and evaluate log files received from the home therapy machines based upon the conditions to generate the notification.
In a sixty-third aspect of the present disclosure, which may be used in combination with any one, or more, or all of the other aspects described herein, the instructions are further structured to cause the computing device to display an indicator indicating whether the same or a different clinician has reviewed the condition associated with the notification
In a sixty-fourth aspect of the present disclosure, any one, or more, or all of the fifty-ninth to sixty-third aspects may be used in combination with any one, or more, or all of the other of the fifty-ninth to sixty-third aspects.
In a sixty-fifth aspect any of the structure and functionality illustrated and described in connection with
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
This application claims priority to U.S. Patent Application Ser. No. 61/647,340, entitled “HOME MEDICAL DEVICE SYSTEMS AND METHODS FOR THERAPY PRESCRIPTION AND TRACKING, SERVICING AND INVENTORY”, filed May 15, 2012, the entire contents of which are incorporated herein by reference and relied upon. This patent application is related to U.S. patent application Ser. No. 12/170,184 filed Jul. 9, 2008 (now U.S. Pat. No. 7,981,281), U.S. patent application Ser. No. 12/170,172 filed Jul. 9, 2008 (now U.S. Pat. No. 8,168,063), U.S. patent application Ser. No. 12/170,204 filed Jul. 9, 2008 (published on Jan. 14, 2010 as U.S. Patent Publication No. 2010/0010426), U.S. patent application Ser. No. 13/274,012 filed Oct. 14, 2011 (now U.S. Pat. No. 8,313,642), which is a continuation of U.S. patent application Ser. No. 12/170,220 filed Jul. 9, 2008 (now U.S. Pat. No. 8,057,679), U.S. patent application Ser. No. 13/251,901 filed Oct. 3, 2011 (now U.S. Pat. No. 8,257,582), which is a continuation of U.S. patent application Ser. No. 12/170,230 filed Jul. 9, 2008 (now U.S. Pat. No. 8,062,513), and U.S. Patent Application Ser. No. 61/647,340 filed May 15, 2012, the contents of each of which are herein incorporated by reference in their entirety and relied upon.
Number | Name | Date | Kind |
---|---|---|---|
3426150 | Tygart | Feb 1969 | A |
3739943 | Williamsen et al. | Jun 1973 | A |
3742938 | Stern | Jul 1973 | A |
3756752 | Stenner | Sep 1973 | A |
3774762 | Lichtenstein | Nov 1973 | A |
3786190 | Pori | Jan 1974 | A |
3809871 | Howard et al. | May 1974 | A |
3810102 | Parks, III et al. | May 1974 | A |
3848112 | Weichselbaum et al. | Nov 1974 | A |
3858574 | Page | Jan 1975 | A |
3910257 | Fletcher et al. | Oct 1975 | A |
3910260 | Sarnoff et al. | Nov 1975 | A |
3921196 | Patterson | Nov 1975 | A |
3971000 | Cromwell | Jul 1976 | A |
3998103 | Bjorklund et al. | Dec 1976 | A |
4032908 | Rice et al. | Jun 1977 | A |
4078562 | Friedman | Mar 1978 | A |
4144496 | Cunningham et al. | Mar 1979 | A |
4151407 | McBride et al. | Apr 1979 | A |
4156867 | Bench et al. | May 1979 | A |
4164320 | Irazoqui et al. | Aug 1979 | A |
4173971 | Karz | Nov 1979 | A |
4199307 | Jassawalla | Apr 1980 | A |
4270532 | Franetzki et al. | Jun 1981 | A |
4273121 | Jassawalla | Jun 1981 | A |
4282872 | Franetzki et al. | Aug 1981 | A |
4308866 | Jelliffe et al. | Jan 1982 | A |
4319338 | Grudowski et al. | Mar 1982 | A |
4320757 | Whitney et al. | Mar 1982 | A |
4354252 | Lamb et al. | Oct 1982 | A |
4369780 | Sakai | Jan 1983 | A |
4370983 | Lichtenstein | Feb 1983 | A |
4373527 | Fischell | Feb 1983 | A |
4381776 | Latham, Jr. | May 1983 | A |
4385630 | Gilcher et al. | May 1983 | A |
4398289 | Schoate | Aug 1983 | A |
4398908 | Siposs | Aug 1983 | A |
4416654 | Schoendorfer et al. | Nov 1983 | A |
4425114 | Schoendorfer et al. | Jan 1984 | A |
4428381 | Hepp | Jan 1984 | A |
4443216 | Chappell | Apr 1984 | A |
4447224 | DeCant, Jr. et al. | May 1984 | A |
4449538 | Corbitt et al. | May 1984 | A |
4451255 | Bujan et al. | May 1984 | A |
4457750 | Hill | Jul 1984 | A |
4458693 | Badzinski et al. | Jul 1984 | A |
4460358 | Somerville et al. | Jul 1984 | A |
4464172 | Lichtenstein | Aug 1984 | A |
4469481 | Kobayashi | Sep 1984 | A |
4475901 | Kraegen et al. | Oct 1984 | A |
4476381 | Rubin | Oct 1984 | A |
4480751 | Lueptow | Nov 1984 | A |
4481670 | Freeburg | Nov 1984 | A |
4487604 | Iwatschenko et al. | Dec 1984 | A |
4490798 | Franks et al. | Dec 1984 | A |
4496351 | Hillel et al. | Jan 1985 | A |
4511352 | Theeuwes et al. | Apr 1985 | A |
4525861 | Freeburg | Jun 1985 | A |
4529401 | Leslie et al. | Jul 1985 | A |
4531527 | Reinhold, Jr. et al. | Jul 1985 | A |
4538138 | Harvey et al. | Aug 1985 | A |
4545071 | Freeburg | Oct 1985 | A |
4551133 | Zegers de Beyl et al. | Nov 1985 | A |
4559038 | Berg et al. | Dec 1985 | A |
4560979 | Rosskopf | Dec 1985 | A |
4561443 | Hogrefe et al. | Dec 1985 | A |
4562751 | Nason | Jan 1986 | A |
4590473 | Burke et al. | May 1986 | A |
4602249 | Abbott | Jul 1986 | A |
4619653 | Fischell | Oct 1986 | A |
4622979 | Katchis et al. | Nov 1986 | A |
4624661 | Arimond | Nov 1986 | A |
4636950 | Caswell et al. | Jan 1987 | A |
4637817 | Archibald et al. | Jan 1987 | A |
4650469 | Berg et al. | Mar 1987 | A |
4652262 | Veracchi | Mar 1987 | A |
4676776 | Howson | Jun 1987 | A |
4681563 | Deckert et al. | Jul 1987 | A |
4688167 | Agarwal | Aug 1987 | A |
4691580 | Fosslien | Sep 1987 | A |
4695954 | Rose et al. | Sep 1987 | A |
4696671 | Epstein et al. | Sep 1987 | A |
4697928 | Csongor | Oct 1987 | A |
4702595 | Mutschler et al. | Oct 1987 | A |
4705506 | Archibald | Nov 1987 | A |
4714462 | DiComenico | Dec 1987 | A |
4717042 | McLaughlin | Jan 1988 | A |
4718576 | Tamura et al. | Jan 1988 | A |
4722224 | Scheller et al. | Feb 1988 | A |
4722349 | Baumberg | Feb 1988 | A |
4722734 | Kolln | Feb 1988 | A |
4730849 | Siegel | Mar 1988 | A |
4731058 | Doan | Mar 1988 | A |
4732411 | Siegel | Mar 1988 | A |
4741732 | Crankshaw et al. | May 1988 | A |
4741736 | Brown | May 1988 | A |
4756706 | Kerns et al. | Jul 1988 | A |
4759756 | Forman | Jul 1988 | A |
4778449 | Weber et al. | Oct 1988 | A |
4779626 | Peel et al. | Oct 1988 | A |
4784645 | Fischell | Nov 1988 | A |
4785799 | Schoon et al. | Nov 1988 | A |
4785969 | McLaughlin | Nov 1988 | A |
4796644 | Polaschegg | Jan 1989 | A |
4797840 | Fraden | Jan 1989 | A |
4803625 | Fu et al. | Feb 1989 | A |
4810090 | Boucher | Mar 1989 | A |
4810243 | Howson | Mar 1989 | A |
4811844 | Moulding, Jr. et al. | Mar 1989 | A |
4816208 | Woods et al. | Mar 1989 | A |
4817044 | Ogren | Mar 1989 | A |
4828545 | Epstein et al. | May 1989 | A |
4830018 | Treach | May 1989 | A |
4831562 | McIntosh et al. | May 1989 | A |
4832033 | Maher et al. | May 1989 | A |
4835372 | Beard et al. | May 1989 | A |
4835521 | Andrejasich et al. | May 1989 | A |
4838275 | Lee | Jun 1989 | A |
4839806 | Goldfischer et al. | Jun 1989 | A |
4845644 | Anthias et al. | Jul 1989 | A |
4847764 | Halvorson | Jul 1989 | A |
4850009 | Zook et al. | Jul 1989 | A |
4850972 | Schulman et al. | Jul 1989 | A |
4853521 | Claeys et al. | Aug 1989 | A |
4854324 | Hirschman et al. | Aug 1989 | A |
4857713 | Brown | Aug 1989 | A |
4857716 | Gombrich et al. | Aug 1989 | A |
4865584 | Epstein et al. | Sep 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4878175 | Norden-Paul et al. | Oct 1989 | A |
4889132 | Hutcheson et al. | Dec 1989 | A |
4889134 | Greenwold et al. | Dec 1989 | A |
4893270 | Beck et al. | Jan 1990 | A |
4897777 | Janke et al. | Jan 1990 | A |
4898576 | Philip | Feb 1990 | A |
4898578 | Rubalcaba, Jr. | Feb 1990 | A |
4901728 | Hutchison | Feb 1990 | A |
4908017 | Howson et al. | Mar 1990 | A |
4912623 | Rantala et al. | Mar 1990 | A |
4916441 | Gombrich et al. | Apr 1990 | A |
4922922 | Pollock et al. | May 1990 | A |
4925444 | Orkin et al. | May 1990 | A |
4933843 | Scheller et al. | Jun 1990 | A |
4937777 | Flood et al. | Jun 1990 | A |
4941808 | Qureshi et al. | Jul 1990 | A |
4943279 | Samiotes et al. | Jul 1990 | A |
4949274 | Hollander et al. | Aug 1990 | A |
4952928 | Carroll et al. | Aug 1990 | A |
4953074 | Kametani et al. | Aug 1990 | A |
4960230 | Marelli | Oct 1990 | A |
4966579 | Polaschegg | Oct 1990 | A |
4967928 | Carter | Nov 1990 | A |
4968295 | Neumann | Nov 1990 | A |
4977590 | Milovancevic | Dec 1990 | A |
4978335 | Arthur | Dec 1990 | A |
4991091 | Allen | Feb 1991 | A |
4992926 | Janke et al. | Feb 1991 | A |
4993068 | Piosenka et al. | Feb 1991 | A |
4998249 | Bennett et al. | Mar 1991 | A |
5002055 | Merki et al. | Mar 1991 | A |
5003296 | Lee | Mar 1991 | A |
5006699 | Felkner et al. | Apr 1991 | A |
5007429 | Treatch et al. | Apr 1991 | A |
5012402 | Akiyama | Apr 1991 | A |
5012411 | Policastro et al. | Apr 1991 | A |
5014875 | McLaughlin et al. | May 1991 | A |
5016172 | Dessertine | May 1991 | A |
5023770 | Siverling | Jun 1991 | A |
5025374 | Roizen et al. | Jun 1991 | A |
5036852 | Leishman | Aug 1991 | A |
5038800 | Oba | Aug 1991 | A |
5041086 | Koenig et al. | Aug 1991 | A |
5045048 | Kaleskas et al. | Sep 1991 | A |
5047959 | Phillips et al. | Sep 1991 | A |
5053031 | Borsanyi | Oct 1991 | A |
5053990 | Kreifels et al. | Oct 1991 | A |
5055001 | Natwick et al. | Oct 1991 | A |
5057076 | Polaschegg | Oct 1991 | A |
5061243 | Winchell et al. | Oct 1991 | A |
5072356 | Watt et al. | Dec 1991 | A |
5072383 | Brimm et al. | Dec 1991 | A |
5072412 | Henderson, Jr. et al. | Dec 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5084828 | Kaufman et al. | Jan 1992 | A |
5087245 | Doan | Feb 1992 | A |
5088904 | Okada | Feb 1992 | A |
5088981 | Howson et al. | Feb 1992 | A |
5088990 | Hivale et al. | Feb 1992 | A |
5096385 | Georgi et al. | Mar 1992 | A |
5098377 | Borsanyi et al. | Mar 1992 | A |
5100380 | Adaniya et al. | Mar 1992 | A |
5104374 | Bishko et al. | Apr 1992 | A |
5108363 | Tuttle et al. | Apr 1992 | A |
5108367 | Epstein et al. | Apr 1992 | A |
5108372 | Swenson | Apr 1992 | A |
5109487 | Ohgomori et al. | Apr 1992 | A |
5109849 | Goodman et al. | May 1992 | A |
5112319 | Lai | May 1992 | A |
5116203 | Natwick et al. | May 1992 | A |
5116312 | Blankenship et al. | May 1992 | A |
5131092 | Sackmann et al. | Jul 1992 | A |
5134574 | Beaverstock et al. | Jul 1992 | A |
5135500 | Zdeb | Aug 1992 | A |
5137023 | Mendelson et al. | Aug 1992 | A |
5151082 | Gorsuch et al. | Sep 1992 | A |
5151978 | Bronikowski et al. | Sep 1992 | A |
5152296 | Simons | Oct 1992 | A |
5153416 | Neeley | Oct 1992 | A |
5153827 | Coutre et al. | Oct 1992 | A |
5155693 | Altmayer et al. | Oct 1992 | A |
5157595 | Lovrenich | Oct 1992 | A |
5158091 | Butterfield et al. | Oct 1992 | A |
5159673 | Sackmann et al. | Oct 1992 | A |
5160320 | Yum et al. | Nov 1992 | A |
5161211 | Taguchi et al. | Nov 1992 | A |
5167235 | Seacord et al. | Dec 1992 | A |
5172698 | Stanko | Dec 1992 | A |
5176004 | Gaudet | Jan 1993 | A |
5179569 | Sawyer | Jan 1993 | A |
5179700 | Aihara et al. | Jan 1993 | A |
5181910 | Scanlon | Jan 1993 | A |
5190185 | Blechl | Mar 1993 | A |
5190522 | Wojcicki et al. | Mar 1993 | A |
5191891 | Righter | Mar 1993 | A |
5208907 | Shelton et al. | May 1993 | A |
5211849 | Benzing et al. | May 1993 | A |
5213099 | Tripp, Jr. | May 1993 | A |
5213232 | Kraft et al. | May 1993 | A |
5213568 | Lattin et al. | May 1993 | A |
5219330 | Bollish et al. | Jun 1993 | A |
5219331 | Vanderveen | Jun 1993 | A |
5225974 | Mathews et al. | Jul 1993 | A |
5226425 | Righter | Jul 1993 | A |
5228450 | Sellers | Jul 1993 | A |
5231990 | Gauglitz | Aug 1993 | A |
5234404 | Tuttle et al. | Aug 1993 | A |
5235510 | Yamada et al. | Aug 1993 | A |
5236416 | McDaniel et al. | Aug 1993 | A |
5238001 | Gallant et al. | Aug 1993 | A |
5240007 | Pytel et al. | Aug 1993 | A |
5244463 | Cordner, Jr. et al. | Sep 1993 | A |
5245704 | Weber et al. | Sep 1993 | A |
5247434 | Peterson et al. | Sep 1993 | A |
5254096 | Rondelet et al. | Oct 1993 | A |
5256156 | Kern et al. | Oct 1993 | A |
5256157 | Samiotes et al. | Oct 1993 | A |
5265010 | Evans-Paganelli et al. | Nov 1993 | A |
5265431 | Gaudet et al. | Nov 1993 | A |
5267174 | Kaufman et al. | Nov 1993 | A |
5271405 | Boyer et al. | Dec 1993 | A |
5272318 | Gorman | Dec 1993 | A |
5272321 | Otsuka et al. | Dec 1993 | A |
5273517 | Barone et al. | Dec 1993 | A |
5277188 | Selker | Jan 1994 | A |
5283861 | Dangler et al. | Feb 1994 | A |
5284150 | Butterfield et al. | Feb 1994 | A |
5286252 | Tuttle et al. | Feb 1994 | A |
5292029 | Pearson | Mar 1994 | A |
5297257 | Struger et al. | Mar 1994 | A |
5298021 | Sherer | Mar 1994 | A |
5304126 | Epstein et al. | Apr 1994 | A |
5307263 | Brown | Apr 1994 | A |
5307372 | Sawyer et al. | Apr 1994 | A |
5307463 | Hyatt et al. | Apr 1994 | A |
5311908 | Barone et al. | May 1994 | A |
5314243 | McDonald et al. | May 1994 | A |
5315505 | Pratt et al. | May 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5319543 | Wilhelm | Jun 1994 | A |
5321618 | Gessman | Jun 1994 | A |
5321829 | Zifferer | Jun 1994 | A |
5324422 | Colleran et al. | Jun 1994 | A |
5325478 | Shelton et al. | Jun 1994 | A |
5327341 | Whalen et al. | Jul 1994 | A |
5331549 | Crawford, Jr. | Jul 1994 | A |
5336245 | Adams et al. | Aug 1994 | A |
5337230 | Baumgartner et al. | Aug 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5339821 | Fujimoto | Aug 1994 | A |
5341291 | Roizen et al. | Aug 1994 | A |
5341412 | Ramot et al. | Aug 1994 | A |
5348008 | Bornn et al. | Sep 1994 | A |
5348539 | Herskowitz | Sep 1994 | A |
5349675 | Fitzgerald et al. | Sep 1994 | A |
5356378 | Doan | Oct 1994 | A |
5361202 | Doue | Nov 1994 | A |
5361758 | Hall et al. | Nov 1994 | A |
5366896 | Margrey et al. | Nov 1994 | A |
5366904 | Qureshi et al. | Nov 1994 | A |
5367555 | Isoyama | Nov 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5370612 | Maeda et al. | Dec 1994 | A |
5371687 | Holmes, II et al. | Dec 1994 | A |
5374251 | Smith | Dec 1994 | A |
5374813 | Shipp | Dec 1994 | A |
5374965 | Kanno | Dec 1994 | A |
5375604 | Kelly et al. | Dec 1994 | A |
5376070 | Colman et al. | Dec 1994 | A |
5377864 | Blechl et al. | Jan 1995 | A |
5378231 | Johnson et al. | Jan 1995 | A |
5379214 | Arbuckle et al. | Jan 1995 | A |
5389078 | Zalesky et al. | Feb 1995 | A |
5390238 | Kirk et al. | Feb 1995 | A |
5392951 | Gardner et al. | Feb 1995 | A |
5395320 | Padda et al. | Mar 1995 | A |
5395321 | Kawahara et al. | Mar 1995 | A |
5398336 | Tantry et al. | Mar 1995 | A |
5401059 | Ferrario | Mar 1995 | A |
5404292 | Hendrickson | Apr 1995 | A |
5404384 | Colburn et al. | Apr 1995 | A |
5406473 | Yoshikura et al. | Apr 1995 | A |
5412715 | Volpe | May 1995 | A |
5415167 | Wilk | May 1995 | A |
5416695 | Miller et al. | May 1995 | A |
5417222 | Dempsey et al. | May 1995 | A |
5420977 | Sztipanovits et al. | May 1995 | A |
5421343 | Feng | Jun 1995 | A |
5423746 | Burkett et al. | Jun 1995 | A |
5429602 | Hauser | Jul 1995 | A |
5431299 | Brewer et al. | Jul 1995 | A |
5431627 | Pastrone et al. | Jul 1995 | A |
5433736 | Nilsson | Jul 1995 | A |
5438607 | Przygoda, Jr. et al. | Aug 1995 | A |
5440699 | Farrand et al. | Aug 1995 | A |
5441047 | David et al. | Aug 1995 | A |
5445294 | Gardner et al. | Aug 1995 | A |
5445621 | Poli et al. | Aug 1995 | A |
5446868 | Gardea, II et al. | Aug 1995 | A |
5453098 | Botts et al. | Sep 1995 | A |
5455851 | Chaco et al. | Oct 1995 | A |
5458123 | Unger | Oct 1995 | A |
5460294 | Williams | Oct 1995 | A |
5460605 | Tuttle et al. | Oct 1995 | A |
5461665 | Shur et al. | Oct 1995 | A |
5462051 | Oka et al. | Oct 1995 | A |
5464392 | Epstein et al. | Nov 1995 | A |
5465286 | Clare et al. | Nov 1995 | A |
5467773 | Bergelson et al. | Nov 1995 | A |
5468110 | McDonald et al. | Nov 1995 | A |
5469855 | Pompei et al. | Nov 1995 | A |
5471382 | Tallman et al. | Nov 1995 | A |
5474552 | Palti | Dec 1995 | A |
5482043 | Zulauf | Jan 1996 | A |
5482446 | Williamson et al. | Jan 1996 | A |
5485408 | Blomquist | Jan 1996 | A |
5486286 | Peterson et al. | Jan 1996 | A |
5490610 | Pearson | Feb 1996 | A |
5494592 | Latham, Jr. et al. | Feb 1996 | A |
5496265 | Langley et al. | Mar 1996 | A |
5496273 | Pastrone et al. | Mar 1996 | A |
5502944 | Kraft et al. | Apr 1996 | A |
5507412 | Ebert et al. | Apr 1996 | A |
5508912 | Schneiderman | Apr 1996 | A |
5509422 | Fukami | Apr 1996 | A |
5513957 | O'Leary | May 1996 | A |
5514088 | Zakko | May 1996 | A |
5514095 | Brightbill et al. | May 1996 | A |
5515426 | Yacenda et al. | May 1996 | A |
5520450 | Colson, Jr. et al. | May 1996 | A |
5520637 | Pager et al. | May 1996 | A |
5522396 | Langer et al. | Jun 1996 | A |
5522798 | Johnson et al. | Jun 1996 | A |
5526428 | Arnold | Jun 1996 | A |
5528503 | Moore et al. | Jun 1996 | A |
5529063 | Hill | Jun 1996 | A |
5531680 | Dumas et al. | Jul 1996 | A |
5531697 | Olsen et al. | Jul 1996 | A |
5531698 | Olsen | Jul 1996 | A |
5533079 | Colburn et al. | Jul 1996 | A |
5533981 | Mandro et al. | Jul 1996 | A |
5534691 | Holdaway et al. | Jul 1996 | A |
5536084 | Curtis et al. | Jul 1996 | A |
5537313 | Pirelli | Jul 1996 | A |
5537853 | Finburgh et al. | Jul 1996 | A |
5542420 | Goldman et al. | Aug 1996 | A |
5544649 | David et al. | Aug 1996 | A |
5544651 | Wilk | Aug 1996 | A |
5544661 | Davis et al. | Aug 1996 | A |
5545140 | Conero et al. | Aug 1996 | A |
5546580 | Seliger et al. | Aug 1996 | A |
5547470 | Johnson et al. | Aug 1996 | A |
5549117 | Tacklind et al. | Aug 1996 | A |
5549460 | O'Leary | Aug 1996 | A |
5553609 | Chen et al. | Sep 1996 | A |
5558638 | Evers et al. | Sep 1996 | A |
5558640 | Pfeiler et al. | Sep 1996 | A |
5560352 | Heim et al. | Oct 1996 | A |
5562232 | Pearson | Oct 1996 | A |
5562621 | Claude et al. | Oct 1996 | A |
5563347 | Martin et al. | Oct 1996 | A |
5564803 | McDonald et al. | Oct 1996 | A |
5568912 | Minami et al. | Oct 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5569187 | Kaiser | Oct 1996 | A |
5571258 | Pearson | Nov 1996 | A |
5573502 | LeCocq et al. | Nov 1996 | A |
5573506 | Vasko | Nov 1996 | A |
5575632 | Morris et al. | Nov 1996 | A |
5576952 | Stutman et al. | Nov 1996 | A |
5579001 | Dempsey et al. | Nov 1996 | A |
5579378 | Arlinghaus, Jr. | Nov 1996 | A |
5581369 | Righter et al. | Dec 1996 | A |
5581687 | Lyle et al. | Dec 1996 | A |
5582593 | Hultman | Dec 1996 | A |
5583758 | McIlroy et al. | Dec 1996 | A |
5588815 | Zaleski, II | Dec 1996 | A |
5589932 | Garcia-Rubio et al. | Dec 1996 | A |
5590648 | Mitchell et al. | Jan 1997 | A |
5593267 | McDonald et al. | Jan 1997 | A |
5594637 | Eisenberg et al. | Jan 1997 | A |
5594786 | Chaco et al. | Jan 1997 | A |
5597995 | Williams et al. | Jan 1997 | A |
5598536 | Slaughter, III et al. | Jan 1997 | A |
5601445 | Schipper et al. | Feb 1997 | A |
5609575 | Larson et al. | Mar 1997 | A |
5609576 | Voss et al. | Mar 1997 | A |
5613115 | Gihl et al. | Mar 1997 | A |
5619428 | Lee et al. | Apr 1997 | A |
5619991 | Sloane | Apr 1997 | A |
5623652 | Vora et al. | Apr 1997 | A |
5623925 | Swenson et al. | Apr 1997 | A |
5626144 | Tacklind et al. | May 1997 | A |
5628619 | Wilson | May 1997 | A |
5630710 | Tune et al. | May 1997 | A |
5631844 | Margrey et al. | May 1997 | A |
5633910 | Cohen | May 1997 | A |
D380260 | Hyman | Jun 1997 | S |
5634893 | Rishton | Jun 1997 | A |
5637082 | Pages et al. | Jun 1997 | A |
5637093 | Hyman et al. | Jun 1997 | A |
5640301 | Roecher et al. | Jun 1997 | A |
5640953 | Bishop et al. | Jun 1997 | A |
5641628 | Bianchi | Jun 1997 | A |
5643193 | Papillon et al. | Jul 1997 | A |
5643212 | Coutre et al. | Jul 1997 | A |
5647853 | Feldmann et al. | Jul 1997 | A |
5647854 | Olsen et al. | Jul 1997 | A |
5651775 | Walker et al. | Jul 1997 | A |
5652566 | Lambert | Jul 1997 | A |
5658240 | Urdahl et al. | Aug 1997 | A |
5658250 | Blomquist et al. | Aug 1997 | A |
5661978 | Holmes et al. | Sep 1997 | A |
5664270 | Bell et al. | Sep 1997 | A |
5666404 | Ciccotelli et al. | Sep 1997 | A |
5678562 | Sellers | Oct 1997 | A |
5678568 | Uchikubo et al. | Oct 1997 | A |
5681285 | Ford et al. | Oct 1997 | A |
5682526 | Smokoff et al. | Oct 1997 | A |
5683367 | Jordan et al. | Nov 1997 | A |
5685844 | Marttila | Nov 1997 | A |
5687717 | Halpern | Nov 1997 | A |
5687734 | Dempsey et al. | Nov 1997 | A |
5695473 | Olsen | Dec 1997 | A |
5697951 | Harpstead | Dec 1997 | A |
5700998 | Palti | Dec 1997 | A |
5701894 | Cherry et al. | Dec 1997 | A |
5704351 | Mortara et al. | Jan 1998 | A |
5704364 | Saltzstein et al. | Jan 1998 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5712798 | Langley et al. | Jan 1998 | A |
5712912 | Tomko et al. | Jan 1998 | A |
5713485 | Liff et al. | Feb 1998 | A |
5713856 | Eggers et al. | Feb 1998 | A |
5715823 | Wood et al. | Feb 1998 | A |
5716114 | Holmes et al. | Feb 1998 | A |
5716194 | Butterfield et al. | Feb 1998 | A |
5718562 | Lawless et al. | Feb 1998 | A |
5719761 | Gatti et al. | Feb 1998 | A |
RE35743 | Pearson | Mar 1998 | E |
5724025 | Tavori | Mar 1998 | A |
5724580 | Levin et al. | Mar 1998 | A |
5732401 | Conway | Mar 1998 | A |
5732709 | Tacklind et al. | Mar 1998 | A |
5733259 | Valcke et al. | Mar 1998 | A |
5735887 | Barreras, Sr. et al. | Apr 1998 | A |
5737539 | Edelson et al. | Apr 1998 | A |
5740185 | Bosse | Apr 1998 | A |
5740800 | Hendrickson et al. | Apr 1998 | A |
5745366 | Higham et al. | Apr 1998 | A |
5745378 | Barker et al. | Apr 1998 | A |
5752917 | Fuchs | May 1998 | A |
5752976 | Duffin et al. | May 1998 | A |
5755563 | Clegg et al. | May 1998 | A |
5764923 | Tallman et al. | Jun 1998 | A |
5766155 | Hyman et al. | Jun 1998 | A |
5769811 | Stacey et al. | Jun 1998 | A |
5771657 | Lasher et al. | Jun 1998 | A |
5772585 | Lavin et al. | Jun 1998 | A |
5772586 | Heinonen et al. | Jun 1998 | A |
5772635 | Dastur | Jun 1998 | A |
5772637 | Heinzmann et al. | Jun 1998 | A |
5776057 | Swenson et al. | Jul 1998 | A |
5778345 | McCartney | Jul 1998 | A |
5778882 | Raymond et al. | Jul 1998 | A |
5781442 | Chamberlain et al. | Jul 1998 | A |
5782805 | Meinzer et al. | Jul 1998 | A |
5782878 | Morgan et al. | Jul 1998 | A |
5785650 | Akasaka et al. | Jul 1998 | A |
5788669 | Peterson | Aug 1998 | A |
5788851 | Kenley et al. | Aug 1998 | A |
5790409 | Fedor et al. | Aug 1998 | A |
5791342 | Woodard | Aug 1998 | A |
5791880 | Wilson | Aug 1998 | A |
5793861 | Haigh | Aug 1998 | A |
5793969 | Kamentsky et al. | Aug 1998 | A |
5795317 | Brierton et al. | Aug 1998 | A |
5795327 | Wilson et al. | Aug 1998 | A |
5797515 | Liff et al. | Aug 1998 | A |
5800387 | Duffy et al. | Sep 1998 | A |
5803906 | Pratt et al. | Sep 1998 | A |
5805442 | Crater et al. | Sep 1998 | A |
5805456 | Higham et al. | Sep 1998 | A |
5805505 | Zheng et al. | Sep 1998 | A |
5807321 | Stoker et al. | Sep 1998 | A |
5807322 | Lindsey et al. | Sep 1998 | A |
5807336 | Chen et al. | Sep 1998 | A |
5810747 | Brudny et al. | Sep 1998 | A |
5814015 | Cowen et al. | Sep 1998 | A |
5815566 | Ramot et al. | Sep 1998 | A |
5822418 | Yacenda et al. | Oct 1998 | A |
5822544 | Chaco et al. | Oct 1998 | A |
5823949 | Goltra | Oct 1998 | A |
5826237 | Macrae et al. | Oct 1998 | A |
5829438 | Gibbs et al. | Nov 1998 | A |
5832448 | Brown | Nov 1998 | A |
5832450 | Myers et al. | Nov 1998 | A |
5833599 | Schrier et al. | Nov 1998 | A |
5841975 | Layne et al. | Nov 1998 | A |
5842841 | Danby et al. | Dec 1998 | A |
5842976 | Williamson | Dec 1998 | A |
5845253 | Rensimer et al. | Dec 1998 | A |
5848593 | McGrady et al. | Dec 1998 | A |
5851186 | Wood et al. | Dec 1998 | A |
5852590 | De La Huerga | Dec 1998 | A |
5853387 | Clegg et al. | Dec 1998 | A |
5855550 | Buyan et al. | Jan 1999 | A |
5857967 | Frid et al. | Jan 1999 | A |
5859972 | Subramaniam et al. | Jan 1999 | A |
5865745 | Schmitt et al. | Feb 1999 | A |
5865786 | Sibalis et al. | Feb 1999 | A |
5867821 | Ballantyne et al. | Feb 1999 | A |
5871465 | Vasko | Feb 1999 | A |
5876926 | Beecham | Mar 1999 | A |
5880443 | McDonald et al. | Mar 1999 | A |
5882338 | Gray | Mar 1999 | A |
5883370 | Walker et al. | Mar 1999 | A |
5883576 | De La Huerga | Mar 1999 | A |
5885245 | Lynch et al. | Mar 1999 | A |
5891035 | Wood et al. | Apr 1999 | A |
5891734 | Gill et al. | Apr 1999 | A |
5893697 | Zimi et al. | Apr 1999 | A |
5894273 | Meador et al. | Apr 1999 | A |
5895371 | Jordan et al. | Apr 1999 | A |
5897493 | Brown | Apr 1999 | A |
5897530 | Jackson | Apr 1999 | A |
5897989 | Beecham | Apr 1999 | A |
5899665 | Makino et al. | May 1999 | A |
5899855 | Brown | May 1999 | A |
5901150 | Dupouy et al. | May 1999 | A |
5904668 | Hyman et al. | May 1999 | A |
5905653 | Higham et al. | May 1999 | A |
5907291 | Chen et al. | May 1999 | A |
5908027 | Butterfield et al. | Jun 1999 | A |
5910107 | Iliff | Jun 1999 | A |
5910252 | Corbin, III et al. | Jun 1999 | A |
5911132 | Sloane | Jun 1999 | A |
5911687 | Sano et al. | Jun 1999 | A |
5912818 | McGrady et al. | Jun 1999 | A |
5913197 | Kameda | Jun 1999 | A |
5913310 | Brown | Jun 1999 | A |
5915240 | Karpf | Jun 1999 | A |
5919154 | Toavs et al. | Jul 1999 | A |
5921938 | Aoyama et al. | Jul 1999 | A |
5923018 | Kameda et al. | Jul 1999 | A |
5924074 | Evans | Jul 1999 | A |
5924103 | Ahmed et al. | Jul 1999 | A |
5927540 | Godlewski | Jul 1999 | A |
5931791 | Saltzstein et al. | Aug 1999 | A |
5935060 | Iliff | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5935106 | Olsen | Aug 1999 | A |
5938413 | Makino et al. | Aug 1999 | A |
5939326 | Chupp et al. | Aug 1999 | A |
5939699 | Perttunen et al. | Aug 1999 | A |
5940306 | Gardner et al. | Aug 1999 | A |
5940802 | Hildebrand et al. | Aug 1999 | A |
5941829 | Saltzstein et al. | Aug 1999 | A |
5942986 | Shabot et al. | Aug 1999 | A |
5943423 | Muftic | Aug 1999 | A |
5943633 | Wilson et al. | Aug 1999 | A |
5944659 | Flach et al. | Aug 1999 | A |
5945651 | Chorosinski et al. | Aug 1999 | A |
5946083 | Melendez et al. | Aug 1999 | A |
5946659 | Lancelot et al. | Aug 1999 | A |
5950006 | Crater et al. | Sep 1999 | A |
5951300 | Brown | Sep 1999 | A |
5951510 | Barak | Sep 1999 | A |
5954640 | Szabo | Sep 1999 | A |
5954885 | Bollish et al. | Sep 1999 | A |
5954971 | Pages et al. | Sep 1999 | A |
5956023 | Lyle et al. | Sep 1999 | A |
5957885 | Bollish et al. | Sep 1999 | A |
5959529 | Kail, IV | Sep 1999 | A |
5960085 | De La Huerga | Sep 1999 | A |
5960403 | Brown | Sep 1999 | A |
5960991 | Ophardt | Oct 1999 | A |
5961446 | Beller et al. | Oct 1999 | A |
5961448 | Swenson et al. | Oct 1999 | A |
5961487 | Davis | Oct 1999 | A |
5964700 | Tallman et al. | Oct 1999 | A |
5966304 | Cook et al. | Oct 1999 | A |
5967975 | Ridgeway | Oct 1999 | A |
5970423 | Langley et al. | Oct 1999 | A |
5971593 | McGrady | Oct 1999 | A |
5971921 | Timbel | Oct 1999 | A |
5971948 | Pages et al. | Oct 1999 | A |
5974124 | Schlueter, Jr. et al. | Oct 1999 | A |
5975737 | Crater et al. | Nov 1999 | A |
5980490 | Tsoukalis | Nov 1999 | A |
5983193 | Heinonen et al. | Nov 1999 | A |
5987519 | Peifer et al. | Nov 1999 | A |
5991731 | Colon et al. | Nov 1999 | A |
5993046 | McGrady et al. | Nov 1999 | A |
5993420 | Hyman et al. | Nov 1999 | A |
5995077 | Wilcox et al. | Nov 1999 | A |
5995965 | Experton | Nov 1999 | A |
5997167 | Crater et al. | Dec 1999 | A |
5997476 | Brown | Dec 1999 | A |
6003006 | Colella et al. | Dec 1999 | A |
6004020 | Bartur | Dec 1999 | A |
6004276 | Wright et al. | Dec 1999 | A |
6009333 | Chaco | Dec 1999 | A |
6010454 | Arieff et al. | Jan 2000 | A |
6011858 | Stock et al. | Jan 2000 | A |
6011999 | Holmes | Jan 2000 | A |
6012034 | Hamparian et al. | Jan 2000 | A |
6013057 | Danby et al. | Jan 2000 | A |
6014631 | Teagarden et al. | Jan 2000 | A |
6016444 | John | Jan 2000 | A |
6017318 | Gauthier et al. | Jan 2000 | A |
6018713 | Coli et al. | Jan 2000 | A |
6019745 | Gray | Feb 2000 | A |
6021392 | Lester et al. | Feb 2000 | A |
6022315 | Iliff | Feb 2000 | A |
6023522 | Draganoff et al. | Feb 2000 | A |
6024539 | Blomquist | Feb 2000 | A |
6024699 | Allen et al. | Feb 2000 | A |
6027217 | McClure et al. | Feb 2000 | A |
6029138 | Khorasani et al. | Feb 2000 | A |
6032119 | Brown et al. | Feb 2000 | A |
6032155 | de la Huerga | Feb 2000 | A |
6033076 | Braeuning et al. | Mar 2000 | A |
6039251 | Crone et al. | Mar 2000 | A |
6039467 | Holmes | Mar 2000 | A |
6047259 | Campbell et al. | Apr 2000 | A |
6050940 | Braun et al. | Apr 2000 | A |
6055487 | Margery et al. | Apr 2000 | A |
6057758 | Dempsey et al. | May 2000 | A |
6059736 | Tapper | May 2000 | A |
6061603 | Papadopoulos et al. | May 2000 | A |
6065819 | Holmes et al. | May 2000 | A |
6068153 | Young et al. | May 2000 | A |
6073046 | Patel et al. | Jun 2000 | A |
6074345 | van Oostrom et al. | Jun 2000 | A |
6079621 | Vardanyan et al. | Jun 2000 | A |
6080106 | Lloyd et al. | Jun 2000 | A |
6081048 | Bergmann et al. | Jun 2000 | A |
6082776 | Feinberg | Jul 2000 | A |
6083206 | Molko | Jul 2000 | A |
6093146 | Filangeri | Jul 2000 | A |
6095985 | Raymond et al. | Aug 2000 | A |
6101407 | Groezinger | Aug 2000 | A |
6101478 | Brown | Aug 2000 | A |
6102856 | Groff et al. | Aug 2000 | A |
6108399 | Hernandez-Guerra et al. | Aug 2000 | A |
6108588 | McGrady | Aug 2000 | A |
6109774 | Holmes et al. | Aug 2000 | A |
6112224 | Peifer et al. | Aug 2000 | A |
RE36871 | Epstein et al. | Sep 2000 | E |
6113554 | Gilcher et al. | Sep 2000 | A |
6116461 | Broadfield et al. | Sep 2000 | A |
6117940 | Mjalli | Sep 2000 | A |
6123524 | Danby et al. | Sep 2000 | A |
6125350 | Dirbas | Sep 2000 | A |
6129517 | Danby et al. | Oct 2000 | A |
6132371 | Dempsey et al. | Oct 2000 | A |
6134504 | Douglas et al. | Oct 2000 | A |
6135949 | Russo et al. | Oct 2000 | A |
6139495 | De La Huerga | Oct 2000 | A |
6144922 | Douglas et al. | Nov 2000 | A |
6145695 | Garrigues | Nov 2000 | A |
6146523 | Barrett et al. | Nov 2000 | A |
6148297 | Swor et al. | Nov 2000 | A |
6149063 | Reynolds et al. | Nov 2000 | A |
6151536 | Arnold et al. | Nov 2000 | A |
6152364 | Schoonen et al. | Nov 2000 | A |
6154668 | Pedersen et al. | Nov 2000 | A |
6154726 | Rensimer et al. | Nov 2000 | A |
6157914 | Seto et al. | Dec 2000 | A |
6158965 | Butterfield et al. | Dec 2000 | A |
6160478 | Jacobsen et al. | Dec 2000 | A |
6161095 | Brown | Dec 2000 | A |
6163737 | Fedor et al. | Dec 2000 | A |
6165154 | Gray et al. | Dec 2000 | A |
6168563 | Brown | Jan 2001 | B1 |
6170007 | Venkatraman et al. | Jan 2001 | B1 |
6170746 | Brook et al. | Jan 2001 | B1 |
6171112 | Clark et al. | Jan 2001 | B1 |
6171237 | Boaz et al. | Jan 2001 | B1 |
6171264 | Bader | Jan 2001 | B1 |
6173198 | Schulze et al. | Jan 2001 | B1 |
6175779 | Barrett | Jan 2001 | B1 |
6175977 | Schumacher et al. | Jan 2001 | B1 |
6182047 | Dirbas | Jan 2001 | B1 |
6183417 | Geheb et al. | Feb 2001 | B1 |
6186145 | Brown | Feb 2001 | B1 |
6188988 | Barry et al. | Feb 2001 | B1 |
6192320 | Margrey et al. | Feb 2001 | B1 |
6193480 | Butterfield | Feb 2001 | B1 |
6195887 | Danby et al. | Mar 2001 | B1 |
6198394 | Jacobsen et al. | Mar 2001 | B1 |
6200264 | Satherley et al. | Mar 2001 | B1 |
6200289 | Hochman et al. | Mar 2001 | B1 |
6203495 | Bardy | Mar 2001 | B1 |
6203528 | Deckert et al. | Mar 2001 | B1 |
6206238 | Ophardt | Mar 2001 | B1 |
6206829 | Iliff | Mar 2001 | B1 |
6210361 | Kamen et al. | Apr 2001 | B1 |
6213391 | Lewis | Apr 2001 | B1 |
6213738 | Danby et al. | Apr 2001 | B1 |
6219439 | Burger | Apr 2001 | B1 |
6219587 | Ahlin et al. | Apr 2001 | B1 |
6221011 | Bardy | Apr 2001 | B1 |
6221012 | Maschke et al. | Apr 2001 | B1 |
6222619 | Herron et al. | Apr 2001 | B1 |
6224549 | Van Drongelen | May 2001 | B1 |
6225901 | Kail, IV | May 2001 | B1 |
6226564 | Stuart | May 2001 | B1 |
6230142 | Benigno et al. | May 2001 | B1 |
6230927 | Schoonen et al. | May 2001 | B1 |
6234997 | Kamen et al. | May 2001 | B1 |
6245013 | Minoz et al. | Jun 2001 | B1 |
6246473 | Smith, Jr. et al. | Jun 2001 | B1 |
6248063 | Barnhill et al. | Jun 2001 | B1 |
6248065 | Brown | Jun 2001 | B1 |
6255951 | De La Huerga | Jul 2001 | B1 |
6256643 | Cork et al. | Jul 2001 | B1 |
6256967 | Hebron et al. | Jul 2001 | B1 |
6259355 | Chaco et al. | Jul 2001 | B1 |
6259654 | De La Huerga | Jul 2001 | B1 |
6266645 | Simpson | Jul 2001 | B1 |
6269340 | Ford et al. | Jul 2001 | B1 |
D446854 | Cheney, II et al. | Aug 2001 | S |
6270455 | Brown | Aug 2001 | B1 |
6270457 | Bardy | Aug 2001 | B1 |
6272394 | Lipps | Aug 2001 | B1 |
6272505 | De La Huerga | Aug 2001 | B1 |
6277072 | Bardy | Aug 2001 | B1 |
6283322 | Liff et al. | Sep 2001 | B1 |
6283944 | McMullen et al. | Sep 2001 | B1 |
6290646 | Cosentino | Sep 2001 | B1 |
6290650 | Butterfield et al. | Sep 2001 | B1 |
6294999 | Yarin et al. | Sep 2001 | B1 |
6295506 | Heinonen | Sep 2001 | B1 |
6304788 | Eady et al. | Oct 2001 | B1 |
6306088 | Krausman et al. | Oct 2001 | B1 |
6307956 | Black | Oct 2001 | B1 |
6308171 | De La Huerga | Oct 2001 | B1 |
6311163 | Sheehan et al. | Oct 2001 | B1 |
6312227 | Davis | Nov 2001 | B1 |
6312378 | Bardy | Nov 2001 | B1 |
6314384 | Goetz | Nov 2001 | B1 |
6317719 | Schrier et al. | Nov 2001 | B1 |
6319200 | Lai | Nov 2001 | B1 |
6321203 | Kameda | Nov 2001 | B1 |
6322504 | Kirshner | Nov 2001 | B1 |
6322515 | Goor et al. | Nov 2001 | B1 |
RE37531 | Chaco et al. | Jan 2002 | E |
6337631 | Pai | Jan 2002 | B1 |
6338007 | Broadfield et al. | Jan 2002 | B1 |
6339732 | Phoon et al. | Jan 2002 | B1 |
6345260 | Cummings, Jr. et al. | Feb 2002 | B1 |
6346886 | De La Huerga | Feb 2002 | B1 |
6352200 | Schoonen et al. | Mar 2002 | B1 |
6353817 | Jacobs et al. | Mar 2002 | B1 |
6358225 | Butterfield | Mar 2002 | B1 |
6358237 | Paukovits | Mar 2002 | B1 |
6361263 | Dewey et al. | Mar 2002 | B1 |
6362591 | Moberg | Mar 2002 | B1 |
6363282 | Nichols et al. | Mar 2002 | B1 |
6363290 | Lyle et al. | Mar 2002 | B1 |
6366282 | Nichols et al. | Mar 2002 | B1 |
6364834 | Reuss et al. | Apr 2002 | B1 |
6368273 | Brown | Apr 2002 | B1 |
6370841 | Chudy et al. | Apr 2002 | B1 |
6381577 | Brown | Apr 2002 | B1 |
6385505 | Lipps | May 2002 | B1 |
6393369 | Carr | May 2002 | B1 |
6397190 | Goetz | May 2002 | B1 |
6402702 | Gilcher et al. | Jun 2002 | B1 |
6406426 | Reuss et al. | Jun 2002 | B1 |
6407335 | Franklin-Lees et al. | Jun 2002 | B1 |
6408330 | De La Huerga | Jun 2002 | B1 |
6416471 | Kumar et al. | Jul 2002 | B1 |
6421650 | Goetz et al. | Jul 2002 | B1 |
6427088 | Bowman, IV et al. | Jul 2002 | B1 |
6434531 | Lancelot et al. | Aug 2002 | B1 |
6434569 | Tomlinson et al. | Aug 2002 | B1 |
6449927 | Hebron et al. | Sep 2002 | B2 |
6450956 | Rappaport et al. | Sep 2002 | B1 |
6458102 | Mann et al. | Oct 2002 | B1 |
6468242 | Wilson et al. | Oct 2002 | B1 |
6470234 | McGrady | Oct 2002 | B1 |
6471089 | Liff et al. | Oct 2002 | B2 |
6471382 | Eichhorn | Oct 2002 | B2 |
6471645 | Warkentin et al. | Oct 2002 | B1 |
6475146 | Frelburger et al. | Nov 2002 | B1 |
6475148 | Jackson et al. | Nov 2002 | B1 |
6475180 | Peterson et al. | Nov 2002 | B2 |
6478737 | Bardy | Nov 2002 | B2 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6511138 | Gardner et al. | Jan 2003 | B1 |
6519569 | White et al. | Feb 2003 | B1 |
6537244 | Paukovits | Mar 2003 | B2 |
6542902 | Dulong et al. | Apr 2003 | B2 |
6542910 | Cork et al. | Apr 2003 | B2 |
6544174 | West et al. | Apr 2003 | B2 |
6544228 | Heitmeier | Apr 2003 | B1 |
6551243 | Bocionek et al. | Apr 2003 | B2 |
6551276 | Mann et al. | Apr 2003 | B1 |
6554791 | Cartledge et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6555986 | Moberg | Apr 2003 | B2 |
6558321 | Burd et al. | May 2003 | B1 |
6561975 | Pool et al. | May 2003 | B1 |
6562001 | Lebel et al. | May 2003 | B2 |
6564104 | Nelson et al. | May 2003 | B2 |
6564105 | Starkweather et al. | May 2003 | B2 |
6571128 | Lebel et al. | May 2003 | B2 |
6575900 | Zweig et al. | Jun 2003 | B1 |
6577899 | Lebel et al. | Jun 2003 | B2 |
6579232 | Sakamaki et al. | Jun 2003 | B2 |
6581069 | Robinson et al. | Jun 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6585157 | Brandt et al. | Jul 2003 | B2 |
6585644 | Lebel et al. | Jul 2003 | B2 |
6585675 | O'Mahony et al. | Jul 2003 | B1 |
6592551 | Cobb | Jul 2003 | B1 |
6593528 | Franklin-Lees et al. | Jul 2003 | B2 |
6607485 | Bardy | Aug 2003 | B2 |
6613009 | Bainbridge et al. | Sep 2003 | B1 |
6635014 | Starkweather et al. | Oct 2003 | B2 |
6648821 | Lebel et al. | Nov 2003 | B2 |
6659948 | Lebel et al. | Dec 2003 | B2 |
6664893 | Eveland et al. | Dec 2003 | B1 |
6668196 | Villegas et al. | Dec 2003 | B1 |
6673314 | Burbank et al. | Jan 2004 | B1 |
6685831 | Donig | Feb 2004 | B2 |
6687546 | Lebel et al. | Feb 2004 | B2 |
6689091 | Bui et al. | Feb 2004 | B2 |
6694191 | Starkweather et al. | Feb 2004 | B2 |
6694334 | Dulong et al. | Feb 2004 | B2 |
6733446 | Lebel et al. | May 2004 | B2 |
6733447 | Lai et al. | May 2004 | B2 |
6740075 | Lebel et al. | May 2004 | B2 |
6746398 | Hervy et al. | Jun 2004 | B2 |
6758810 | Lebel et al. | Jul 2004 | B2 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6790198 | White et al. | Sep 2004 | B1 |
6804656 | Rosenfeld et al. | Oct 2004 | B1 |
6810290 | Lebel et al. | Oct 2004 | B2 |
6811533 | Lebel et al. | Nov 2004 | B2 |
6811534 | Bowman, IV et al. | Nov 2004 | B2 |
6811707 | Rovatti et al. | Nov 2004 | B2 |
6813519 | Lebel et al. | Nov 2004 | B2 |
6820093 | De La Huerga | Nov 2004 | B2 |
6854088 | Massengale et al. | Feb 2005 | B2 |
6871211 | Labounty et al. | Mar 2005 | B2 |
6873268 | Lebel et al. | Mar 2005 | B2 |
6880034 | Manke et al. | Apr 2005 | B2 |
6885288 | Pincus | Apr 2005 | B2 |
6912549 | Rotter et al. | Jun 2005 | B2 |
6913590 | Sorenson et al. | Jul 2005 | B2 |
6928452 | De La Huerga | Aug 2005 | B2 |
6950708 | Bowman, IV et al. | Sep 2005 | B2 |
6958705 | Lebel et al. | Oct 2005 | B2 |
6974437 | Lebel et al. | Dec 2005 | B2 |
6976628 | Krupa | Dec 2005 | B2 |
6979306 | Moll | Dec 2005 | B2 |
6980958 | Surwit et al. | Dec 2005 | B1 |
7024245 | Lebel et al. | Apr 2006 | B2 |
7039878 | Auer et al. | May 2006 | B2 |
7044927 | Mueller et al. | May 2006 | B2 |
7051002 | Keresman, III et al. | May 2006 | B2 |
7061831 | De La Huerga | Jun 2006 | B2 |
7072769 | Fletcher-Haynes et al. | Jul 2006 | B2 |
7076520 | Nelson et al. | Jul 2006 | B2 |
7089780 | Sunshine et al. | Aug 2006 | B2 |
7092796 | Vanderveen | Aug 2006 | B2 |
7096072 | Engleson et al. | Aug 2006 | B2 |
7117239 | Hansen | Oct 2006 | B1 |
7156808 | Quy | Jan 2007 | B2 |
7161484 | Tsoukalis | Jan 2007 | B2 |
7165221 | Monteleone et al. | Jan 2007 | B2 |
7171274 | Starkweather et al. | Jan 2007 | B2 |
7188151 | Kumar et al. | Mar 2007 | B2 |
7194336 | DeGianfilippo et al. | Mar 2007 | B2 |
7216802 | De La Huerga | May 2007 | B1 |
7231263 | Choi | Jun 2007 | B2 |
7238156 | Adamczyk | Jul 2007 | B1 |
7251610 | Alban et al. | Jul 2007 | B2 |
7264148 | Tachibana | Sep 2007 | B2 |
7274799 | Cohen et al. | Sep 2007 | B2 |
7275220 | Brummel et al. | Sep 2007 | B2 |
7292141 | Staats et al. | Nov 2007 | B2 |
7300418 | Zaleski | Nov 2007 | B2 |
7304582 | Robert et al. | Dec 2007 | B2 |
7308894 | Hickle | Dec 2007 | B2 |
7309323 | Gura et al. | Dec 2007 | B2 |
7315825 | Rosenfeld et al. | Jan 2008 | B2 |
7316648 | Kelly et al. | Jan 2008 | B2 |
7316662 | Delnevo et al. | Jan 2008 | B2 |
7317967 | DeGianfilippo et al. | Jan 2008 | B2 |
7319386 | Collins, Jr. et al. | Jan 2008 | B2 |
7321862 | Rosenfeld et al. | Jan 2008 | B2 |
7343224 | DeGianfilippo et al. | Mar 2008 | B2 |
7347819 | Lebel et al. | Mar 2008 | B2 |
7356382 | Vanderveen | Apr 2008 | B2 |
7369913 | Heminway et al. | May 2008 | B2 |
7383196 | Tang et al. | Jun 2008 | B1 |
7384410 | Eggers et al. | Jun 2008 | B2 |
7428494 | Hasan et al. | Sep 2008 | B2 |
7430608 | Noonan et al. | Sep 2008 | B2 |
7438216 | Ambekar et al. | Oct 2008 | B2 |
7440904 | Hasan et al. | Oct 2008 | B2 |
7464042 | Beraja et al. | Dec 2008 | B2 |
7467055 | Seshimo et al. | Dec 2008 | B2 |
7475020 | Hasan et al. | Jan 2009 | B2 |
7483756 | Engleson et al. | Jan 2009 | B2 |
7490021 | Holland et al. | Feb 2009 | B2 |
7495552 | Zhang et al. | Feb 2009 | B2 |
7509264 | Hasan et al. | Mar 2009 | B2 |
7533030 | Hasan et al. | May 2009 | B2 |
7551078 | Carlson et al. | Jun 2009 | B2 |
7552101 | Bleines | Jun 2009 | B2 |
7565197 | Haubrich et al. | Jul 2009 | B2 |
7565301 | Moubayed et al. | Jul 2009 | B2 |
7590551 | Auer | Sep 2009 | B2 |
7593972 | Silva-Craig et al. | Sep 2009 | B2 |
7595723 | Heitzmann et al. | Sep 2009 | B2 |
7612679 | Fackler et al. | Nov 2009 | B1 |
7630789 | Broadfield et al. | Dec 2009 | B2 |
7630791 | Nguyen et al. | Dec 2009 | B2 |
7634419 | Travis et al. | Dec 2009 | B1 |
7636718 | Steen et al. | Dec 2009 | B1 |
7645258 | White et al. | Jan 2010 | B2 |
7647237 | Malave et al. | Jan 2010 | B2 |
7650146 | Eberhart | Jan 2010 | B2 |
7657443 | Crass et al. | Feb 2010 | B2 |
7664660 | Korpman et al. | Feb 2010 | B2 |
7668977 | Krueger et al. | Feb 2010 | B2 |
7671733 | McNeal et al. | Mar 2010 | B2 |
7678071 | Lebel et al. | Mar 2010 | B2 |
7685003 | Hasan et al. | Mar 2010 | B2 |
7686778 | Burbank et al. | Mar 2010 | B2 |
7689394 | Furem et al. | Mar 2010 | B2 |
7693730 | Hasan et al. | Apr 2010 | B2 |
7698154 | Marchosky | Apr 2010 | B2 |
7703042 | Brummel et al. | Apr 2010 | B2 |
7707047 | Hasan et al. | Apr 2010 | B2 |
7715277 | De La Huerga | May 2010 | B2 |
7717903 | Estes et al. | May 2010 | B2 |
7719414 | Smith et al. | May 2010 | B1 |
7720691 | Hasan et al. | May 2010 | B2 |
7724147 | Brown | May 2010 | B2 |
7737581 | Spurlin et al. | Jun 2010 | B2 |
7771385 | Eggers et al. | Aug 2010 | B2 |
7771386 | Eggers et al. | Aug 2010 | B2 |
7779183 | Koehler et al. | Aug 2010 | B2 |
7788038 | Oshita et al. | Aug 2010 | B2 |
7788369 | McAllen et al. | Aug 2010 | B2 |
7801746 | Moll et al. | Sep 2010 | B2 |
7813879 | Bush et al. | Oct 2010 | B2 |
7818184 | Penny et al. | Oct 2010 | B2 |
7827178 | Ishii et al. | Nov 2010 | B2 |
7831310 | Lebel et al. | Nov 2010 | B2 |
7831446 | Korpman et al. | Nov 2010 | B2 |
7835972 | Schlotterbeck et al. | Nov 2010 | B2 |
7839266 | Hoglund et al. | Nov 2010 | B2 |
7843328 | Knauper | Nov 2010 | B2 |
7853036 | Cohen et al. | Dec 2010 | B2 |
7860583 | Condurso et al. | Dec 2010 | B2 |
7864041 | Godlewski | Jan 2011 | B2 |
7865374 | Ash et al. | Jan 2011 | B2 |
7871394 | Halbert et al. | Jan 2011 | B2 |
7873489 | Dolgos et al. | Jan 2011 | B2 |
7884729 | Reggiardo et al. | Feb 2011 | B2 |
7885823 | Wager | Feb 2011 | B2 |
7886231 | Hopermann et al. | Feb 2011 | B2 |
7890341 | McNally | Feb 2011 | B2 |
7893876 | Brown et al. | Feb 2011 | B2 |
7895053 | Holland et al. | Feb 2011 | B2 |
7896842 | Palmroos et al. | Mar 2011 | B2 |
7904822 | Monteleone et al. | Mar 2011 | B2 |
7920061 | Klein et al. | Apr 2011 | B2 |
7933780 | De La Huerga | Apr 2011 | B2 |
7941306 | Furem et al. | May 2011 | B2 |
7941327 | Brown | May 2011 | B2 |
7941534 | De La Huerga | May 2011 | B2 |
7942844 | Moberg et al. | May 2011 | B2 |
7945452 | Fathallah et al. | May 2011 | B2 |
7958485 | Steiner et al. | Jun 2011 | B2 |
7962544 | Torok et al. | Jun 2011 | B2 |
7970621 | Crooks et al. | Jun 2011 | B2 |
7976508 | Hoag | Jul 2011 | B2 |
7978564 | De La Huerga | Jul 2011 | B2 |
7983753 | Severin | Jul 2011 | B2 |
7983932 | Kane | Jul 2011 | B2 |
7990251 | Ford, Jr. | Aug 2011 | B1 |
7991625 | Rosenfeld et al. | Aug 2011 | B2 |
7991627 | Hutchinson et al. | Aug 2011 | B2 |
7996245 | Gejdos et al. | Aug 2011 | B2 |
8000980 | Beraja et al. | Aug 2011 | B2 |
8000984 | Hasan et al. | Aug 2011 | B2 |
8005688 | Coffman et al. | Aug 2011 | B2 |
8005691 | Kumar et al. | Aug 2011 | B2 |
8010384 | Beraja et al. | Aug 2011 | B2 |
8016790 | Walborn et al. | Sep 2011 | B2 |
8019620 | Miller et al. | Sep 2011 | B2 |
8019623 | McCallie et al. | Sep 2011 | B2 |
8020564 | Batch | Sep 2011 | B2 |
8028694 | Hickle | Oct 2011 | B2 |
8036911 | Bellon et al. | Oct 2011 | B2 |
8038593 | Friedman et al. | Oct 2011 | B2 |
8040238 | Perkins | Oct 2011 | B2 |
8041418 | Giftakis et al. | Oct 2011 | B2 |
8041542 | Pearson | Oct 2011 | B2 |
8055511 | McCallie et al. | Nov 2011 | B2 |
8060315 | Brossette et al. | Nov 2011 | B2 |
8060317 | Brossette et al. | Nov 2011 | B2 |
8060381 | Dyer et al. | Nov 2011 | B2 |
8062513 | Yu et al. | Nov 2011 | B2 |
8065035 | Ross et al. | Nov 2011 | B2 |
8065161 | Howard et al. | Nov 2011 | B2 |
8069418 | Monteleone | Nov 2011 | B2 |
8073710 | Hasan et al. | Dec 2011 | B2 |
8075514 | Butterfield et al. | Dec 2011 | B2 |
8076580 | Kolasa et al. | Dec 2011 | B2 |
8078480 | Gorup et al. | Dec 2011 | B2 |
8078598 | Bell et al. | Dec 2011 | B2 |
8078983 | Davis et al. | Dec 2011 | B2 |
8079594 | Greenawalt | Dec 2011 | B1 |
8079954 | Cohen | Dec 2011 | B2 |
8082160 | Collins, Jr. et al. | Dec 2011 | B2 |
8082161 | DeVerter et al. | Dec 2011 | B2 |
8087062 | Koeda | Dec 2011 | B2 |
8089354 | Perkins | Jan 2012 | B2 |
8095379 | Saus et al. | Jan 2012 | B2 |
8095390 | Bluemler et al. | Jan 2012 | B2 |
8095692 | Mehta et al. | Jan 2012 | B2 |
8099301 | Keresman et al. | Jan 2012 | B2 |
8099304 | Maughan et al. | Jan 2012 | B2 |
8103525 | Kelly et al. | Jan 2012 | B2 |
8105282 | Susi et al. | Jan 2012 | B2 |
D653753 | Ecabert et al. | Feb 2012 | S |
8109921 | Estes et al. | Feb 2012 | B2 |
8112291 | Dyer et al. | Feb 2012 | B2 |
8112293 | Howell et al. | Feb 2012 | B2 |
8117663 | Cross et al. | Feb 2012 | B2 |
8126728 | Bartlett et al. | Feb 2012 | B2 |
8126729 | Bartlett et al. | Feb 2012 | B2 |
8126730 | Bartlett et al. | Feb 2012 | B2 |
8126731 | Dicks et al. | Feb 2012 | B2 |
8126732 | Bartlett et al. | Feb 2012 | B2 |
8126733 | Bartlett et al. | Feb 2012 | B2 |
8126734 | Bartlett et al. | Feb 2012 | B2 |
8126735 | Bartlett et al. | Feb 2012 | B2 |
8126861 | Brackett et al. | Feb 2012 | B2 |
8131563 | Hasan et al. | Mar 2012 | B2 |
8131564 | Dicks et al. | Mar 2012 | B2 |
8131565 | Dicks et al. | Mar 2012 | B2 |
8131566 | Dicks et al. | Mar 2012 | B2 |
8134459 | Brown et al. | Mar 2012 | B2 |
8135876 | Levin | Mar 2012 | B2 |
8140354 | Ash et al. | Mar 2012 | B2 |
8140356 | Bartlett et al. | Mar 2012 | B2 |
8145800 | Levin | Mar 2012 | B2 |
8146149 | Steinkogler et al. | Mar 2012 | B2 |
8149131 | Blomquist | Apr 2012 | B2 |
8150709 | Miller et al. | Apr 2012 | B2 |
8150711 | Gannon et al. | Apr 2012 | B2 |
8150712 | DeVerter et al. | Apr 2012 | B2 |
8155982 | Bartlett et al. | Apr 2012 | B2 |
8170891 | Kelly et al. | May 2012 | B2 |
8171094 | Chan et al. | May 2012 | B2 |
8172752 | Russ | May 2012 | B2 |
8178040 | Brauer | May 2012 | B2 |
8185322 | Schroeder et al. | May 2012 | B2 |
8186358 | Crivelli et al. | May 2012 | B2 |
8190651 | Treu et al. | May 2012 | B2 |
8199685 | Hwang | Jun 2012 | B2 |
8202267 | Field et al. | Jun 2012 | B2 |
8209060 | Ledford | Jun 2012 | B2 |
8211054 | Dewey | Jul 2012 | B2 |
8214227 | Patterson et al. | Jul 2012 | B2 |
8214234 | Hasan et al. | Jul 2012 | B2 |
8219413 | Martinez et al. | Jul 2012 | B2 |
8219982 | Harkanyi et al. | Jul 2012 | B2 |
8225015 | Gao-Saari et al. | Jul 2012 | B2 |
8229760 | Hasan et al. | Jul 2012 | B2 |
8229885 | Steen et al. | Jul 2012 | B2 |
8231578 | Fathallah et al. | Jul 2012 | B2 |
8234128 | Martucci et al. | Jul 2012 | B2 |
8239216 | McCallie, Jr. et al. | Aug 2012 | B2 |
8239780 | Manetta et al. | Aug 2012 | B2 |
8244555 | Masson et al. | Aug 2012 | B2 |
8246563 | Wariar | Aug 2012 | B2 |
8249895 | Faulkner et al. | Aug 2012 | B2 |
8251904 | Zivits | Aug 2012 | B2 |
8255585 | Levin | Aug 2012 | B2 |
8257322 | Koehler | Sep 2012 | B2 |
8257582 | Yu et al. | Sep 2012 | B2 |
8260633 | Beraja et al. | Sep 2012 | B2 |
8260635 | Hasan et al. | Sep 2012 | B2 |
8265954 | Hasan et al. | Sep 2012 | B2 |
8267308 | Devergne et al. | Sep 2012 | B2 |
8271106 | Wehba et al. | Sep 2012 | B2 |
8271297 | Crooks et al. | Sep 2012 | B2 |
8273018 | Fackler et al. | Sep 2012 | B1 |
8275576 | Furem et al. | Sep 2012 | B2 |
8284059 | Ross | Oct 2012 | B2 |
8286088 | Shaffer et al. | Oct 2012 | B2 |
8287487 | Estes | Oct 2012 | B2 |
8291337 | Gannin et al. | Oct 2012 | B2 |
8292173 | Yturralde et al. | Oct 2012 | B2 |
8306797 | Furem et al. | Nov 2012 | B2 |
8309444 | Hui et al. | Nov 2012 | B2 |
8313433 | Cohen et al. | Nov 2012 | B2 |
8317752 | Cozmi et al. | Nov 2012 | B2 |
8321044 | Plahey et al. | Nov 2012 | B2 |
8321239 | Hasan et al. | Nov 2012 | B2 |
8323503 | Levin et al. | Dec 2012 | B2 |
8327020 | Sarathi et al. | Dec 2012 | B1 |
8340792 | Condurso et al. | Dec 2012 | B2 |
8344847 | Moberg et al. | Jan 2013 | B2 |
8348885 | Moberg et al. | Jan 2013 | B2 |
8350195 | Hedmann et al. | Jan 2013 | B2 |
8352290 | Bartz et al. | Jan 2013 | B2 |
8354029 | Hank | Jan 2013 | B2 |
8359338 | Butterfield et al. | Jan 2013 | B2 |
8361006 | Kraemer | Jan 2013 | B2 |
8361031 | Halbert et al. | Jan 2013 | B2 |
8366921 | Beden et al. | Feb 2013 | B2 |
8367731 | Wieslander et al. | Feb 2013 | B2 |
8370352 | Lita et al. | Feb 2013 | B2 |
8372059 | Ziman | Feb 2013 | B2 |
8372105 | Nishiuchi et al. | Feb 2013 | B2 |
8373557 | Smith et al. | Feb 2013 | B2 |
8377293 | Beden et al. | Feb 2013 | B2 |
8380536 | Howard et al. | Feb 2013 | B2 |
8382721 | Woehr et al. | Feb 2013 | B2 |
8392210 | Beraja et al. | Mar 2013 | B2 |
8392211 | Beraja et al. | Mar 2013 | B2 |
8392212 | Beraja et al. | Mar 2013 | B2 |
8392213 | Beraja et al. | Mar 2013 | B2 |
8395761 | Fulkerson et al. | Mar 2013 | B2 |
8396689 | Pfeifer et al. | Mar 2013 | B2 |
8397211 | Ionfrida et al. | Mar 2013 | B2 |
8398619 | Doyle et al. | Mar 2013 | B2 |
8402151 | Young et al. | Mar 2013 | B2 |
8403886 | Bialecki et al. | Mar 2013 | B2 |
8409127 | Gronau et al. | Apr 2013 | B2 |
8409445 | Levin et al. | Apr 2013 | B2 |
8414523 | Blomquist et al. | Apr 2013 | B2 |
8419688 | Woehr et al. | Apr 2013 | B2 |
8425780 | Beiriger | Apr 2013 | B2 |
8429230 | Amberg et al. | Apr 2013 | B2 |
8430833 | Gagel et al. | Apr 2013 | B2 |
8430834 | Kopperschmidt | Apr 2013 | B2 |
8432465 | Kramp et al. | Apr 2013 | B2 |
8435206 | Evans et al. | May 2013 | B2 |
8435454 | Elizarov et al. | May 2013 | B2 |
8439857 | Kopperschmidt et al. | May 2013 | B2 |
8444595 | Brukalo et al. | May 2013 | B2 |
8447706 | Schneegaß | May 2013 | B2 |
8449523 | Brukalo et al. | May 2013 | B2 |
8449686 | Schlaeper et al. | May 2013 | B2 |
8454550 | Koenig et al. | Jun 2013 | B2 |
8457704 | Sweitzer et al. | Jun 2013 | B2 |
8460247 | Woehr et al. | Jun 2013 | B2 |
8460552 | Kopperschmidt et al. | Jun 2013 | B2 |
8460558 | Brugger et al. | Jun 2013 | B2 |
8465237 | Lynderup | Jun 2013 | B2 |
8465641 | Maierhofer et al. | Jun 2013 | B2 |
8469331 | Burbank et al. | Jun 2013 | B2 |
8473502 | Ledford et al. | Jun 2013 | B2 |
8475399 | Fulkerson | Jul 2013 | B2 |
8479147 | Nelson et al. | Jul 2013 | B2 |
8483417 | Huttinger | Jul 2013 | B2 |
8485998 | Moll et al. | Jul 2013 | B2 |
8488013 | Jia et al. | Jul 2013 | B2 |
8490622 | Stenzler et al. | Jul 2013 | B2 |
8493224 | Coon | Jul 2013 | B2 |
8494879 | Davis et al. | Jul 2013 | B2 |
8504179 | Blomquist | Aug 2013 | B2 |
8506885 | Kotsas et al. | Aug 2013 | B2 |
8521563 | Severin | Aug 2013 | B2 |
8543416 | Palmroos et al. | Sep 2013 | B2 |
8543420 | Darby et al. | Sep 2013 | B2 |
8579813 | Causey, III et al. | Nov 2013 | B2 |
8585604 | Bennett et al. | Nov 2013 | B2 |
8591430 | Amurthur et al. | Nov 2013 | B2 |
8612257 | Zaitsu et al. | Dec 2013 | B2 |
8615299 | Goetz | Dec 2013 | B2 |
8630722 | Condurso et al. | Jan 2014 | B2 |
8632485 | Schlaeper et al. | Jan 2014 | B2 |
8638997 | Dirckx | Jan 2014 | B2 |
8648910 | Heydlauf | Feb 2014 | B2 |
8652093 | Lee et al. | Feb 2014 | B2 |
8655676 | Wehba et al. | Feb 2014 | B2 |
8662388 | Belkin | Mar 2014 | B2 |
8663103 | Causey, III et al. | Mar 2014 | B2 |
8666488 | Duke | Mar 2014 | B2 |
8666760 | Batch | Mar 2014 | B2 |
8666769 | Butler et al. | Mar 2014 | B2 |
8679075 | Lurvey | Mar 2014 | B2 |
8683461 | Ladic et al. | Mar 2014 | B2 |
8684927 | Basaglia | Apr 2014 | B2 |
8695429 | Urban et al. | Apr 2014 | B2 |
8696613 | Mastalli et al. | Apr 2014 | B2 |
8700421 | Feng et al. | Apr 2014 | B2 |
8715180 | Cohen et al. | May 2014 | B2 |
8731957 | Herbst et al. | May 2014 | B2 |
8761906 | Condurso et al. | Jun 2014 | B2 |
8769625 | Wang | Jul 2014 | B2 |
8793623 | Halbert et al. | Jul 2014 | B2 |
8799012 | Butler et al. | Aug 2014 | B2 |
20010001237 | Stroda et al. | May 2001 | A1 |
20010003177 | Schena et al. | Jun 2001 | A1 |
20010007053 | Bardy | Jul 2001 | A1 |
20010007932 | Kamen et al. | Jul 2001 | A1 |
20010011153 | Bardy | Aug 2001 | A1 |
20010016699 | Burbank et al. | Aug 2001 | A1 |
20010017817 | De La Huerga | Aug 2001 | A1 |
20010021801 | Bardy | Sep 2001 | A1 |
20010025138 | Bardy | Sep 2001 | A1 |
20010025156 | Bui et al. | Sep 2001 | A1 |
20010027634 | Hebron et al. | Oct 2001 | A1 |
20010028308 | De La Huerga | Oct 2001 | A1 |
20010030234 | Wiklof | Oct 2001 | A1 |
20010031944 | Peterson et al. | Oct 2001 | A1 |
20010032101 | Statius Muller | Oct 2001 | A1 |
20010034502 | Moberg et al. | Oct 2001 | A1 |
20010034616 | Giannini | Oct 2001 | A1 |
20010037057 | Bardy | Nov 2001 | A1 |
20010037083 | Hartlaub et al. | Nov 2001 | A1 |
20010037217 | Abensour et al. | Nov 2001 | A1 |
20010037220 | Merry et al. | Nov 2001 | A1 |
20010041920 | Starkweather et al. | Nov 2001 | A1 |
20010044588 | Mault | Nov 2001 | A1 |
20010044731 | Coffman et al. | Nov 2001 | A1 |
20010051764 | Bardy | Dec 2001 | A1 |
20010053885 | Gielen et al. | Dec 2001 | A1 |
20020002326 | Causey, III et al. | Jan 2002 | A1 |
20020002473 | Schrier et al. | Jan 2002 | A1 |
20020004645 | Carlisle et al. | Jan 2002 | A1 |
20020010568 | Rubbert et al. | Jan 2002 | A1 |
20020013612 | Whitehurst | Jan 2002 | A1 |
20020016567 | Hochman et al. | Feb 2002 | A1 |
20020016568 | Lebel et al. | Feb 2002 | A1 |
20020016719 | Nemeth et al. | Feb 2002 | A1 |
20020016722 | Kameda | Feb 2002 | A1 |
20020019606 | Lebel et al. | Feb 2002 | A1 |
20020019748 | Brown | Feb 2002 | A1 |
20020022776 | Bardy | Feb 2002 | A1 |
20020025796 | Taylor et al. | Feb 2002 | A1 |
20020026104 | Bardy | Feb 2002 | A1 |
20020029157 | Marchosky | Mar 2002 | A1 |
20020029776 | Blomquist | Mar 2002 | A1 |
20020032602 | Lanzillo, Jr. et al. | Mar 2002 | A1 |
20020038392 | De La Huerga | Mar 2002 | A1 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20020040282 | Bailey | Apr 2002 | A1 |
20020044043 | Chaco et al. | Apr 2002 | A1 |
20020046062 | Kameda | Apr 2002 | A1 |
20020046185 | Villart et al. | Apr 2002 | A1 |
20020046346 | Evans | Apr 2002 | A1 |
20020052539 | Haller et al. | May 2002 | A1 |
20020052542 | Bardy | May 2002 | A1 |
20020052574 | Hochman et al. | May 2002 | A1 |
20020065540 | Lebel et al. | May 2002 | A1 |
20020067273 | Jaques et al. | Jun 2002 | A1 |
20020072733 | Flaherty | Jun 2002 | A1 |
20020077852 | Ford et al. | Jun 2002 | A1 |
20020077865 | Sullivan | Jun 2002 | A1 |
20020082480 | Riff et al. | Jun 2002 | A1 |
20020082728 | Mueller | Jun 2002 | A1 |
20020082865 | Bianco et al. | Jun 2002 | A1 |
20020082868 | Pories et al. | Jun 2002 | A1 |
20020084904 | De La Huerga | Jul 2002 | A1 |
20020087120 | Rogers et al. | Jul 2002 | A1 |
20020087361 | Benigno et al. | Jul 2002 | A1 |
20020099283 | Christ et al. | Jul 2002 | A1 |
20020099301 | Bardy | Jul 2002 | A1 |
20020100762 | Liff et al. | Aug 2002 | A1 |
20020103453 | Burbank et al. | Aug 2002 | A1 |
20020107476 | Mann et al. | Aug 2002 | A1 |
20020107707 | Naparstek et al. | Aug 2002 | A1 |
20020116509 | De La Huerga | Aug 2002 | A1 |
20020128606 | Cowan et al. | Sep 2002 | A1 |
20020128871 | Adamson et al. | Sep 2002 | A1 |
20020128880 | Kunikiyo | Sep 2002 | A1 |
20020133377 | Brown | Sep 2002 | A1 |
20020140675 | Ali et al. | Oct 2002 | A1 |
20020143254 | Maruyama | Oct 2002 | A1 |
20020147423 | Burbank et al. | Oct 2002 | A1 |
20020156462 | Stultz | Oct 2002 | A1 |
20020158128 | Ashiuro | Oct 2002 | A1 |
20020165491 | Reilly | Nov 2002 | A1 |
20020169636 | Eggers et al. | Nov 2002 | A1 |
20020198513 | Lebel et al. | Dec 2002 | A1 |
20030023177 | Bardy | Jan 2003 | A1 |
20030036783 | Bauhahn et al. | Feb 2003 | A1 |
20030050621 | Lebel et al. | Mar 2003 | A1 |
20030052787 | Zerhusen | Mar 2003 | A1 |
20030060753 | Starkweather et al. | Mar 2003 | A1 |
20030060754 | Reilly | Mar 2003 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030060768 | Kiyatake | Mar 2003 | A1 |
20030065287 | Spohn et al. | Apr 2003 | A1 |
20030078534 | Hochman et al. | Apr 2003 | A1 |
20030083901 | Bosch et al. | May 2003 | A1 |
20030088238 | Poulsen et al. | May 2003 | A1 |
20030097092 | Flaherty | May 2003 | A1 |
20030114836 | Estes et al. | Jun 2003 | A1 |
20030125611 | Bardy | Jul 2003 | A1 |
20030139701 | White et al. | Jul 2003 | A1 |
20030140929 | Wilkes et al. | Jul 2003 | A1 |
20030141368 | Pascual et al. | Jul 2003 | A1 |
20030144878 | Wilkes et al. | Jul 2003 | A1 |
20030144880 | Talachian et al. | Jul 2003 | A1 |
20030144881 | Talachian et al. | Jul 2003 | A1 |
20030144882 | Talachian et al. | Jul 2003 | A1 |
20030154108 | Fletcher-Haynes et al. | Aug 2003 | A1 |
20030160683 | Blomquist | Aug 2003 | A1 |
20030163088 | Blomquist | Aug 2003 | A1 |
20030163223 | Blomquist | Aug 2003 | A1 |
20030163789 | Blomquist | Aug 2003 | A1 |
20030167035 | Flaherty et al. | Sep 2003 | A1 |
20030176933 | Lebel et al. | Sep 2003 | A1 |
20030181851 | Mann et al. | Sep 2003 | A1 |
20030182164 | Shabot et al. | Sep 2003 | A1 |
20030195397 | Bardy | Oct 2003 | A1 |
20030201697 | Richardson | Oct 2003 | A1 |
20030204414 | Wilkes et al. | Oct 2003 | A1 |
20030204416 | Radpay et al. | Oct 2003 | A1 |
20030204419 | Wilkes et al. | Oct 2003 | A1 |
20030204420 | Wilkes et al. | Oct 2003 | A1 |
20030212379 | Bylund et al. | Nov 2003 | A1 |
20030220598 | Busby | Nov 2003 | A1 |
20030225596 | Richardson et al. | Dec 2003 | A1 |
20030225728 | Moura | Dec 2003 | A1 |
20040010425 | Wilkes et al. | Jan 2004 | A1 |
20040115132 | Brown | Jan 2004 | A1 |
20040039260 | Bardy | Feb 2004 | A1 |
20040039264 | Bardy | Feb 2004 | A1 |
20040051368 | Caputo et al. | Mar 2004 | A1 |
20040088374 | Webb et al. | May 2004 | A1 |
20040111293 | Firanek et al. | Jun 2004 | A1 |
20040111294 | McNally et al. | Jun 2004 | A1 |
20040116862 | Ray | Jun 2004 | A1 |
20040117215 | Marchosky | Jun 2004 | A1 |
20040121767 | Simpson et al. | Jun 2004 | A1 |
20040167465 | Mihai et al. | Aug 2004 | A1 |
20040172222 | Simpson et al. | Sep 2004 | A1 |
20040172283 | Vanderveen et al. | Sep 2004 | A1 |
20040172300 | Mihai et al. | Sep 2004 | A1 |
20040172301 | Mihai et al. | Sep 2004 | A1 |
20040172302 | Martucci et al. | Sep 2004 | A1 |
20040176667 | Mihai et al. | Sep 2004 | A1 |
20040193328 | Zaitsu et al. | Sep 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040215490 | Duchon et al. | Oct 2004 | A1 |
20040220829 | Baharav et al. | Nov 2004 | A1 |
20040235446 | Flaherty et al. | Nov 2004 | A1 |
20040260233 | Garibotto et al. | Dec 2004 | A1 |
20050021370 | Riff et al. | Jan 2005 | A1 |
20050038680 | McMahon | Feb 2005 | A1 |
20050054923 | Pan | Mar 2005 | A1 |
20050055242 | Bello et al. | Mar 2005 | A1 |
20050065817 | Mihai et al. | Mar 2005 | A1 |
20050070767 | Maschke | Mar 2005 | A1 |
20050071194 | Bormann et al. | Mar 2005 | A1 |
20050080651 | Morrison et al. | Apr 2005 | A1 |
20050177096 | Bollish et al. | Apr 2005 | A1 |
20050102167 | Kapoor | May 2005 | A1 |
20050131340 | Sorenson et al. | Jun 2005 | A1 |
20050131741 | Tang et al. | Jun 2005 | A1 |
20050135306 | McAllen et al. | Jun 2005 | A1 |
20050137573 | McLaughlin | Jun 2005 | A1 |
20050139651 | Lim et al. | Jun 2005 | A1 |
20050143671 | Hastings et al. | Jun 2005 | A1 |
20050148890 | Hastings | Jul 2005 | A1 |
20050171815 | Vanderveen | Aug 2005 | A1 |
20050177395 | Blomquist | Aug 2005 | A1 |
20050201345 | Williamson | Sep 2005 | A1 |
20050228693 | Webb et al. | Oct 2005 | A1 |
20050231374 | Diem et al. | Oct 2005 | A1 |
20050234381 | Niemetz et al. | Oct 2005 | A1 |
20050246416 | Blomquist | Nov 2005 | A1 |
20050267780 | Ray et al. | Dec 2005 | A1 |
20050277890 | Stewart et al. | Dec 2005 | A1 |
20050277911 | Stewart et al. | Dec 2005 | A1 |
20050278194 | Holland et al. | Dec 2005 | A1 |
20050283385 | Hunkeler et al. | Dec 2005 | A1 |
20060015015 | Kawamoto et al. | Jan 2006 | A1 |
20060167722 | Struys et al. | Jan 2006 | A1 |
20060064020 | Burnes et al. | Mar 2006 | A1 |
20060064053 | Bollish et al. | Mar 2006 | A1 |
20060065713 | Kingery | Mar 2006 | A1 |
20060089539 | Miodownik et al. | Apr 2006 | A1 |
20060089854 | Holland et al. | Apr 2006 | A1 |
20060089855 | Holland et al. | Apr 2006 | A1 |
20060100907 | Holland et al. | May 2006 | A1 |
20060106647 | Brummel et al. | May 2006 | A1 |
20060106649 | Eggers et al. | May 2006 | A1 |
20060116639 | Russell | Jun 2006 | A1 |
20060143051 | Eggers et al. | Jun 2006 | A1 |
20060149591 | Hanf et al. | Jul 2006 | A1 |
20060173713 | Petro et al. | Aug 2006 | A1 |
20060190302 | Eggers et al. | Aug 2006 | A1 |
20060200369 | Batch et al. | Sep 2006 | A1 |
20060206356 | Vanderveen | Sep 2006 | A1 |
20060211994 | Roman et al. | Sep 2006 | A1 |
20060229551 | Martinez et al. | Oct 2006 | A1 |
20060247606 | Batch | Nov 2006 | A1 |
20060253301 | Simms et al. | Nov 2006 | A1 |
20060258985 | Russell | Nov 2006 | A1 |
20060259327 | Hoag | Nov 2006 | A1 |
20060277070 | Hungerford et al. | Dec 2006 | A1 |
20070033073 | Tajaliawal | Feb 2007 | A1 |
20070073266 | Chmiel et al. | Mar 2007 | A1 |
20070083386 | Chuang et al. | Apr 2007 | A1 |
20070083390 | Gorup et al. | Apr 2007 | A1 |
20070088578 | Hoffman et al. | Apr 2007 | A1 |
20070124002 | Estes et al. | May 2007 | A1 |
20070129983 | Scherpbier et al. | Jun 2007 | A1 |
20070135866 | Baker et al. | Jun 2007 | A1 |
20070156452 | Batch | Jul 2007 | A1 |
20070158268 | DeComo | Jul 2007 | A1 |
20070179807 | Nessinger et al. | Aug 2007 | A1 |
20070185738 | Anuszewski et al. | Aug 2007 | A1 |
20070197878 | Shklarski | Aug 2007 | A1 |
20070198293 | Ash et al. | Aug 2007 | A1 |
20070203753 | Hasan et al. | Aug 2007 | A1 |
20070214003 | Holland et al. | Sep 2007 | A1 |
20070233035 | Wehba et al. | Oct 2007 | A1 |
20070233049 | Wehba et al. | Oct 2007 | A1 |
20070233050 | Wehba et al. | Oct 2007 | A1 |
20070233281 | Wehba et al. | Oct 2007 | A1 |
20070233520 | Wehba et al. | Oct 2007 | A1 |
20070233521 | Wehba et al. | Oct 2007 | A1 |
20070255126 | Moberg et al. | Nov 2007 | A1 |
20070265879 | Charlson et al. | Nov 2007 | A1 |
20070276869 | Charlson et al. | Nov 2007 | A1 |
20070293817 | Feng et al. | Dec 2007 | A1 |
20080015895 | Charlson et al. | Jan 2008 | A1 |
20080021741 | Holla et al. | Jan 2008 | A1 |
20080033360 | Evans et al. | Feb 2008 | A1 |
20080033749 | Blomquist | Feb 2008 | A1 |
20080034323 | Blomquist | Feb 2008 | A1 |
20080040151 | Moore | Feb 2008 | A1 |
20080045932 | Beau et al. | Feb 2008 | A1 |
20080052317 | Francis et al. | Feb 2008 | A1 |
20080059239 | Gerst et al. | Mar 2008 | A1 |
20080076969 | Kraft et al. | Mar 2008 | A1 |
20080077436 | Muradia | Mar 2008 | A1 |
20080091466 | Butler et al. | Apr 2008 | A1 |
20080097912 | Dicks et al. | Apr 2008 | A1 |
20080097913 | Dicks et al. | Apr 2008 | A1 |
20080097914 | Dicks et al. | Apr 2008 | A1 |
20080103554 | Dicks et al. | May 2008 | A1 |
20080114292 | Rasch-Menges et al. | May 2008 | A1 |
20080126969 | Blomquist | May 2008 | A1 |
20080133265 | Silkaitis et al. | Jun 2008 | A1 |
20080143515 | Wood et al. | Jun 2008 | A1 |
20080161754 | Marano-Ford | Jul 2008 | A1 |
20080176210 | Moll et al. | Jul 2008 | A1 |
20080195422 | Nessinger et al. | Aug 2008 | A1 |
20080201168 | Brown | Aug 2008 | A1 |
20080215627 | Higgins et al. | Sep 2008 | A1 |
20080243549 | Woronka et al. | Oct 2008 | A1 |
20080255874 | Crooks et al. | Oct 2008 | A1 |
20080281165 | Rai et al. | Nov 2008 | A1 |
20080287749 | Reuter | Nov 2008 | A1 |
20080306796 | Zimmerman et al. | Dec 2008 | A1 |
20080312584 | Montgomery et al. | Dec 2008 | A1 |
20080312960 | Nikolic | Dec 2008 | A1 |
20090008447 | Godlewski | Jan 2009 | A1 |
20090036750 | Weinstein et al. | Feb 2009 | A1 |
20090037020 | Brown | Feb 2009 | A1 |
20090037220 | Chambers et al. | Feb 2009 | A1 |
20090048868 | Portnoy et al. | Feb 2009 | A1 |
20090050544 | Zhang | Feb 2009 | A1 |
20090076844 | Koegen | Mar 2009 | A1 |
20090076856 | Darby et al. | Mar 2009 | A1 |
20090076857 | Eletreby et al. | Mar 2009 | A1 |
20090096751 | Ross et al. | Apr 2009 | A1 |
20090099862 | Fireman et al. | Apr 2009 | A1 |
20090099867 | Newman | Apr 2009 | A1 |
20090105566 | Smith et al. | Apr 2009 | A1 |
20090105567 | Smith et al. | Apr 2009 | A1 |
20090108011 | Heffron | Apr 2009 | A1 |
20090108016 | Brown et al. | Apr 2009 | A1 |
20090112179 | Zoltan et al. | Apr 2009 | A1 |
20090125336 | Wehba et al. | May 2009 | A1 |
20090146822 | Soliman | Jun 2009 | A1 |
20090150549 | Young et al. | Jun 2009 | A1 |
20090150865 | Young et al. | Jun 2009 | A1 |
20090153463 | Arrizza et al. | Jun 2009 | A1 |
20090153595 | Cozmi et al. | Jun 2009 | A1 |
20090156991 | Roberts | Jun 2009 | A1 |
20090157430 | Rule et al. | Jun 2009 | A1 |
20090163855 | Shin et al. | Jun 2009 | A1 |
20090171312 | Moubayed et al. | Jul 2009 | A1 |
20090177180 | Rubalcaba, Jr. et al. | Jul 2009 | A1 |
20090177188 | Steinkogler | Jul 2009 | A1 |
20090177769 | Roberts | Jul 2009 | A1 |
20090177992 | Rubalcaba, Jr. et al. | Jul 2009 | A1 |
20090183105 | Teel, IV et al. | Jul 2009 | A1 |
20090183147 | Davis et al. | Jul 2009 | A1 |
20090203329 | White et al. | Aug 2009 | A1 |
20090210249 | Rasch-Menges et al. | Aug 2009 | A1 |
20090216562 | Faulkner et al. | Aug 2009 | A1 |
20090222119 | Plahey et al. | Sep 2009 | A1 |
20090223880 | Zhang et al. | Sep 2009 | A2 |
20090234672 | Dicks et al. | Sep 2009 | A1 |
20090240525 | Sadler et al. | Sep 2009 | A1 |
20090240526 | Vesto et al. | Sep 2009 | A1 |
20090249076 | Reed et al. | Oct 2009 | A1 |
20090254365 | Gravina | Oct 2009 | A1 |
20090270810 | DeBelser et al. | Oct 2009 | A1 |
20090270833 | DeBelser et al. | Oct 2009 | A1 |
20090306573 | Gagner et al. | Dec 2009 | A1 |
20090307008 | Smith et al. | Dec 2009 | A1 |
20090326389 | Ralfs | Dec 2009 | A1 |
20090326722 | Pohlman et al. | Dec 2009 | A1 |
20100010426 | Childers et al. | Jan 2010 | A1 |
20100010428 | Yu et al. | Jan 2010 | A1 |
20100016776 | Roher et al. | Jan 2010 | A1 |
20100019910 | Hassing et al. | Jan 2010 | A1 |
20100023342 | Johannes et al. | Jan 2010 | A1 |
20100030302 | Blowers et al. | Feb 2010 | A1 |
20100049114 | Brown et al. | Feb 2010 | A1 |
20100063840 | Hoyme et al. | Mar 2010 | A1 |
20100067553 | McKinney et al. | Mar 2010 | A1 |
20100069730 | Bergstrom et al. | Mar 2010 | A1 |
20100070550 | Hein | Mar 2010 | A1 |
20100076453 | Morris et al. | Mar 2010 | A1 |
20100082458 | Godlewski | Apr 2010 | A1 |
20100094098 | Smith et al. | Apr 2010 | A1 |
20100100071 | Ross | Apr 2010 | A1 |
20100106530 | Hanf et al. | Apr 2010 | A1 |
20100106531 | Hanf et al. | Apr 2010 | A1 |
20100114601 | Manasco et al. | May 2010 | A1 |
20100121654 | Portnoy et al. | May 2010 | A1 |
20100131434 | Magent et al. | May 2010 | A1 |
20100137693 | Porras | Jun 2010 | A1 |
20100138238 | Sobie | Jun 2010 | A1 |
20100138524 | Sobie | Jun 2010 | A1 |
20100165795 | Elder et al. | Jul 2010 | A1 |
20100169109 | Pelegrin et al. | Jul 2010 | A1 |
20100169120 | Herbst et al. | Jul 2010 | A1 |
20100169355 | Rosenberger et al. | Jul 2010 | A1 |
20100169771 | Pelegrin et al. | Jul 2010 | A1 |
20100174229 | Hsu et al. | Jul 2010 | A1 |
20100179819 | Herbst et al. | Jul 2010 | A1 |
20100179821 | Gedeon et al. | Jul 2010 | A1 |
20100179823 | Carter et al. | Jul 2010 | A1 |
20100179828 | Kelly et al. | Jul 2010 | A1 |
20100179829 | Gedeon et al. | Jul 2010 | A1 |
20100179830 | Bagwandeen | Jul 2010 | A1 |
20100179834 | Wager | Jul 2010 | A1 |
20100179835 | Wager | Jul 2010 | A1 |
20100198196 | Wei | Aug 2010 | A1 |
20100198314 | Wei | Aug 2010 | A1 |
20100198618 | Oliver et al. | Aug 2010 | A1 |
20100211402 | Eggena et al. | Aug 2010 | A1 |
20100213127 | Castellarnau | Aug 2010 | A1 |
20100222846 | Goetz | Sep 2010 | A1 |
20100235179 | Kienle et al. | Sep 2010 | A1 |
20100241458 | Hasan et al. | Sep 2010 | A1 |
20100251114 | Wehba et al. | Sep 2010 | A1 |
20100257189 | Campbell et al. | Oct 2010 | A1 |
20100271218 | Hoag et al. | Oct 2010 | A1 |
20100274592 | Nitzan et al. | Oct 2010 | A1 |
20100280395 | Lin | Nov 2010 | A1 |
20100280486 | Khair et al. | Nov 2010 | A1 |
20100287006 | Cannon et al. | Nov 2010 | A1 |
20100312176 | Lauer et al. | Dec 2010 | A1 |
20100318062 | Lauer et al. | Dec 2010 | A1 |
20100318699 | Gao-Saari et al. | Dec 2010 | A1 |
20100324936 | Vishnubhatla et al. | Dec 2010 | A1 |
20110004186 | Butterfield | Jan 2011 | A1 |
20110009707 | Kaudinya et al. | Jan 2011 | A1 |
20110009814 | Tsoukalis | Jan 2011 | A1 |
20110010275 | Hull | Jan 2011 | A1 |
20110015693 | Williamson | Jan 2011 | A1 |
20110016026 | Godlewski | Jan 2011 | A1 |
20110028881 | Basaglia | Feb 2011 | A1 |
20110028882 | Basaglia | Feb 2011 | A1 |
20110030034 | Ross | Feb 2011 | A1 |
20110033833 | Blomquist et al. | Feb 2011 | A1 |
20110040572 | Svore et al. | Feb 2011 | A1 |
20110047176 | Hoffman | Feb 2011 | A1 |
20110050428 | Istoc | Mar 2011 | A1 |
20110060758 | Schlotterbeck et al. | Mar 2011 | A1 |
20110066006 | Banet et al. | Mar 2011 | A1 |
20110066043 | Banet et al. | Mar 2011 | A1 |
20110066693 | Basaglia | Mar 2011 | A1 |
20110071844 | Cannon et al. | Mar 2011 | A1 |
20110072379 | Gannon et al. | Mar 2011 | A1 |
20110072381 | Gannon et al. | Mar 2011 | A1 |
20110072422 | Brauer | Mar 2011 | A1 |
20110074576 | Ross | Mar 2011 | A1 |
20110077965 | Nolte et al. | Mar 2011 | A1 |
20110077973 | Breitenstein et al. | Mar 2011 | A1 |
20110078608 | Gannon et al. | Mar 2011 | A1 |
20110081888 | Waniss | Apr 2011 | A1 |
20110087499 | Menon et al. | Apr 2011 | A1 |
20110093293 | G. N. et al. | Apr 2011 | A1 |
20110093504 | Butler et al. | Apr 2011 | A1 |
20110093510 | Beck et al. | Apr 2011 | A1 |
20110105979 | Schlaeper et al. | May 2011 | A1 |
20110107251 | Guaitoli et al. | May 2011 | A1 |
20110115624 | Tran | May 2011 | A1 |
20110118573 | McKenna | May 2011 | A1 |
20110119612 | Gannon et al. | May 2011 | A1 |
20110139871 | Yturralde | Jun 2011 | A1 |
20110152830 | Ruchti et al. | Jun 2011 | A1 |
20110153343 | Tremblay et al. | Jun 2011 | A1 |
20110163034 | Castellarnau | Jul 2011 | A1 |
20110167250 | Dicks et al. | Jul 2011 | A1 |
20110172744 | Davis et al. | Jul 2011 | A1 |
20110179405 | Dicks et al. | Jul 2011 | A1 |
20110187509 | Raptis et al. | Aug 2011 | A1 |
20110187544 | Trembley et al. | Aug 2011 | A1 |
20110196306 | De La Huerga | Aug 2011 | A1 |
20110218514 | Rebours | Sep 2011 | A1 |
20110231204 | De La Huerga | Sep 2011 | A1 |
20110237960 | Rantala | Sep 2011 | A1 |
20110241878 | Hoag | Oct 2011 | A1 |
20110257607 | Whitley | Oct 2011 | A1 |
20110257891 | Akonur | Oct 2011 | A1 |
20110259954 | Bartz et al. | Oct 2011 | A1 |
20110264045 | Thompson et al. | Oct 2011 | A1 |
20110275904 | Lebel et al. | Oct 2011 | A1 |
20110266999 | Yodfat et al. | Nov 2011 | A1 |
20110276605 | Masson et al. | Nov 2011 | A1 |
20110282688 | Raggousis | Nov 2011 | A1 |
20110282691 | Coffman et al. | Nov 2011 | A1 |
20110288428 | Valentine | Nov 2011 | A1 |
20110301478 | Ben-Sira | Dec 2011 | A1 |
20110319825 | Goral et al. | Dec 2011 | A1 |
20110320049 | Chossat et al. | Dec 2011 | A1 |
20120010554 | Vantard et al. | Jan 2012 | A1 |
20120011253 | Friedman et al. | Jan 2012 | A1 |
20120012112 | Dunsmore et al. | Jan 2012 | A1 |
20120016215 | Condurso et al. | Jan 2012 | A1 |
20120016295 | Tsoukalis | Jan 2012 | A1 |
20120029312 | Beaudry et al. | Feb 2012 | A1 |
20120029314 | Paquet et al. | Feb 2012 | A1 |
20120029315 | Raptis et al. | Feb 2012 | A1 |
20120029316 | Raptis et al. | Feb 2012 | A1 |
20120029937 | Neftel | Feb 2012 | A1 |
20120029944 | Brossette et al. | Feb 2012 | A1 |
20120035552 | Woehr | Feb 2012 | A1 |
20120041771 | Abrahamson et al. | Feb 2012 | A1 |
20120041775 | Cosentino et al. | Feb 2012 | A1 |
20120062387 | Borges et al. | Mar 2012 | A1 |
20120066197 | Bhattacharya et al. | Mar 2012 | A1 |
20120066609 | Assadi et al. | Mar 2012 | A1 |
20120075061 | Barnes | Mar 2012 | A1 |
20120084303 | Ledford et al. | Apr 2012 | A1 |
20120096545 | Koeda | Apr 2012 | A1 |
20120102010 | Brueggerhoff et al. | Apr 2012 | A1 |
20120116796 | Bellon et al. | May 2012 | A1 |
20120116800 | McCallie et al. | May 2012 | A1 |
20120124174 | Nudelman et al. | May 2012 | A1 |
20120130308 | Silkaitis et al. | May 2012 | A1 |
20120143124 | Mastalli et al. | Jun 2012 | A1 |
20120143628 | Miller et al. | Jun 2012 | A1 |
20120154264 | Wang et al. | Jun 2012 | A1 |
20120172802 | Blomquist | Jul 2012 | A1 |
20120179490 | Fuhrmann et al. | Jul 2012 | A1 |
20120182939 | Rajan et al. | Jul 2012 | A1 |
20120193359 | Mai | Aug 2012 | A1 |
20120205441 | Utech et al. | Aug 2012 | A1 |
20120211422 | Thys | Aug 2012 | A1 |
20120212434 | Bluemler et al. | Aug 2012 | A1 |
20120212455 | Kloeffel | Aug 2012 | A1 |
20120220940 | Estes et al. | Aug 2012 | A1 |
20120221634 | Treu et al. | Aug 2012 | A1 |
20120238851 | Kamen | Sep 2012 | A1 |
20120239824 | Nguyen et al. | Sep 2012 | A1 |
20120253835 | Tracy et al. | Oct 2012 | A1 |
20120260012 | Gao-Saari et al. | Oct 2012 | A1 |
20120275943 | Coates et al. | Nov 2012 | A1 |
20120290328 | McCallie, Jr. et al. | Nov 2012 | A1 |
20120296673 | Ackerson et al. | Nov 2012 | A1 |
20120296674 | Ackerson et al. | Nov 2012 | A1 |
20120302991 | Blomquist et al. | Nov 2012 | A1 |
20120303388 | Vishnubhatla et al. | Nov 2012 | A1 |
20120310152 | Wehba et al. | Dec 2012 | A1 |
20120323591 | Bechtel et al. | Dec 2012 | A1 |
20130001165 | Pohlmeier et al. | Jan 2013 | A1 |
20130004593 | Kloeffel et al. | Jan 2013 | A1 |
20130005834 | Fichert et al. | Jan 2013 | A1 |
20130006171 | Griessmann et al. | Jan 2013 | A1 |
20130006211 | Takemoto | Jan 2013 | A1 |
20130006651 | Saus et al. | Jan 2013 | A1 |
20130006865 | Spates | Jan 2013 | A1 |
20130011273 | Kjaergaard et al. | Jan 2013 | A1 |
20130012785 | Lombardi et al. | Jan 2013 | A1 |
20130012861 | Zhang | Jan 2013 | A1 |
20130012876 | DeBelser et al. | Jan 2013 | A1 |
20130012877 | DeBelser et al. | Jan 2013 | A1 |
20130012878 | Blomquist | Jan 2013 | A1 |
20130012914 | Burbank et al. | Jan 2013 | A1 |
20130013338 | DeBelser et al. | Jan 2013 | A1 |
20130013543 | Dull et al. | Jan 2013 | A1 |
20130014276 | Gudenus et al. | Jan 2013 | A1 |
20130015302 | Orter et al. | Jan 2013 | A1 |
20130015980 | Evans et al. | Jan 2013 | A1 |
20130018301 | Weaver et al. | Jan 2013 | A1 |
20130018315 | Blomquist | Jan 2013 | A1 |
20130018355 | Brand et al. | Jan 2013 | A1 |
20130020250 | Keller et al. | Jan 2013 | A1 |
20130020807 | Thomsen | Jan 2013 | A1 |
20130023734 | Okamura | Jan 2013 | A1 |
20130023826 | Ishida | Jan 2013 | A1 |
20130025697 | Blasek et al. | Jan 2013 | A1 |
20130026084 | Schneider et al. | Jan 2013 | A1 |
20130026098 | Haecker et al. | Jan 2013 | A1 |
20130028788 | Gronau et al. | Jan 2013 | A1 |
20130030346 | Gronau et al. | Jan 2013 | A1 |
20130030348 | Lauer | Jan 2013 | A1 |
20130030388 | Brehm | Jan 2013 | A1 |
20130030830 | Schmoll et al. | Jan 2013 | A1 |
20130034439 | Bauer et al. | Feb 2013 | A1 |
20130035627 | Bongers | Feb 2013 | A1 |
20130035663 | Ho | Feb 2013 | A1 |
20130036323 | Goose et al. | Feb 2013 | A1 |
20130037142 | Farrell | Feb 2013 | A1 |
20130037462 | Levin et al. | Feb 2013 | A1 |
20130042458 | Carr et al. | Feb 2013 | A1 |
20130045764 | Vik et al. | Feb 2013 | A1 |
20130046163 | Sweitzer et al. | Feb 2013 | A1 |
20130046241 | Okamura et al. | Feb 2013 | A1 |
20130046255 | Ziman et al. | Feb 2013 | A1 |
20130046871 | Vik et al. | Feb 2013 | A1 |
20130047113 | Hume et al. | Feb 2013 | A1 |
20130053651 | Tarn et al. | Feb 2013 | A1 |
20130053754 | Heppe | Feb 2013 | A1 |
20130053781 | Woehr et al. | Feb 2013 | A1 |
20130053791 | Clark | Feb 2013 | A1 |
20130053986 | Goose et al. | Feb 2013 | A1 |
20130056418 | Kopperschmidt et al. | Mar 2013 | A1 |
20130056678 | Fenn et al. | Mar 2013 | A1 |
20130057686 | Genc et al. | Mar 2013 | A1 |
20130058554 | Battle et al. | Mar 2013 | A1 |
20130060197 | Woehr et al. | Mar 2013 | A1 |
20130060198 | Woehr et al. | Mar 2013 | A1 |
20130060552 | Aparicio et al. | Mar 2013 | A1 |
20130060553 | Patel et al. | Mar 2013 | A1 |
20130060554 | Aparicio et al. | Mar 2013 | A1 |
20130062265 | Balschat et al. | Mar 2013 | A1 |
20130062283 | Peters et al. | Mar 2013 | A1 |
20130072882 | Ogawa et al. | Mar 2013 | A1 |
20130072893 | Takemoto | Mar 2013 | A1 |
20130075018 | Heppe | Mar 2013 | A1 |
20130075314 | Nikolic et al. | Mar 2013 | A1 |
20130076019 | Takemoto | Mar 2013 | A1 |
20130076650 | Vik et al. | Mar 2013 | A1 |
20130079698 | Bocket et al. | Mar 2013 | A1 |
20130081998 | Chamney et al. | Apr 2013 | A1 |
20130086163 | Neff | Apr 2013 | A1 |
20130086872 | Barra et al. | Apr 2013 | A1 |
20130087210 | Brandl et al. | Apr 2013 | A1 |
20130091191 | Levin et al. | Apr 2013 | A1 |
20130092728 | Vik et al. | Apr 2013 | A1 |
20130096502 | Kawamoto et al. | Apr 2013 | A1 |
20130102976 | Woehr et al. | Apr 2013 | A1 |
20130103419 | Beaudry et al. | Apr 2013 | A1 |
20130103801 | Hansen et al. | Apr 2013 | A1 |
20130104120 | Arrizza | Apr 2013 | A1 |
20130106609 | Singh et al. | May 2013 | A1 |
20130110028 | Bachmann et al. | May 2013 | A1 |
20130110538 | Butterfield et al. | May 2013 | A1 |
20130110552 | Horiguchi et al. | May 2013 | A1 |
20130112629 | Brandl et al. | May 2013 | A1 |
20130113816 | Sudarsky et al. | May 2013 | A1 |
20130116631 | Ziman et al. | May 2013 | A1 |
20130116651 | Takagi et al. | May 2013 | A1 |
20130118961 | Beden et al. | May 2013 | A1 |
20130118970 | Beden et al. | May 2013 | A1 |
20130125525 | Hein et al. | May 2013 | A1 |
20130126015 | Bremer et al. | May 2013 | A1 |
20130132977 | Doyle | May 2013 | A1 |
20130133036 | Wang et al. | May 2013 | A1 |
20130134357 | Schweitzer et al. | May 2013 | A1 |
20130141329 | Halbert et al. | Jun 2013 | A1 |
20130144139 | Zhang et al. | Jun 2013 | A1 |
20130144246 | Takemoto | Jun 2013 | A1 |
20130146541 | Weigel et al. | Jun 2013 | A1 |
20130150712 | Field | Jun 2013 | A1 |
20130153474 | Frorip et al. | Jun 2013 | A1 |
20130158504 | Ruchti et al. | Jun 2013 | A1 |
20130167052 | Niesslein et al. | Jun 2013 | A1 |
20130172806 | Griessmann | Jul 2013 | A1 |
20130174518 | Tachikawa et al. | Jul 2013 | A1 |
20130175871 | Knuppel et al. | Jul 2013 | A1 |
20130180905 | Wong | Jul 2013 | A1 |
20130184805 | Sawada | Jul 2013 | A1 |
20130190168 | Wong et al. | Jul 2013 | A1 |
20130193039 | Kopperschmidt | Aug 2013 | A1 |
20130196703 | Masoud et al. | Aug 2013 | A1 |
20130197597 | Anderson et al. | Aug 2013 | A1 |
20130197927 | Vanderveen et al. | Aug 2013 | A1 |
20130197928 | Vanderveen et al. | Aug 2013 | A1 |
20130197929 | Vanderveen et al. | Aug 2013 | A1 |
20130197930 | Garibaldi et al. | Aug 2013 | A1 |
20130197931 | Gupta et al. | Aug 2013 | A1 |
20130199534 | Steinhauer et al. | Aug 2013 | A1 |
20130204098 | Chamney et al. | Aug 2013 | A1 |
20130204433 | Gupta et al. | Aug 2013 | A1 |
20130204637 | Vanderveen et al. | Aug 2013 | A1 |
20130211206 | Sands et al. | Aug 2013 | A1 |
20130237896 | Meibaum et al. | Sep 2013 | A1 |
20130238120 | Ross | Sep 2013 | A1 |
20130243292 | Khurd et al. | Sep 2013 | A1 |
20130245530 | Brandl et al. | Sep 2013 | A1 |
20130245531 | Brandl et al. | Sep 2013 | A1 |
20130248629 | Brand et al. | Sep 2013 | A1 |
20130262138 | Jaskela et al. | Oct 2013 | A1 |
20130272587 | Fang et al. | Oct 2013 | A1 |
20130274642 | Soykan et al. | Oct 2013 | A1 |
20130277287 | Moissl et al. | Oct 2013 | A1 |
20130296823 | Melker et al. | Nov 2013 | A1 |
20130298062 | Dolgos et al. | Nov 2013 | A1 |
20130298063 | Joy et al. | Nov 2013 | A1 |
20130312066 | Suerez et al. | Nov 2013 | A1 |
20130322722 | Vija et al. | Dec 2013 | A1 |
20130323119 | Alwan | Dec 2013 | A1 |
20130324940 | Mann et al. | Dec 2013 | A1 |
20130324941 | Mann et al. | Dec 2013 | A1 |
20130327713 | Jirka et al. | Dec 2013 | A1 |
20130345625 | Causey, III et al. | Dec 2013 | A1 |
20140000605 | Steinhauer et al. | Jan 2014 | A1 |
20140002234 | Alwan | Jan 2014 | A1 |
20140002246 | Steinhauer et al. | Jan 2014 | A1 |
20140028464 | Garibaldi | Jan 2014 | A1 |
20140039446 | Day | Feb 2014 | A1 |
20140067416 | Duelsner et al. | Mar 2014 | A1 |
20140067426 | Neff | Mar 2014 | A1 |
20140074506 | Oliver et al. | Mar 2014 | A1 |
20140094744 | Blomquist | Apr 2014 | A1 |
20140094764 | Blomquist | Apr 2014 | A1 |
20140095485 | Blomquist | Apr 2014 | A1 |
20140095499 | Blomquist | Apr 2014 | A1 |
20140102957 | Broeker et al. | Apr 2014 | A1 |
20140107567 | Goetz | Apr 2014 | A1 |
20140121845 | Mueller | May 2014 | A1 |
20140129250 | Daniel et al. | May 2014 | A1 |
20140148104 | Marterstock | May 2014 | A1 |
20140162563 | Mastrototaro | Jun 2014 | A1 |
20140180716 | Batch | Jun 2014 | A1 |
20140221910 | Mastalli et al. | Aug 2014 | A1 |
Number | Date | Country |
---|---|---|
685495 | May 1995 | AU |
1293566 | Dec 1991 | CA |
2133913 | Apr 1995 | CA |
2110774 | Jun 1995 | CA |
2145714 | Oct 1995 | CA |
2112098 | Dec 1998 | CA |
2309409 | Dec 2000 | CA |
2314513 | Jan 2001 | CA |
2314517 | Jan 2001 | CA |
2055952 | Jan 2002 | CA |
1131076 | Sep 1996 | CN |
1216257 | May 1999 | CN |
2440518 | Aug 2001 | CN |
1131076 | Dec 2003 | CN |
1950125 | Apr 2007 | CN |
1960775 | May 2007 | CN |
101057983 | Oct 2007 | CN |
201076636 | Jun 2008 | CN |
101606157 | Dec 2009 | CN |
101611409 | Dec 2009 | CN |
201370828 | Dec 2009 | CN |
201524302 | Jul 2010 | CN |
201832201 | May 2011 | CN |
201832202 | May 2011 | CN |
3826550 | Jan 1994 | DE |
0237588 | Sep 1987 | EP |
0287651 | Oct 1988 | EP |
0302752 | Feb 1989 | EP |
0329464 | Aug 1989 | EP |
0366854 | May 1990 | EP |
0387630 | Sep 1990 | EP |
0429866 | May 1991 | EP |
0436663 | Jul 1991 | EP |
0462466 | Dec 1991 | EP |
0505627 | Sep 1992 | EP |
0522527 | Jan 1993 | EP |
0531889 | Mar 1993 | EP |
0 544 393 | Jun 1993 | EP |
0567962 | Nov 1993 | EP |
0580299 | Jan 1994 | EP |
0595474 | May 1994 | EP |
0611228 | Aug 1994 | EP |
0439355 | Sep 1994 | EP |
0757541 | Jan 1996 | EP |
0784283 | Jul 1997 | EP |
0812441 | Dec 1997 | EP |
0833266 | Apr 1998 | EP |
0844581 | May 1998 | EP |
0847008 | Jun 1998 | EP |
0890919 | Jan 1999 | EP |
0365614 | Aug 1999 | EP |
0958778 | Nov 1999 | EP |
0960627 | Dec 1999 | EP |
0 970 655 | Jan 2000 | EP |
1048264 | Feb 2000 | EP |
1057448 | Dec 2000 | EP |
1072994 | Feb 2001 | EP |
1081627 | Mar 2001 | EP |
1107158 | Jun 2001 | EP |
0674162 | Jan 2002 | EP |
1195708 | Apr 2002 | EP |
1 235 614 | Sep 2002 | EP |
1574178 | Sep 2005 | EP |
1 574 178 | Nov 2006 | EP |
2043014 | Apr 2009 | EP |
2043408 | Apr 2009 | EP |
2 126 768 | Dec 2009 | EP |
100566768 | Dec 2009 | EP |
2157984 | Mar 2010 | EP |
2 172 859 | Apr 2010 | EP |
2 248 545 | Nov 2010 | EP |
2 292 284 | Mar 2011 | EP |
2292284 | Mar 2011 | EP |
2 320 621 | May 2011 | EP |
2368588 | Sep 2011 | EP |
2 394 232 | Dec 2011 | EP |
2 394 242 | Dec 2011 | EP |
1 332 440 | Apr 2012 | EP |
2 514 474 | Oct 2012 | EP |
2514474 | Oct 2012 | EP |
2 554 202 | Feb 2013 | EP |
2 554 206 | Feb 2013 | EP |
2 558 142 | Feb 2013 | EP |
2 558 177 | Feb 2013 | EP |
2 559 451 | Feb 2013 | EP |
2 560 700 | Feb 2013 | EP |
2 567 721 | Mar 2013 | EP |
2 567 722 | Mar 2013 | EP |
2 569 028 | Mar 2013 | EP |
2 571 566 | Mar 2013 | EP |
2 590 562 | Mar 2013 | EP |
2563469 | Mar 2013 | EP |
2 574 362 | Apr 2013 | EP |
2 575 665 | Apr 2013 | EP |
2 575 924 | Apr 2013 | EP |
2 575 946 | Apr 2013 | EP |
2 579 910 | Apr 2013 | EP |
2 579 912 | Apr 2013 | EP |
2013059615 | Apr 2013 | EP |
2 585 155 | May 2013 | EP |
2 588 158 | May 2013 | EP |
2 589 367 | May 2013 | EP |
2 589 368 | May 2013 | EP |
2 589 409 | May 2013 | EP |
2 591 418 | May 2013 | EP |
2 595 531 | May 2013 | EP |
2 596 821 | May 2013 | EP |
2013074635 | May 2013 | EP |
2587394 | May 2013 | EP |
2595531 | May 2013 | EP |
2 598 186 | Jun 2013 | EP |
2 600 925 | Jun 2013 | EP |
2 603 777 | Jun 2013 | EP |
2 605 780 | Jun 2013 | EP |
2 605 810 | Jun 2013 | EP |
2013091814 | Jun 2013 | EP |
2591884 | Jun 1987 | FR |
20090061806 | Jun 2009 | FR |
2210713 | Feb 1987 | GB |
2279784 | Jan 1995 | GB |
2285135 | Jun 1995 | GB |
53137644 | Dec 1978 | JP |
61066950 | Apr 1986 | JP |
63068133 | Mar 1988 | JP |
02111375 | Apr 1990 | JP |
06086813 | Mar 1994 | JP |
06327636 | Nov 1994 | JP |
10014890 | Jan 1998 | JP |
10079770 | Mar 1998 | JP |
03055131 | Apr 2000 | JP |
2002-092181 | Mar 2002 | JP |
2002520718 | Jul 2002 | JP |
2004174235 | Jun 2004 | JP |
2004-326436 | Nov 2004 | JP |
2006252560 | Sep 2006 | JP |
2007-29371 | Feb 2007 | JP |
2007-094943 | Apr 2007 | JP |
03958733 | May 2007 | JP |
04176404 | Nov 2008 | JP |
2009-112651 | May 2009 | JP |
2009-116499 | May 2009 | JP |
04499050 | Apr 2010 | JP |
2010-152878 | Jul 2010 | JP |
2011065248 | Mar 2011 | JP |
2011-527617 | Nov 2011 | JP |
05032200 | Jul 2012 | JP |
5032210 | Sep 2012 | JP |
5193794 | Feb 2013 | JP |
100730991 | Jun 2007 | KR |
8400493 | Feb 1984 | WO |
8404685 | Dec 1984 | WO |
8802700 | Apr 1988 | WO |
8909017 | Oct 1989 | WO |
9004231 | Apr 1990 | WO |
9014850 | Dec 1990 | WO |
9104704 | Apr 1991 | WO |
9300047 | Jan 1993 | WO |
9302720 | Feb 1993 | WO |
9405355 | Mar 1994 | WO |
9408647 | Apr 1994 | WO |
9412235 | Jun 1994 | WO |
9424929 | Nov 1994 | WO |
1994024929 | Nov 1994 | WO |
9424929 | Nov 1994 | WO |
9502426 | Jan 1995 | WO |
9520804 | Aug 1995 | WO |
9523378 | Aug 1995 | WO |
9524010 | Sep 1995 | WO |
9532480 | Nov 1995 | WO |
9625214 | Aug 1996 | WO |
9625877 | Aug 1996 | WO |
9628209 | Sep 1996 | WO |
9626670 | Sep 1996 | WO |
9627163 | Sep 1996 | WO |
9634291 | Oct 1996 | WO |
9636923 | Nov 1996 | WO |
9701141 | Jan 1997 | WO |
9712680 | Apr 1997 | WO |
9715021 | Apr 1997 | WO |
9741525 | Nov 1997 | WO |
9813783 | Apr 1998 | WO |
9814275 | Apr 1998 | WO |
9815092 | Apr 1998 | WO |
9816893 | Apr 1998 | WO |
9820793 | May 1998 | WO |
1998019734 | May 1998 | WO |
9824358 | Jun 1998 | WO |
9826365 | Jun 1998 | WO |
9828676 | Jul 1998 | WO |
9829790 | Jul 1998 | WO |
9833433 | Aug 1998 | WO |
9835747 | Aug 1998 | WO |
9856450 | Dec 1998 | WO |
9856451 | Dec 1998 | WO |
9856450 | Dec 1998 | WO |
9856451 | Dec 1998 | WO |
9859487 | Dec 1998 | WO |
9904043 | Jan 1999 | WO |
1991010029 | Mar 1999 | WO |
9910029 | Mar 1999 | WO |
9914882 | Mar 1999 | WO |
9915216 | Apr 1999 | WO |
9922330 | May 1999 | WO |
9946657 | Jul 1999 | WO |
9933390 | Jul 1999 | WO |
9942933 | Aug 1999 | WO |
9945490 | Sep 1999 | WO |
9944162 | Sep 1999 | WO |
9946657 | Sep 1999 | WO |
9952025 | Oct 1999 | WO |
9952025 | Oct 1999 | WO |
9959472 | Nov 1999 | WO |
9963886 | Dec 1999 | WO |
9964971 | Dec 1999 | WO |
0003344 | Jan 2000 | WO |
0013588 | Mar 2000 | WO |
0013726 | Mar 2000 | WO |
0014652 | Mar 2000 | WO |
0023908 | Apr 2000 | WO |
0021590 | Apr 2000 | WO |
0028460 | May 2000 | WO |
0029983 | May 2000 | WO |
2000032098 | Jun 2000 | WO |
0033231 | Jun 2000 | WO |
0040145 | Jul 2000 | WO |
0042911 | Jul 2000 | WO |
0043941 | Jul 2000 | WO |
0048112 | Aug 2000 | WO |
0051519 | Sep 2000 | WO |
0052437 | Sep 2000 | WO |
0052438 | Sep 2000 | WO |
0052626 | Sep 2000 | WO |
0053082 | Sep 2000 | WO |
0057339 | Sep 2000 | WO |
0062660 | Oct 2000 | WO |
0060522 | Oct 2000 | WO |
0065522 | Nov 2000 | WO |
0066271 | Nov 2000 | WO |
0069331 | Nov 2000 | WO |
0072181 | Nov 2000 | WO |
0078374 | Dec 2000 | WO |
0079466 | Dec 2000 | WO |
0101305 | Jan 2001 | WO |
0102979 | Jan 2001 | WO |
0106468 | Jan 2001 | WO |
0108077 | Feb 2001 | WO |
0125972 | Apr 2001 | WO |
200137786 | May 2001 | WO |
0130422 | May 2001 | WO |
0145014 | Jun 2001 | WO |
2001045774 | Jun 2001 | WO |
0150397 | Jul 2001 | WO |
2001070301 | Sep 2001 | WO |
0165232 | Sep 2001 | WO |
0165463 | Sep 2001 | WO |
0188828 | Nov 2001 | WO |
0188828 | Nov 2001 | WO |
0208941 | Jan 2002 | WO |
0211049 | Feb 2002 | WO |
0225566 | Mar 2002 | WO |
2003025826 | Mar 2002 | WO |
0217777 | Mar 2002 | WO |
0231738 | Apr 2002 | WO |
0230250 | Apr 2002 | WO |
0233961 | Apr 2002 | WO |
0236044 | May 2002 | WO |
0239250 | May 2002 | WO |
0241135 | May 2002 | WO |
0241232 | May 2002 | WO |
02069099 | Sep 2002 | WO |
02082984 | Oct 2002 | WO |
2002078783 | Oct 2002 | WO |
0291276 | Nov 2002 | WO |
03007816 | Jan 2003 | WO |
2003021485 | Mar 2003 | WO |
03030979 | Apr 2003 | WO |
03032827 | Apr 2003 | WO |
2003055542 | Jul 2003 | WO |
03055542 | Jul 2003 | WO |
03091836 | Nov 2003 | WO |
03091838 | Nov 2003 | WO |
03091840 | Nov 2003 | WO |
2004012043 | Feb 2004 | WO |
2004029853 | Apr 2004 | WO |
2004030525 | Apr 2004 | WO |
04029853 | Apr 2004 | WO |
04030525 | Apr 2004 | WO |
2004061745 | Jul 2004 | WO |
04061745 | Jul 2004 | WO |
2004069095 | Aug 2004 | WO |
2004070546 | Aug 2004 | WO |
2004070548 | Aug 2004 | WO |
2004070549 | Aug 2004 | WO |
2004070556 | Aug 2004 | WO |
2004070557 | Aug 2004 | WO |
2004070562 | Aug 2004 | WO |
2004070994 | Aug 2004 | WO |
2004070995 | Aug 2004 | WO |
2004072828 | Aug 2004 | WO |
04072828 | Aug 2004 | WO |
2004088567 | Oct 2004 | WO |
04088567 | Oct 2004 | WO |
2005001739 | Jan 2005 | WO |
2005036447 | Apr 2005 | WO |
2005038588 | Apr 2005 | WO |
2005049115 | Jun 2005 | WO |
2005050526 | Jun 2005 | WO |
2005055954 | Jun 2005 | WO |
2005056083 | Jun 2005 | WO |
2005056087 | Jun 2005 | WO |
2005057466 | Jun 2005 | WO |
2005060673 | Jul 2005 | WO |
2005066872 | Jul 2005 | WO |
2005089263 | Sep 2005 | WO |
2005101276 | Oct 2005 | WO |
2005101279 | Oct 2005 | WO |
2005102417 | Nov 2005 | WO |
2005102418 | Nov 2005 | WO |
2005103999 | Nov 2005 | WO |
2005114524 | Dec 2005 | WO |
2006015260 | Feb 2006 | WO |
2006015330 | Feb 2006 | WO |
2006019623 | Feb 2006 | WO |
2006026270 | Mar 2006 | WO |
2006034178 | Mar 2006 | WO |
2006048554 | May 2006 | WO |
2006050206 | May 2006 | WO |
2006058151 | Jun 2006 | WO |
2006062912 | Jun 2006 | WO |
2006060291 | Aug 2006 | WO |
2006086701 | Aug 2006 | WO |
2006086735 | Aug 2006 | WO |
2006098927 | Sep 2006 | WO |
2006098960 | Sep 2006 | WO |
2006110851 | Oct 2006 | WO |
2006122167 | Nov 2006 | WO |
2006122322 | Nov 2006 | WO |
2006124202 | Nov 2006 | WO |
2006128536 | Dec 2006 | WO |
2006131345 | Dec 2006 | WO |
2007061368 | Mar 2007 | WO |
2007056592 | May 2007 | WO |
2007058821 | May 2007 | WO |
2007076069 | Jul 2007 | WO |
2007078937 | Jul 2007 | WO |
2007081837 | Jul 2007 | WO |
2007113890 | Oct 2007 | WO |
2007126948 | Nov 2007 | WO |
2007127879 | Nov 2007 | WO |
2007133279 | Nov 2007 | WO |
2008008916 | Jan 2008 | WO |
2008016621 | Feb 2008 | WO |
2008019014 | Feb 2008 | WO |
2008031821 | Mar 2008 | WO |
2008051939 | May 2008 | WO |
2008051983 | May 2008 | WO |
2008052034 | May 2008 | WO |
2008057729 | May 2008 | WO |
2008063966 | May 2008 | WO |
2008070322 | Jun 2008 | WO |
2008074316 | Jun 2008 | WO |
2008106589 | Sep 2008 | WO |
2008124644 | Oct 2008 | WO |
2008137683 | Nov 2008 | WO |
2009013575 | Jan 2009 | WO |
2009020879 | Feb 2009 | WO |
2009023634 | Feb 2009 | WO |
2009032400 | Mar 2009 | WO |
2009047178 | Apr 2009 | WO |
2009051829 | Apr 2009 | WO |
2009051830 | Apr 2009 | WO |
2009051831 | Apr 2009 | WO |
2009051832 | Apr 2009 | WO |
2009061883 | Apr 2009 | WO |
2009058871 | May 2009 | WO |
2009058904 | May 2009 | WO |
2009059013 | May 2009 | WO |
2009079453 | Jun 2009 | WO |
2009089029 | Jul 2009 | WO |
2009095021 | Aug 2009 | WO |
2009124133 | Oct 2009 | WO |
2009149209 | Dec 2009 | WO |
2010028860 | Mar 2010 | WO |
2010053702 | May 2010 | WO |
2010065472 | Jun 2010 | WO |
2010077762 | Jul 2010 | WO |
2010089083 | Aug 2010 | WO |
2010091184 | Aug 2010 | WO |
2010089083 | Oct 2010 | WO |
2010129720 | Nov 2010 | WO |
2010144314 | Dec 2010 | WO |
2011005697 | Jan 2011 | WO |
2011014517 | Feb 2011 | WO |
2011026645 | Mar 2011 | WO |
2011026646 | Mar 2011 | WO |
2011035329 | Mar 2011 | WO |
2011041312 | Apr 2011 | WO |
2011066556 | Jun 2011 | WO |
2011075687 | Jun 2011 | WO |
2011084435 | Jul 2011 | WO |
2011087710 | Jul 2011 | WO |
2011097116 | Aug 2011 | WO |
2011097118 | Aug 2011 | WO |
2011101135 | Aug 2011 | WO |
2011104296 | Sep 2011 | WO |
2011107569 | Sep 2011 | WO |
2011130592 | Oct 2011 | WO |
11130592 | Oct 2011 | WO |
2011141186 | Nov 2011 | WO |
2011144747 | Nov 2011 | WO |
2011146283 | Nov 2011 | WO |
2011153084 | Dec 2011 | WO |
2012003989 | Jan 2012 | WO |
2012010588 | Jan 2012 | WO |
2012015768 | Feb 2012 | WO |
2012015808 | Feb 2012 | WO |
2012015841 | Feb 2012 | WO |
2012015848 | Feb 2012 | WO |
2012033598 | Mar 2012 | WO |
2012037079 | Mar 2012 | WO |
2012040248 | Mar 2012 | WO |
2012044389 | Apr 2012 | WO |
2012067950 | May 2012 | WO |
2012092919 | Jul 2012 | WO |
2012112399 | Aug 2012 | WO |
12110251 | Aug 2012 | WO |
2012121103 | Sep 2012 | WO |
2012125980 | Sep 2012 | WO |
2012138604 | Oct 2012 | WO |
2012142151 | Oct 2012 | WO |
2013000569 | Jan 2013 | WO |
2013004362 | Jan 2013 | WO |
2013005607 | Jan 2013 | WO |
2013010642 | Jan 2013 | WO |
2013010666 | Jan 2013 | WO |
2013017236 | Feb 2013 | WO |
2013017239 | Feb 2013 | WO |
2013017240 | Feb 2013 | WO |
2013017247 | Feb 2013 | WO |
2013017252 | Feb 2013 | WO |
2013019856 | Feb 2013 | WO |
2013020989 | Feb 2013 | WO |
2013022837 | Feb 2013 | WO |
2013025394 | Feb 2013 | WO |
2013025395 | Feb 2013 | WO |
2013025957 | Feb 2013 | WO |
2013028260 | Feb 2013 | WO |
2013028407 | Feb 2013 | WO |
2013029786 | Mar 2013 | WO |
2013030350 | Mar 2013 | WO |
2013032601 | Mar 2013 | WO |
2013032770 | Mar 2013 | WO |
2013034292 | Mar 2013 | WO |
2013038887 | Mar 2013 | WO |
2013041196 | Mar 2013 | WO |
2013043598 | Mar 2013 | WO |
13029786 | Mar 2013 | WO |
2013045448 | Apr 2013 | WO |
2013047205 | Apr 2013 | WO |
2013047416 | Apr 2013 | WO |
2013050127 | Apr 2013 | WO |
13051927 | Apr 2013 | WO |
2013067223 | May 2013 | WO |
2013074769 | May 2013 | WO |
2013079169 | Jun 2013 | WO |
2013085884 | Jun 2013 | WO |
2013101888 | Jul 2013 | WO |
2013102496 | Jul 2013 | WO |
2013103607 | Jul 2013 | WO |
2013104536 | Jul 2013 | WO |
14009876 | Jan 2014 | WO |
Entry |
---|
Google patents search, Jan. 20, 2016. |
Google patents search, Jun. 21, 2017. |
EIC Search report, dated Apr. 10, 2018. |
Supplementary International Search Report for Application No. PCT/US2013/040967 dated Jun. 19, 2014. |
International Search Report for PCT/US2013/040967 dated Oct. 8, 2013. |
Carson, Ewart et al., “A Systems Methodology for the Development and Evaluation of a Telematic Home Haemodialysis Service,” Proceedings—19th International Conference—IEEE/EMBS Oct. 30-Nov. 2, 1997, Chicago, Illinois, pp. 907-910. |
Lefkowitz, Sheldon et al., “A Trial of the Use of Bar Code Technology to Restructure a Drug Distribution and Administration System,” 1991, pp. 239-242, Hospital Pharmacy, vol. 26. |
Tohme, Walid G. et al., “Design of a Multimedia PC-based Telemedicine Network for the Monitoring of Renal Dialysis Patients,” SPIE vol. 3035, 1997, Downloaded from the Internet [http://proceedings.spiedigitallibrary.org] on Nov. 12, 2012, pp. 580-585. |
Pesce, James, “Bedside Terminals: Medtake,” Clinical Computing, Jan./Feb. 1988, pp. 16-21, vol. 5, No. 1. |
Hughes, Shirley, “Bedside Terminals: Clinicom,” Clinical Computing, Jan./Feb. 1988, pp. 22-28, vol. 5, No. 1. |
Standard Specification for Transferring Clinical Laboratory Data Messages Between Independent computer Systems, Annual Book of ASTM Standards, Mar. 25, 1988, pp. 1-16, E 1238-88, Global Engineering Documents, Philadelphia, PA. |
Standard Specification for Transferring Information Between Clinical Instruments and Computer Systems, Annual Book of ASTM Standards, Jun. 1991, 15 pages, E 1394-91, Philadelphia, PA. |
Standard Specification for Transferring Clinical Observations Between Independent Computer Systems, Annual Book of ASTM Standards, Jun. Mar. 1994, pp. 132.210, E 1238-91, Philadelphia, PA. |
“Global Med Announces First SAFETRACE TX™ Sale,” Apr. 1, 1999, 2 pages. |
PCA II Multi-Mode Cartridge Operator's Manual, Sep. 1995, approx. 40 pages, Baxter Healthcare Corporation, Deerfield, IL. |
Auto Syringe® AS40A Infusion Pump Technical Manual, 1995, 89 pages, Baxter Healthcare Corporation, Deerfield, IL. |
Auto Syringe® AS40A: Model AS40A Infusion Pump Operation Manual, undated, 78 pages, Baxter Healthcare Corporation, Deerfield, IL. |
Medcin® Technical Overview, undated, 111 pages, Medicomp Systems. |
Website information for Cartharsis Medical Technology Products, Dec. 9, 2001, 15 pages. |
Website information for MedPoint™, Mar. 13, 2003, 20 pages, Bridge Medical, Solana Beach, CA. |
Vincenzo Della Mae et al., “HTML generation and semantic markup for telepathology,” Computer Networks and ISDN Systems, 1996, pp. 1085-1094, vol. 28, Elsevier Science B.V. |
Daniel Andresen et al., “Scalability Issues for High Performance Digital Libraries on the World Wide Web,” Proceedings of ADL '96, 1996, pp. 139-148, IEEE. |
Michael H. Mackin, “Impact of Technology on Environmental Therapeutic Device Design,” Medical Instrumentation, Feb. 1987, pp. 33-35, vol. 21, No. 1, Association for the Advancement of Medical Instrumentation. |
Henry J. Lowe et al., “WebReport: A World Wide Web Based Clinical Multimedia Reporting System,” 1996, pp. 314-318, AMIA, Inc. |
H. Paul Hammann et al., “A World Wide Web Accessible Multi-Species ECG Database,” 1997, pp. 7-12, ISA. |
Valeriy Nenov et al., “Remote Analysis of Physiological Data from Neurosurgical ICU Patients,” Journal of the American Medical Informatics Association, Sep./Oct. 1996, pp. 318-327, vol. 3, No. 5. |
“Hospitals battle errors with bar codes,” Mar. 24, 2004, 3 pages, MSNBC. |
Fred Puckett, “Medication-management component of a point-of-care information system,” Am. J. Health-Syst.Pharm., Jun. 15, 1995, pp. 1305-1309, vol. 52, American Society of Health-System Pharmacists, Inc. |
Paul H. Perlstein et al., “Future Directions for Device Design and Infant Management,” Medical Instrumentation, Feb. 1987, pp. 36-41, vol. 21, No. 1, Association for the Advancement of Medical Instrumentation. |
Albert A. Cook, “An integrated nursing-pharmacy approach to a computerized medication dispensing/administration system,” Hospital Pharmacy, May 1985, pp. 321-325, vol. 20, JB Lippincott Company, Philadelphia, PA. |
Paul H. Perlstein et al., “Computer-Assisted Newborn Intensive Care,” Pediatrics, Apr. 1976, pp. 494-501, vol. 57, No. 4, American Academy of Pediatrics, Inc., Evanston, Illinois. |
Global Med Technologies, Inc. Introduces PeopleMed™.com, inc., A Chronic Disease Management Application Service Provider (ASP) Subsidiary, Jan. 11, 2000, 2 pages, Global med Technologies, Inc., Denver, CO. |
Kenneth N. Barker et al., “Effect of an automated bedside dispensing machine on medication errors,” American Journal of Hospital Pharmacy, Jul. 1984, pp. 1352-1358, vol. 41, No. 7, American Society of Hospital Pharmacists. |
Darryl V. Wareham et al., “Combination Medication Cart and Computer Terminal in Decentralized Drug Distribution,” American Journal of Hospital Pharmacy, Jun. 1983, pp. 976-978, vol. 40, American Society of Hospital Pharmacists. |
Gretchen A. Barry et al., “Bar-code technology for documenting administration of large-volume intravenous solutions,” American Journal of Hospital Pharmacy, Feb. 1989, pp. 282-287, vol. 46, American Society of Hospital Pharmacists. |
Dennis D. Cote et al., “Robotic system for i.v. antineoplastic drug preparation: Description and preliminary evaluation under simulated conditions,” American Journal of Hospital Pharmacy, Nov. 1989, pp. 2286-2293, vol. 46, American Society of Hospital Pharmacists. |
William R. Dito et al., “Bar codes and the clinical laboratory: adaptation perspectives,” Clinical Laboratory Management Review, Jan./Feb. 1992, pp. 72-85, Clinical Laboratory Management Association, Inc. |
Yvonne Mari Abdoo, “Designing a Patient Care Medication and Recording System that Uses Bar Code Technology,” Computers in Nursing, May/Jun. 1992, pp. 116-120, vol. 10, No. 3. |
Victor J. Perini et al., Comparison of automated medication-management systems,: Am. J. Hosp. Pharm., Aug. 1, 1994, pp. 1883-1891, vol. 51, American Society of Hospital Pharmacists, Inc. |
Ann Slone Endo, “Using Computers in Newborn Intensive Care Settings,” American Journal of Nursing, Jul. 1981, pp. 1336-1337. |
Gerald E. Meyer et al., Use of bar codes in inpatient drug distribution,: Am. J. Hosp. Pharm., May 1991, pp. 953-966, vol. 48, American Society of Hospital Pharmacists, Inc. |
Standard Specification for Transferring Clinical Observations Between Independent Computer Systems, Aug. 10, 1997, 79 pages, ASTM E 1238-94, West Conshohocken, PA, United States. |
Deborah J. Mayhew, “Principles and Guidelines in Software user Interface Designs,” 1992, selected portions of Chapter 9, 17 pages, Prentice-Hall, Inc. |
Ben Schneiderman, “Designing the User Interface: Strategies for Effective Human-Computer Interaction,” 2d Ed., 1992, Chapter 5: Direct Manipulation (56 pages), Addison-Wesley Publishing Company. |
Product literature, Baxter Healthcare Corporation, “MultiPlex™ Series 100 Fluid Management System,” 1988, 2 pages. |
Product literature, Baxter Healthcare Corporation, “Flor-Gard® 6201 Volumetric Infusion Pump,” 1992, 2 pages. |
Peter Lord et al., MiniMed Technologies Programmable Implantable Infusion System, Annals New York Academy of Science, pp. 66-71, describing clinical trials from Nov. 1986. |
“Block Medical: Growing with Home Infusion Therapy,” taken from Invivo, the Business and Medicine Report, Apr. 1991, pp. 7-9. |
James Kazmer et al., “The Creation of Virtual Medical Record,” 1996, 17pages. |
Daniel J. Nigrin et al., “Glucoweb: A Case Study of Secure, Remote Biomonitoring and Communication,” Proceedings of the 2000, 5 pages, American Medical Informatics Association, Bethesda, MD. |
Charles Safran, M.D. et al., “Computer-Based Support for Clinical Decision Making,” M.D. Computing, 1990, pp. 319-322, vol. 7, No. 5. |
Gilad J. Kuperman, M.D. et al., “Innovations and research review: The impact of the HELPS computer on the LDS Hospital paper medical record,” Topics in Health Record Management, 1991, pp. 76-85, vol. 12, Issue 2, Aspen Publishers, Inc. |
“The Longitudinal Clinical Record: A View of the Patient,” taken from Proceedings of the 1994 Annual HIMSS Conference, Feb. 14, 1994, pp. 239-250, Healthcare Information and Management Systems Society, Chicago, Illinois, USA. |
Clayton M. Curtis, “A Computer-based Patient Record Emerging from the Public Sector: The Decentralized Hospital Computer Program,” First Annual Nicholas E. Davies Award Proceedings of the CPR Recognition Symposium, 1995, pp. 75-132, Computer-based Patient Record Institute, Inc., Bethesda, MD. |
Howard L. Bleich et al., “Clinical Computing in a Teaching Hospital,” Use and Impact of Computers in Clinical Medicine, 1987, pp. 205-223 and selected pages, Springer-Verlag, New York, NY. |
T.E. Bozeman et al., “The Development and Implementation of a Computer-Based Patient Record in a Rural Integrated Health System,” Third Annual Nicholas E. David Award Proceedings of the CPR Recognition Symposium, 1997, pp. 101-130, Computer-based Patient Record Institute, Inc., Bethesda, MD. |
Suzanne Carter, RN, Ed.D. et al., “The Computer-based Patient Record: The Jacobi Medical Center Experience,” Second Annual Nicholas E. Davies Award Proceedings of the CPR Recognition Symposium, 1996, pp. 71-95, Computer-based Patient Record Institute, Inc., Bethesda, MD. |
Bell Atlantic Healthcare Systems, Inc., court exhibit, StatLan Functions and Features, Specification, release 3.5, dated Nov. 12, 1992, 49 pages. |
Clement J. McDonald, M.D. et al., The Regenstrief Medical Record System: 20 Years of Experience in Hospitals, Clinics, and Neighborhood Health Centers,: M.D. Computing, 1992 pp. 206-217, vol. 9, No. 4, Springer-Verlag, New York, NY. |
Clement J. McDonald, M.D. et al, “The Three-Legged Stool: Regenstrief Institute for Health Care,” Third Annual Nicholas E. Davies Award Proceedings of the CPR Recognition Symposium, 1997, pp. 131-158, Computer-based Patient Record Institute, Inc., Bethesda, MD. |
Allan T. Pryor, “Current State of Computer-based Patient Record Systems,” Aspects of the Computer-based Patient Record, 1992, pp. 67-82, Springer-Verlag, New York, NY. |
Karen E. Bradshaw et al., “Physician decision-making—Evaluation of data used in a computerized ICU,” International Journal of Clinical Monitoring and Computing, 1984, pp. 81-91, vol. 1, Martinus Nijhoff Publishers, Netherlands. |
T. Allan Pryor et al., “help—A Total Hospital Information System,” Proceedings of the Fourth Annual Symposium on Computer Applications in Medical Care, Nov. 2-5, 1980, pp. 3-7, vol. 1, Institute for Electrical and Electronics Engineers, New York, NY. |
Larry B. Grandia, B.S.E. et al., “Building a computer-based Patient Record System in an Evolving Integrated Health System,” First Annual Nicholas E. Davies Award Proceedings of the CPR Recognition Symposium, 1995, pp. 19-55, Computer-based Patient Record Institute, Inc., Bethesda, MD. |
A.H.McMorris et al., “Are Process Control Rooms Obsolete?” taken from Control Engineering, pp. 42-47, Jul. 1971. |
Specifications for Low-Level Protocol to Transfer Messages Between Clinical Laboratory Instruments and Computer Systems, Mar. 11, 1991, 7 pages, ASTM E 1381-91, Philadelphia, PA, United States. |
Standard Specification for Transferring Clinical Observations Between Independent computer Systems, Nov. 14, 1991, 64 pages, ASTM E 1238-91, Philadelphia, PA, United States. |
Standard Specification for Transferring Information Between Clinical Instruments and Computer Systems, Dec. 10, 1997, 15 pages, ASTM E 1394-97, West Conshohocken, PA, United States. |
Web site information, Information Data Management, Inc.'s PCMS: Plasma Center Management System, Dec. 14, 2001, 11 pages. |
Web site Information, Wyndgate Technologies' SafeTrace Tx™, undated, 15 pages. |
Japanese Office Action dated Jul. 24, 2012, for corresponding Japanese Application No. 2009-238780. |
Office Action dated Nov. 13, 2012 for corresponding Japanese Application No. 2011-154618. |
Office Action dated Nov. 27, 2012 for corresponding Japanese Application No. 2006-503207. |
International Search Report for International Application PCT/US2004/002821, dated May 18, 2005. |
Japanese Office Action for Japanese Application No. 2011-154618, dated Aug. 8, 2013. |
Canadian Office Action dated Mar. 27, 2013 for Canadian Application No. 2,556,841. |
Japanese Office Action dated Apr. 23, 2012 for corresponding Japanese Patent Application No. 2006-503207. |
Canadian Office Action for Canadian Application No. 2,513,687, dated Dec. 19, 2013. |
Canadian Office Action for Canadian Application No. 2,514,571, dated Jun. 6, 2014. |
Manns et al., The acu-menTM: A new device for continuous renal replacement therapy in actue renal failure, Kidney International, 1998, pp. 268-274, vol. 54. |
Patent Examination Report No. 1—Australia, date of Issue Aug. 18, 2015, Patent Application No. 2013263015—7 pages. |
Canadian Office Action dated Feb. 24, 2017 in corresponding Canadian Application No. 2,873,621—4 pages. |
Japanese Office Action dated Apr. 4, 2017 in corresponding Japanese Application No. 2015-512760. |
Australian Office Action dated May 9, 2017 in corresponding Australian Application No. 2016216665. |
4008H Hemodialysis Machine Operation Instructions, Software Version 4.2, Fresenius Medical Care. |
Tsavdaris, et al., “Monitoring and Supporting Home Maemodialysis using Telematic Services”, Decision Support Systems Laboratory, National Technical University of Athens, Wire Communications Laboratory, University of Patras. |
B. Agroyannis, et al. “Telemedicine technology and applications for home hemodialysis”, The International Journal of Artificial Organs, vol. 22/No. 10, 1999/ pp. 679-683. |
Contents, The International Journal of Artificial Organs, vol. 22/No. 10-1999/pp. 657-722. |
Proceedings of the 19th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Oct. 30-Nov. 2, 1997, Chicago, IL USA. |
Notice of opposition to a European patent, Patent No. EP 1 235 614, dated May 8, 2013. |
Opposition Statement, Patent No. EP 1 235 614 B, dated May 8, 2013. |
Notice of opposition to a European patent, Patent No. EP2368588, dated Jun. 14, 2016. |
Reexamination Certificate, U.S. Pat. No. B1 5,211,849, Certificate Issued May 27, 1997. |
Decision on Opposition, European Patent No. 1 235 614 dated Jul. 30, 2015. |
Non-Final Office Action dated Jun. 20, 2016 in U.S. Appl. No. 15/088,966. |
Final Office Action dated Nov. 25, 2016 in U.S. Appl. No. 15/088,966. |
Non-Final Office Action dated Jun. 28, 2016 in U.S. Appl. No. 15/135,810. |
Final Office Action dated Jan. 4, 2017 in U.S. Appl. No. 15/135,810. |
Non-Final Office Action dated Aug. 12, 2016 in U.S. Appl. No. 15/135,837. |
Final Office Action dated Feb. 3, 2017 in U.S. Appl. No. 15/135,837. |
Wang, Samuel J. et al. User-Definable Medication Favorites for an Outpatient Electronic Medical Record System. Proc AMIA Symp. 2001: 1055. |
Opposition against EP 2368588 (EP Application 11075130.2) dated May 13, 2016, 36 pages. |
Office Action issued in U.S. Appl. No. 15/088,966, dated Jun. 20, 2016, 17 pages. |
Office Action issued in U.S. Appl. No. 15/135,837, dated Aug. 12, 2016, 17 pages. |
Office Action issued in U.S. Appl. No. 13/828,900, dated Aug. 8, 2016, 28 pages. |
Office Action issued in U.S. Appl. No. 13/828,900, dated Jan. 25, 2016, 28 pages. |
Office Action issued in CN Application 201380031530.6 dated Aug. 1, 2016, 12 pages. |
Office Action issued in AU Application 2013263015 dated Aug. 16, 2016, 6 pages. |
Office Action issued in U.S. Appl. No. 15/135,810, dated Jun. 28, 2016, 18 pages. |
Mexican Office Action dated Dec. 14, 2016 in corresponding Mexican Application No. MX/a/2014/013920. |
Chinese Office Action dated Feb. 21, 2017 in corresponding Chinese Application No. 201380031530.6. |
New Zealand Office Action dated Mar. 10, 2017 in corresponding New Zealand Application No. 702249. |
Chinese Office Action dated Aug. 4, 2017 in corresponding Chinese Application No. 201380031530.6. |
Mexican Office Action dated Jul. 10, 2017 in corresponding Mexican Application No. MX/2017/018965. |
Dialog + Dialog with the future B BRAUN Sharing Expertise—14 pages. |
Korean Office Action dated Oct. 24, 2017 (and English language translation) in corresponding Korean Application No. 10-2014-7034964. |
Canadian Office Action for related Canadian Application No. 2,873,621; dated Nov. 29, 2017; (5 pages). |
Chinese Office Action for related Chinese Application No. 201380031530.6; dated Dec. 15, 2017; (17 pages). |
Mexican Office Action for related Mexican Application No. MX/a/2014/013920; dated Jan. 30, 2018; (6 pages). |
U.S. Appl. No. 12/885,076, filed Sep. 17, 2010, Kelly et al. |
U.S. Appl. No. 13/947,771, filed Jul. 22, 2013, Yu et al. |
Letter from Mexican associate regarding office action for MX/a/2007/014394 dated Mar. 12, 2013. |
European office action for Application No. 11 075 130.2-1651 dated Sep. 23, 2013. |
European office action for Application No. 11 075 130.2-1651 dated Oct. 6, 2014. |
Number | Date | Country | |
---|---|---|---|
20130310726 A1 | Nov 2013 | US |
Number | Date | Country | |
---|---|---|---|
61647340 | May 2012 | US |